{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":"Activist Defense","value":72},{"name":"Capital Markets","value":26},{"name":"Construction and Procurement","value":40},{"name":"Corporate Governance","value":27},{"name":"Emerging Companies and Venture Capital","value":80},{"name":"Employee Benefits and Executive Compensation","value":28},{"name":"Energy and Infrastructure Projects","value":35},{"name":"Financial Restructuring","value":10},{"name":"Fund Finance","value":134},{"name":"Global Human Capital and Compliance ","value":121},{"name":"Investment Funds and Asset Management","value":78},{"name":"Leveraged Finance","value":29},{"name":"Mergers and Acquisitions (M\u0026A)","value":32},{"name":"Middle East and Islamic Finance and Investment","value":31},{"name":"Private Equity","value":33},{"name":"Public Companies","value":126},{"name":"Real Estate","value":36},{"name":"Structured Finance and Securitization","value":82},{"name":"Tax","value":37},{"name":"Technology Transactions","value":115},{"name":"Government Matters","value":"cg-2"},{"name":"Antitrust","value":1},{"name":"Data, Privacy and Security","value":6},{"name":"Environmental, Health and Safety","value":71},{"name":"FDA and Life Sciences","value":21},{"name":"Government Advocacy and Public Policy","value":23},{"name":"Government Contracts","value":116},{"name":"Healthcare","value":24},{"name":"Innovation Protection","value":135},{"name":"International Trade","value":25},{"name":"National Security and Corporate Espionage","value":110},{"name":"Securities Enforcement and Regulation","value":20},{"name":"Special Matters and Government Investigations","value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":"Antitrust ","value":129},{"name":"Appellate, Constitutional and Administrative Law","value":2},{"name":"Bankruptcy and Insolvency Litigation","value":38},{"name":"Class Action Defense","value":3},{"name":"Commercial Litigation","value":5},{"name":"Corporate and Securities Litigation","value":19},{"name":"E-Discovery","value":7},{"name":"Global Construction and Infrastructure Disputes","value":4},{"name":"Innovation Protection","value":136},{"name":"Intellectual Property","value":13},{"name":"International Arbitration and Litigation","value":14},{"name":"Labor and Employment","value":15},{"name":"Product Liability","value":17},{"name":"Professional Liability","value":18},{"name":"Toxic \u0026 Environmental Torts","value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":"Artificial Intelligence (AI) and Machine Learning","value":133},{"name":"Automotive, Transportation and Mobility","value":106},{"name":"Buy American","value":124},{"name":"Crisis Management","value":111},{"name":"Doing Business in Latin America","value":132},{"name":"Energy Transition","value":131},{"name":"Energy","value":102},{"name":"Environmental Agenda","value":125},{"name":"Environmental, Social and Governance (ESG)","value":127},{"name":"Financial Services","value":107},{"name":"Focus on Women's Health","value":112},{"name":"Food and Beverage","value":105},{"name":"Higher Education","value":109},{"name":"Life Sciences and Healthcare","value":103},{"name":"Russia/Ukraine","value":128},{"name":"Special Purpose Acquisition Companies (SPACs)","value":123},{"name":"Technology","value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"103","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"B","per_page":12,"people":[{"id":442768,"version":1,"owner_type":"Person","owner_id":5372,"payload":{"bio":"\u003cp\u003eMel Bailey focuses his practice on high profile product liability, business litigation and personal injury cases for more than 30 years. He has achieved success at trial attorney in some of the most challenging venues in the United States, including Texas, California, New York, New Jersey, Wyoming, Utah, Oklahoma, Georgia, Maryland, Nevada and Florida. His extensive courtroom experience has resulted in representation of leading corporate clients in complex and high stake litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMel has tried more than 65 cases to verdict in his career and has served as lead trial counsel on behalf of numerous Fortune 100 Companies in both product liability and toxic tort litigation.\u003c/p\u003e","slug":"melvin-bailey","email":"mbailey@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":17,"guid":"17.capabilities","index":0,"source":"capabilities"},{"id":16,"guid":"16.capabilities","index":1,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":2,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":5,"source":"smartTags"},{"id":764,"guid":"764.smart_tags","index":6,"source":"smartTags"}],"is_active":true,"last_name":"Bailey","nick_name":"Mel","clerkships":[],"first_name":"Melvin","title_rank":9999,"updated_by":101,"law_schools":[{"id":1896,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1987-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"D.","name_suffix":"","recognitions":[{"title":"Super Lawyer","detail":"Superlawyer’s Magazine (2003-2018)"},{"title":"Texas Lawyer","detail":"Superlawyer’s Edition (2006-2018)"},{"title":"Best Lawyers in Dallas","detail":"Dallas D Magazine"},{"title":"Best Lawyers in America","detail":"2017-2018"},{"title":"International Association of Defense Counsel Trial Academy","detail":"2017"}],"linked_in_url":"https://www.linkedin.com/in/mel-bailey-10aa2033/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eMel Bailey focuses his practice on high profile product liability, business litigation and personal injury cases for more than 30 years. He has achieved success at trial attorney in some of the most challenging venues in the United States, including Texas, California, New York, New Jersey, Wyoming, Utah, Oklahoma, Georgia, Maryland, Nevada and Florida. His extensive courtroom experience has resulted in representation of leading corporate clients in complex and high stake litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMel has tried more than 65 cases to verdict in his career and has served as lead trial counsel on behalf of numerous Fortune 100 Companies in both product liability and toxic tort litigation.\u003c/p\u003e","recognitions":[{"title":"Super Lawyer","detail":"Superlawyer’s Magazine (2003-2018)"},{"title":"Texas Lawyer","detail":"Superlawyer’s Edition (2006-2018)"},{"title":"Best Lawyers in Dallas","detail":"Dallas D Magazine"},{"title":"Best Lawyers in America","detail":"2017-2018"},{"title":"International Association of Defense Counsel Trial Academy","detail":"2017"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6358}]},"capability_group_id":3},"created_at":"2025-11-13T04:56:46.000Z","updated_at":"2025-11-13T04:56:46.000Z","searchable_text":"Bailey{{ FIELD }}{:title=\u0026gt;\"Super Lawyer\", :detail=\u0026gt;\"Superlawyer’s Magazine (2003-2018)\"}{{ FIELD }}{:title=\u0026gt;\"Texas Lawyer\", :detail=\u0026gt;\"Superlawyer’s Edition (2006-2018)\"}{{ FIELD }}{:title=\u0026gt;\"Best Lawyers in Dallas\", :detail=\u0026gt;\"Dallas D Magazine\"}{{ FIELD }}{:title=\u0026gt;\"Best Lawyers in America\", :detail=\u0026gt;\"2017-2018\"}{{ FIELD }}{:title=\u0026gt;\"International Association of Defense Counsel Trial Academy\", :detail=\u0026gt;\"2017\"}{{ FIELD }}Mel Bailey focuses his practice on high profile product liability, business litigation and personal injury cases for more than 30 years. He has achieved success at trial attorney in some of the most challenging venues in the United States, including Texas, California, New York, New Jersey, Wyoming, Utah, Oklahoma, Georgia, Maryland, Nevada and Florida. His extensive courtroom experience has resulted in representation of leading corporate clients in complex and high stake litigation.\nMel has tried more than 65 cases to verdict in his career and has served as lead trial counsel on behalf of numerous Fortune 100 Companies in both product liability and toxic tort litigation. Partner Super Lawyer Superlawyer’s Magazine (2003-2018) Texas Lawyer Superlawyer’s Edition (2006-2018) Best Lawyers in Dallas Dallas D Magazine Best Lawyers in America 2017-2018 International Association of Defense Counsel Trial Academy 2017 U.S. District Court for the Eastern District of Texas U.S. District Court for the Northern District of Texas U.S. District Court for the Southern District of Texas Texas Fellow, American College of Trial Lawyers Member, International Association of Defense Counsel Fellow, Litigation of Trial Counsel Member, The Trial Lawyer Honorary Society Former Member, American Board Trial Advocates Member, Diversity Law Institute Member, Trial Law Institute Inactive  Member, American Board of Trial Advocates IADC Trial Academy Faculty, Stanford University","searchable_name":"Melvin D. Bailey (Mel)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":427219,"version":1,"owner_type":"Person","owner_id":6490,"payload":{"bio":"\u003cp\u003eAdam Baker represents global financial institutions, healthcare and life sciences companies, and other public corporations in complex government and internal investigations and regulatory matters. He has extensive experience counseling clients facing investigations by the Department of Justice, Securities and Exchange Commission, State Attorneys General, Financial Industry Regulatory Authority, as well as other criminal and civil authorities. In particular, Adam has defended clients in matters implicating various federal laws and regulations, including insider trading, Foreign Corrupt Practices Act, Anti-Kickback Statute, healthcare fraud, and the Food, Drug \u0026amp; Cosmetic Act. [[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Adam served as a criminal Assistant United States Attorney in the Health Care Fraud/Opioid Abuse Prevention and Enforcement Unit in the District of New Jersey. In that role, he led a number of large-scale investigations and prosecutions of major pharmaceutical companies for healthcare fraud, diversion of controlled substances, and violations of the Federal Anti-Kickback Statute.\u0026nbsp; He also partnered with the DOJ\u0026rsquo;s Consumer Protection Branch on a significant investigation into potential violations by an opioid manufacturer and related individuals of the Food, Drug \u0026amp; Cosmetic Act.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to his government service, Adam was a Partner at another AmLaw 50 firm where he oversaw complex investigations and regulatory matters for financial institutions and its employees.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAdam is active within the LGBTQ+ community. He helped found Boston Colleges\u0026rsquo; first gay-straight alliance and served on his prior firm\u0026rsquo;s Diversity \u0026amp; LGBTQ+ committees. He serves on Boston College Law School\u0026rsquo;s national alumni board and formerly served as a Corp member for Teach For America.\u0026nbsp;\u0026nbsp;\u003c/p\u003e","slug":"adam-baker","email":"abaker@kslaw.com","phone":null,"matters":["\u003cp\u003eConducted an internal investigation on behalf of the Special Committee of an international corporation concerning potential financial improprieties resulting in a restatement and violations of the Foreign Corrupt Practices Act, and represented the Special Committee in resulting parallel investigations by the DOJ and SEC.\u003c/p\u003e","\u003cp\u003eRepresented a multinational financial services institution in investigations by the SEC and FINRA related to potential insider trading by current and former employees involved in a nonpublic M\u0026amp;A deal.\u003c/p\u003e","\u003cp\u003eRepresented a multinational financial services institution in an internal investigation of potential violations of the Foreign Corrupt Practices Act and OFAC regulations by an employee who attempted to broker deals with the Iranian government.\u003c/p\u003e","\u003cp\u003eRepresented the former CEO of a publicly-traded company in insider trading investigations by the DOJ and SEC.\u003c/p\u003e","\u003cp\u003eRepresented a men\u0026rsquo;s college basketball coach in investigations by the DOJ and NCAA Enforcement regarding potential provision of payments and benefits to players.\u003c/p\u003e","\u003cp\u003eRepresented a key figure in the \u0026ldquo;Bridgegate\u0026rdquo; matter in parallel investigations by the New Jersey Legislative Select Committee and U.S. Attorney\u0026rsquo;s Office, District of New Jersey.\u003c/p\u003e","\u003cp\u003eRepresented a former Dewey \u0026amp; Leboeuf employee in the New York County District Attorney\u0026rsquo;s Office\u0026rsquo;s investigation of the downfall of the firm, successfully obtaining immunity for the client.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":2,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":3,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":6,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":7,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":8,"source":"smartTags"},{"id":1248,"guid":"1248.smart_tags","index":9,"source":"smartTags"},{"id":1434,"guid":"1434.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"Baker","nick_name":"Adam","clerkships":[],"first_name":"Adam","title_rank":9999,"updated_by":32,"law_schools":[{"id":245,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2008-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/adam-baker-4a471038/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAdam Baker represents global financial institutions, healthcare and life sciences companies, and other public corporations in complex government and internal investigations and regulatory matters. He has extensive experience counseling clients facing investigations by the Department of Justice, Securities and Exchange Commission, State Attorneys General, Financial Industry Regulatory Authority, as well as other criminal and civil authorities. In particular, Adam has defended clients in matters implicating various federal laws and regulations, including insider trading, Foreign Corrupt Practices Act, Anti-Kickback Statute, healthcare fraud, and the Food, Drug \u0026amp; Cosmetic Act. [[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Adam served as a criminal Assistant United States Attorney in the Health Care Fraud/Opioid Abuse Prevention and Enforcement Unit in the District of New Jersey. In that role, he led a number of large-scale investigations and prosecutions of major pharmaceutical companies for healthcare fraud, diversion of controlled substances, and violations of the Federal Anti-Kickback Statute.\u0026nbsp; He also partnered with the DOJ\u0026rsquo;s Consumer Protection Branch on a significant investigation into potential violations by an opioid manufacturer and related individuals of the Food, Drug \u0026amp; Cosmetic Act.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to his government service, Adam was a Partner at another AmLaw 50 firm where he oversaw complex investigations and regulatory matters for financial institutions and its employees.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAdam is active within the LGBTQ+ community. He helped found Boston Colleges\u0026rsquo; first gay-straight alliance and served on his prior firm\u0026rsquo;s Diversity \u0026amp; LGBTQ+ committees. He serves on Boston College Law School\u0026rsquo;s national alumni board and formerly served as a Corp member for Teach For America.\u0026nbsp;\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003eConducted an internal investigation on behalf of the Special Committee of an international corporation concerning potential financial improprieties resulting in a restatement and violations of the Foreign Corrupt Practices Act, and represented the Special Committee in resulting parallel investigations by the DOJ and SEC.\u003c/p\u003e","\u003cp\u003eRepresented a multinational financial services institution in investigations by the SEC and FINRA related to potential insider trading by current and former employees involved in a nonpublic M\u0026amp;A deal.\u003c/p\u003e","\u003cp\u003eRepresented a multinational financial services institution in an internal investigation of potential violations of the Foreign Corrupt Practices Act and OFAC regulations by an employee who attempted to broker deals with the Iranian government.\u003c/p\u003e","\u003cp\u003eRepresented the former CEO of a publicly-traded company in insider trading investigations by the DOJ and SEC.\u003c/p\u003e","\u003cp\u003eRepresented a men\u0026rsquo;s college basketball coach in investigations by the DOJ and NCAA Enforcement regarding potential provision of payments and benefits to players.\u003c/p\u003e","\u003cp\u003eRepresented a key figure in the \u0026ldquo;Bridgegate\u0026rdquo; matter in parallel investigations by the New Jersey Legislative Select Committee and U.S. Attorney\u0026rsquo;s Office, District of New Jersey.\u003c/p\u003e","\u003cp\u003eRepresented a former Dewey \u0026amp; Leboeuf employee in the New York County District Attorney\u0026rsquo;s Office\u0026rsquo;s investigation of the downfall of the firm, successfully obtaining immunity for the client.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10412}]},"capability_group_id":2},"created_at":"2025-05-26T04:59:19.000Z","updated_at":"2025-05-26T04:59:19.000Z","searchable_text":"Baker{{ FIELD }}Conducted an internal investigation on behalf of the Special Committee of an international corporation concerning potential financial improprieties resulting in a restatement and violations of the Foreign Corrupt Practices Act, and represented the Special Committee in resulting parallel investigations by the DOJ and SEC.{{ FIELD }}Represented a multinational financial services institution in investigations by the SEC and FINRA related to potential insider trading by current and former employees involved in a nonpublic M\u0026amp;A deal.{{ FIELD }}Represented a multinational financial services institution in an internal investigation of potential violations of the Foreign Corrupt Practices Act and OFAC regulations by an employee who attempted to broker deals with the Iranian government.{{ FIELD }}Represented the former CEO of a publicly-traded company in insider trading investigations by the DOJ and SEC.{{ FIELD }}Represented a men’s college basketball coach in investigations by the DOJ and NCAA Enforcement regarding potential provision of payments and benefits to players.{{ FIELD }}Represented a key figure in the “Bridgegate” matter in parallel investigations by the New Jersey Legislative Select Committee and U.S. Attorney’s Office, District of New Jersey.{{ FIELD }}Represented a former Dewey \u0026amp; Leboeuf employee in the New York County District Attorney’s Office’s investigation of the downfall of the firm, successfully obtaining immunity for the client.{{ FIELD }}Adam Baker represents global financial institutions, healthcare and life sciences companies, and other public corporations in complex government and internal investigations and regulatory matters. He has extensive experience counseling clients facing investigations by the Department of Justice, Securities and Exchange Commission, State Attorneys General, Financial Industry Regulatory Authority, as well as other criminal and civil authorities. In particular, Adam has defended clients in matters implicating various federal laws and regulations, including insider trading, Foreign Corrupt Practices Act, Anti-Kickback Statute, healthcare fraud, and the Food, Drug \u0026amp; Cosmetic Act. \nPreviously, Adam served as a criminal Assistant United States Attorney in the Health Care Fraud/Opioid Abuse Prevention and Enforcement Unit in the District of New Jersey. In that role, he led a number of large-scale investigations and prosecutions of major pharmaceutical companies for healthcare fraud, diversion of controlled substances, and violations of the Federal Anti-Kickback Statute.  He also partnered with the DOJ’s Consumer Protection Branch on a significant investigation into potential violations by an opioid manufacturer and related individuals of the Food, Drug \u0026amp; Cosmetic Act.   \nPrior to his government service, Adam was a Partner at another AmLaw 50 firm where he oversaw complex investigations and regulatory matters for financial institutions and its employees. \nAdam is active within the LGBTQ+ community. He helped found Boston Colleges’ first gay-straight alliance and served on his prior firm’s Diversity \u0026amp; LGBTQ+ committees. He serves on Boston College Law School’s national alumni board and formerly served as a Corp member for Teach For America.   Partner Boston College Boston College Law School Boston College Boston College Law School Fordham University Fordham University School of Law U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York New York Conducted an internal investigation on behalf of the Special Committee of an international corporation concerning potential financial improprieties resulting in a restatement and violations of the Foreign Corrupt Practices Act, and represented the Special Committee in resulting parallel investigations by the DOJ and SEC. Represented a multinational financial services institution in investigations by the SEC and FINRA related to potential insider trading by current and former employees involved in a nonpublic M\u0026amp;A deal. Represented a multinational financial services institution in an internal investigation of potential violations of the Foreign Corrupt Practices Act and OFAC regulations by an employee who attempted to broker deals with the Iranian government. Represented the former CEO of a publicly-traded company in insider trading investigations by the DOJ and SEC. Represented a men’s college basketball coach in investigations by the DOJ and NCAA Enforcement regarding potential provision of payments and benefits to players. Represented a key figure in the “Bridgegate” matter in parallel investigations by the New Jersey Legislative Select Committee and U.S. Attorney’s Office, District of New Jersey. Represented a former Dewey \u0026amp; Leboeuf employee in the New York County District Attorney’s Office’s investigation of the downfall of the firm, successfully obtaining immunity for the client.","searchable_name":"Adam Baker","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":32,"capability_group_featured":null,"home_page_featured":null},{"id":445229,"version":1,"owner_type":"Person","owner_id":639,"payload":{"bio":"\u003cp\u003eRay represents private equity and hedge funds, and counsels corporations, in merger and acquisition transactions, financings and related matters.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Baltz is a senior partner in King \u0026amp; Spalding\u0026rsquo;s Corporate, Finance and Investment Group and the former head of the Global Corporate Department.\u0026nbsp; Mr. Baltz has extensive experience representing private equity and hedge funds in a wide variety of matters. Mr. Baltz has handled private equity buyouts totaling over $30\u0026nbsp;billion in the past several years.\u0026nbsp; Mr. Baltz is an adept business lawyer who is especially skilled at structuring private equity acquisitions and investments involving middle-market companies and executing leveraged buyouts on behalf of institutional buy-side clients.\u0026nbsp; Mr. Baltz also is a member of the Southeast chapter of the Business Executives for National Security (BENS), and a former member of the Boards of Directors of Big Brothers Big Sisters and Buckhead Baseball.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Clients:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eArcapita\u003c/p\u003e\n\u003cp\u003eAssured Investment Management\u003c/p\u003e\n\u003cp\u003eBrookfield Asset Management\u003c/p\u003e\n\u003cp\u003eEagle Merchant Partners\u003c/p\u003e\n\u003cp\u003eLevel 5 Capital Partners\u003c/p\u003e\n\u003cp\u003eNorthlane Capital Partners\u003c/p\u003e\n\u003cp\u003ePower Sustainable Lios\u003c/p\u003e\n\u003cp\u003eRed Dog Equity\u003c/p\u003e\n\u003cp\u003eRoark Capital\u003c/p\u003e\n\u003cp\u003eSlate Asset Management\u003c/p\u003e\n\u003cp\u003eSource Capital\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e","slug":"raymond-baltz","email":"rbaltz@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cem\u003eDecember 23, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Power Sustainable Lios on its acquisition of Crofters Food.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 12, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Slate Asset Management on its acquisition of Cold-Link Logistics.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 10, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of MBA Mission USA.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 26, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of Reach Cambridge.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 24, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisitions of EnviroSmart Sumter Solidification and High Pressure Investments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 5, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Guidewell Education.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 2, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Red Dog Equity on its sale of Superio USA Waste to GFL Environmental.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 9, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of Empower Community Care to NexPhase Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 1, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of C\u0026amp;K Paving Contractors.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 1, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of The Difference Card to Stone Point Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFebruary 27, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Strategic Claim Consultants.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJanuary 16, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Plus Delta Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 12, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Stellar Public Adjusting Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 11, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Sam the Concrete Man.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 5, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Source Capital and Backyard Products on their acquisition of KidKraft in a Chapter 11 process.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 1, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of BrandMuscle Holdings to Truelink Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 27, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of VMG Health to Incline Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFebruary 28, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of AYA Medical Spa.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 27, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Capital Partners on its sale of Rotomaster to MidOcean Partners and Cloyes Gear \u0026amp; Products.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 26, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its sale of Waste Harmonics to TPG and Keter Environmental Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 30, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Capital Partners on its sale of Cardone Industries to First Brands Group.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 30, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita and Nationwide Property \u0026amp; Appraisal Services on their acquisition of Integrity Appraisal Management.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 28, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northland Capital Partners and VMG Health on their acquisition of the assets of BSM Financial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 28, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Impact Home Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 31, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of AmeriSpec and Furniture Medic from Roark Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 21, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Eskola Roofing.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 12, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of assets from Driven Brands.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 1, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Atlantic Pipe Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 29, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Enviro-Master International Franchise.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 24, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Source Capital and Backyard Products in its completion of a continuation fund involving Timber Bay Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 31, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Nationwide Property \u0026amp; Appraisal Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 24, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its sale of Caliber Car Wash to Percheon Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 21, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its sale of Recreational Group to Sentinel Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 15, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its investment in Impact Auto.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 24, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Illinois.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 17, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Missouri.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAugust 19, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Utah.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 19, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of One Plus Systems.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 30, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its sale of Stratus Unlimited to Vestar Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 1, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of The Difference Card.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 30, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Red Dog Equity on its acquisition of PureMagic Carwash.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 29, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Empower Community Care.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJanuary 28, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Source Capital and Backyard Products on their acquisition of Yardistry Limited.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 24, 2020\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on is sale of Lone Star Overnight to WeDo Logistics.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 11, 2020\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its investment in Code Ninjas.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 17, 2020\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of VMG Health.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 30, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on the sale of Planet Fitness studio franchises to American Securities.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 26, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Waste Harmonics, a leading provider of waste and recycling management solutions.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 19, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Infrastructure Group and Public Sector Pension Investment on their sale of Wind Energy Transmission Texas to Axiom Infrastructure.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 27, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital on its sale of Corepower Yoga studio franchises to TSG Consumer Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 4, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its sale of Chicken Salad Chick to Brentwood Associates.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAugust 30, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Icon Investment Holdings, a manufacturer, servicer and installer of commercial signage.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 8, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised BlueMountain Capital Management in connection with the sale of AdaptHealth Holdings to DFB Healthcare Acquisitions Corp. (NASDAQ: DFBH), a special purpose acquisition company sponsored by Deerfield Management.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 19, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness studio franchises from affiliates of Michigan OT Partnership.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 11, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Principal Credit (\"BPC\") on a transaction which resulted in BPC acquiring 85% of the limited partnership interests of Cardone Industries, a leading aftermarket auto parts manufacturer of new and remanufactured auto parts.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 15, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of Science Care to Levine Leichtman Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFebruary 27, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised BlueMountain Capital Management in connection with its investment in common equity and subordinated debt of AdaptHealth Holdings.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJanuary 28, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Coastal Sign and Wayfinding, Inc., a manufacturer, servicer and installer of commercial signage.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":42}]},"expertise":[{"id":33,"guid":"33.capabilities","index":0,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":1,"source":"capabilities"},{"id":27,"guid":"27.capabilities","index":2,"source":"capabilities"},{"id":26,"guid":"26.capabilities","index":3,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":105,"guid":"105.capabilities","index":6,"source":"capabilities"},{"id":75,"guid":"75.capabilities","index":7,"source":"capabilities"},{"id":1141,"guid":"1141.smart_tags","index":8,"source":"smartTags"},{"id":1192,"guid":"1192.smart_tags","index":9,"source":"smartTags"},{"id":123,"guid":"123.capabilities","index":10,"source":"capabilities"},{"id":124,"guid":"124.capabilities","index":11,"source":"capabilities"},{"id":1220,"guid":"1220.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Baltz","nick_name":"Ray","clerkships":[],"first_name":"Raymond","title_rank":9999,"updated_by":35,"law_schools":[],"middle_name":"E.","name_suffix":"Jr.","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eRay represents private equity and hedge funds, and counsels corporations, in merger and acquisition transactions, financings and related matters.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Baltz is a senior partner in King \u0026amp; Spalding\u0026rsquo;s Corporate, Finance and Investment Group and the former head of the Global Corporate Department.\u0026nbsp; Mr. Baltz has extensive experience representing private equity and hedge funds in a wide variety of matters. Mr. Baltz has handled private equity buyouts totaling over $30\u0026nbsp;billion in the past several years.\u0026nbsp; Mr. Baltz is an adept business lawyer who is especially skilled at structuring private equity acquisitions and investments involving middle-market companies and executing leveraged buyouts on behalf of institutional buy-side clients.\u0026nbsp; Mr. Baltz also is a member of the Southeast chapter of the Business Executives for National Security (BENS), and a former member of the Boards of Directors of Big Brothers Big Sisters and Buckhead Baseball.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Clients:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eArcapita\u003c/p\u003e\n\u003cp\u003eAssured Investment Management\u003c/p\u003e\n\u003cp\u003eBrookfield Asset Management\u003c/p\u003e\n\u003cp\u003eEagle Merchant Partners\u003c/p\u003e\n\u003cp\u003eLevel 5 Capital Partners\u003c/p\u003e\n\u003cp\u003eNorthlane Capital Partners\u003c/p\u003e\n\u003cp\u003ePower Sustainable Lios\u003c/p\u003e\n\u003cp\u003eRed Dog Equity\u003c/p\u003e\n\u003cp\u003eRoark Capital\u003c/p\u003e\n\u003cp\u003eSlate Asset Management\u003c/p\u003e\n\u003cp\u003eSource Capital\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003e\u003cem\u003eDecember 23, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Power Sustainable Lios on its acquisition of Crofters Food.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 12, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Slate Asset Management on its acquisition of Cold-Link Logistics.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 10, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of MBA Mission USA.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 26, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of Reach Cambridge.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 24, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisitions of EnviroSmart Sumter Solidification and High Pressure Investments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 5, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Guidewell Education.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 2, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Red Dog Equity on its sale of Superio USA Waste to GFL Environmental.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 9, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of Empower Community Care to NexPhase Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 1, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of C\u0026amp;K Paving Contractors.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 1, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of The Difference Card to Stone Point Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFebruary 27, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Strategic Claim Consultants.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJanuary 16, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Plus Delta Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 12, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Stellar Public Adjusting Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 11, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Sam the Concrete Man.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 5, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Source Capital and Backyard Products on their acquisition of KidKraft in a Chapter 11 process.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 1, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of BrandMuscle Holdings to Truelink Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 27, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of VMG Health to Incline Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFebruary 28, 2024\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of AYA Medical Spa.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 27, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Capital Partners on its sale of Rotomaster to MidOcean Partners and Cloyes Gear \u0026amp; Products.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 26, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its sale of Waste Harmonics to TPG and Keter Environmental Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 30, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Capital Partners on its sale of Cardone Industries to First Brands Group.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 30, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita and Nationwide Property \u0026amp; Appraisal Services on their acquisition of Integrity Appraisal Management.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 28, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northland Capital Partners and VMG Health on their acquisition of the assets of BSM Financial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 28, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Impact Home Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 31, 2023\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of AmeriSpec and Furniture Medic from Roark Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOctober 21, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Eskola Roofing.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 12, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of assets from Driven Brands.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 1, 2025\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Atlantic Pipe Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 29, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its acquisition of Enviro-Master International Franchise.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 24, 2022\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Source Capital and Backyard Products in its completion of a continuation fund involving Timber Bay Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 31, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Nationwide Property \u0026amp; Appraisal Services.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 24, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its sale of Caliber Car Wash to Percheon Capital.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 21, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its sale of Recreational Group to Sentinel Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 15, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its investment in Impact Auto.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 24, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Illinois.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSeptember 17, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Missouri.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAugust 19, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Utah.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 19, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of One Plus Systems.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 30, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its sale of Stratus Unlimited to Vestar Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 1, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of The Difference Card.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 30, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Red Dog Equity on its acquisition of PureMagic Carwash.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 29, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of Empower Community Care.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJanuary 28, 2021\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Source Capital and Backyard Products on their acquisition of Yardistry Limited.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 24, 2020\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on is sale of Lone Star Overnight to WeDo Logistics.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 11, 2020\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its investment in Code Ninjas.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 17, 2020\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its acquisition of VMG Health.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 30, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on the sale of Planet Fitness studio franchises to American Securities.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 26, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Waste Harmonics, a leading provider of waste and recycling management solutions.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eDecember 19, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Infrastructure Group and Public Sector Pension Investment on their sale of Wind Energy Transmission Texas to Axiom Infrastructure.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 27, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital on its sale of Corepower Yoga studio franchises to TSG Consumer Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNovember 4, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Eagle Merchant Partners on its sale of Chicken Salad Chick to Brentwood Associates.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAugust 30, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Icon Investment Holdings, a manufacturer, servicer and installer of commercial signage.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJuly 8, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised BlueMountain Capital Management in connection with the sale of AdaptHealth Holdings to DFB Healthcare Acquisitions Corp. (NASDAQ: DFBH), a special purpose acquisition company sponsored by Deerfield Management.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJune 19, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness studio franchises from affiliates of Michigan OT Partnership.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApril 11, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Brookfield Principal Credit (\"BPC\") on a transaction which resulted in BPC acquiring 85% of the limited partnership interests of Cardone Industries, a leading aftermarket auto parts manufacturer of new and remanufactured auto parts.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMarch 15, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Northlane Capital Partners on its sale of Science Care to Levine Leichtman Capital Partners.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFebruary 27, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised BlueMountain Capital Management in connection with its investment in common equity and subordinated debt of AdaptHealth Holdings.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJanuary 28, 2019\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAdvised Arcapita on its acquisition of Coastal Sign and Wayfinding, Inc., a manufacturer, servicer and installer of commercial signage.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11849}]},"capability_group_id":1},"created_at":"2026-01-23T16:43:44.000Z","updated_at":"2026-01-23T16:43:44.000Z","searchable_text":"Baltz{{ FIELD }}December 23, 2025\nAdvised Power Sustainable Lios on its acquisition of Crofters Food.{{ FIELD }}December 12, 2025\nAdvised Slate Asset Management on its acquisition of Cold-Link Logistics.{{ FIELD }}October 10, 2025\nAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of MBA Mission USA.{{ FIELD }}September 26, 2025\nAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of Reach Cambridge.{{ FIELD }}September 24, 2025\nAdvised Eagle Merchant Partners on its acquisitions of EnviroSmart Sumter Solidification and High Pressure Investments.{{ FIELD }}September 5, 2025\nAdvised Eagle Merchant Partners on its acquisition of Guidewell Education.{{ FIELD }}September 2, 2025\nAdvised Red Dog Equity on its sale of Superio USA Waste to GFL Environmental.{{ FIELD }}July 9, 2025\nAdvised Northlane Capital Partners on its sale of Empower Community Care to NexPhase Capital.{{ FIELD }}July 1, 2025\nAdvised Arcapita on its acquisition of C\u0026amp;K Paving Contractors.{{ FIELD }}July 1, 2025\nAdvised Northlane Capital Partners on its sale of The Difference Card to Stone Point Capital.{{ FIELD }}February 27, 2025\nAdvised Northlane Capital Partners on its acquisition of Strategic Claim Consultants.{{ FIELD }}January 16, 2025\nAdvised Northlane Capital Partners on its acquisition of Plus Delta Partners.{{ FIELD }}November 12, 2024\nAdvised Northlane Capital Partners on its acquisition of Stellar Public Adjusting Services.{{ FIELD }}October 11, 2024\nAdvised Eagle Merchant Partners on its acquisition of Sam the Concrete Man.{{ FIELD }}July 5, 2024\nAdvised Source Capital and Backyard Products on their acquisition of KidKraft in a Chapter 11 process.{{ FIELD }}July 1, 2024\nAdvised Northlane Capital Partners on its sale of BrandMuscle Holdings to Truelink Capital Partners.{{ FIELD }}April 27, 2024\nAdvised Northlane Capital Partners on its sale of VMG Health to Incline Partners.{{ FIELD }}February 28, 2024\nAdvised Eagle Merchant Partners on its acquisition of AYA Medical Spa.{{ FIELD }}October 27, 2023\nAdvised Brookfield Capital Partners on its sale of Rotomaster to MidOcean Partners and Cloyes Gear \u0026amp; Products.{{ FIELD }}September 26, 2023\nAdvised Arcapita on its sale of Waste Harmonics to TPG and Keter Environmental Services.{{ FIELD }}June 30, 2023\nAdvised Brookfield Capital Partners on its sale of Cardone Industries to First Brands Group.{{ FIELD }}June 30, 2023\nAdvised Arcapita and Nationwide Property \u0026amp; Appraisal Services on their acquisition of Integrity Appraisal Management.{{ FIELD }}April 28, 2023\nAdvised Northland Capital Partners and VMG Health on their acquisition of the assets of BSM Financial.{{ FIELD }}April 28, 2023\nAdvised Eagle Merchant Partners on its acquisition of Impact Home Services.{{ FIELD }}March 31, 2023\nAdvised Eagle Merchant Partners on its acquisition of AmeriSpec and Furniture Medic from Roark Capital.{{ FIELD }}October 21, 2022\nAdvised Eagle Merchant Partners on its acquisition of Eskola Roofing.{{ FIELD }}September 12, 2022\nAdvised Eagle Merchant Partners on its acquisition of assets from Driven Brands.{{ FIELD }}December 1, 2025\nAdvised Eagle Merchant Partners on its acquisition of Atlantic Pipe Services.{{ FIELD }}March 29, 2022\nAdvised Eagle Merchant Partners on its acquisition of Enviro-Master International Franchise.{{ FIELD }}March 24, 2022\nAdvised Source Capital and Backyard Products in its completion of a continuation fund involving Timber Bay Partners.{{ FIELD }}December 31, 2021\nAdvised Arcapita on its acquisition of Nationwide Property \u0026amp; Appraisal Services.{{ FIELD }}December 24, 2021\nAdvised Eagle Merchant Partners on its sale of Caliber Car Wash to Percheon Capital.{{ FIELD }}December 21, 2021\nAdvised Eagle Merchant Partners on its sale of Recreational Group to Sentinel Capital Partners.{{ FIELD }}December 15, 2021\nAdvised Eagle Merchant Partners on its investment in Impact Auto.{{ FIELD }}September 24, 2021\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Illinois.{{ FIELD }}September 17, 2021\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Missouri.{{ FIELD }}August 19, 2021\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Utah.{{ FIELD }}July 19, 2021\nAdvised Arcapita on its acquisition of One Plus Systems.{{ FIELD }}June 30, 2021\nAdvised Arcapita on its sale of Stratus Unlimited to Vestar Capital Partners.{{ FIELD }}June 1, 2021\nAdvised Northlane Capital Partners on its acquisition of The Difference Card.{{ FIELD }}April 30, 2021\nAdvised Red Dog Equity on its acquisition of PureMagic Carwash.{{ FIELD }}March 29, 2021\nAdvised Northlane Capital Partners on its acquisition of Empower Community Care.{{ FIELD }}January 28, 2021\nAdvised Source Capital and Backyard Products on their acquisition of Yardistry Limited.{{ FIELD }}November 24, 2020\nAdvised Eagle Merchant Partners on is sale of Lone Star Overnight to WeDo Logistics.{{ FIELD }}June 11, 2020\nAdvised Eagle Merchant Partners on its investment in Code Ninjas.{{ FIELD }}March 17, 2020\nAdvised Northlane Capital Partners on its acquisition of VMG Health.{{ FIELD }}December 30, 2019\nAdvised Eagle Merchant Partners on the sale of Planet Fitness studio franchises to American Securities.{{ FIELD }}December 26, 2019\nAdvised Arcapita on its acquisition of Waste Harmonics, a leading provider of waste and recycling management solutions.{{ FIELD }}December 19, 2019\nAdvised Brookfield Infrastructure Group and Public Sector Pension Investment on their sale of Wind Energy Transmission Texas to Axiom Infrastructure.{{ FIELD }}November 27, 2019\nAdvised Level 5 Capital on its sale of Corepower Yoga studio franchises to TSG Consumer Partners.{{ FIELD }}November 4, 2019\nAdvised Eagle Merchant Partners on its sale of Chicken Salad Chick to Brentwood Associates.{{ FIELD }}August 30, 2019\nAdvised Arcapita on its acquisition of Icon Investment Holdings, a manufacturer, servicer and installer of commercial signage.{{ FIELD }}July 8, 2019\nAdvised BlueMountain Capital Management in connection with the sale of AdaptHealth Holdings to DFB Healthcare Acquisitions Corp. (NASDAQ: DFBH), a special purpose acquisition company sponsored by Deerfield Management.{{ FIELD }}June 19, 2019\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness studio franchises from affiliates of Michigan OT Partnership.{{ FIELD }}April 11, 2019\nAdvised Brookfield Principal Credit (\"BPC\") on a transaction which resulted in BPC acquiring 85% of the limited partnership interests of Cardone Industries, a leading aftermarket auto parts manufacturer of new and remanufactured auto parts.{{ FIELD }}March 15, 2019\nAdvised Northlane Capital Partners on its sale of Science Care to Levine Leichtman Capital Partners.{{ FIELD }}February 27, 2019\nAdvised BlueMountain Capital Management in connection with its investment in common equity and subordinated debt of AdaptHealth Holdings.{{ FIELD }}January 28, 2019\nAdvised Arcapita on its acquisition of Coastal Sign and Wayfinding, Inc., a manufacturer, servicer and installer of commercial signage.{{ FIELD }}Ray represents private equity and hedge funds, and counsels corporations, in merger and acquisition transactions, financings and related matters. \nMr. Baltz is a senior partner in King \u0026amp; Spalding’s Corporate, Finance and Investment Group and the former head of the Global Corporate Department.  Mr. Baltz has extensive experience representing private equity and hedge funds in a wide variety of matters. Mr. Baltz has handled private equity buyouts totaling over $30 billion in the past several years.  Mr. Baltz is an adept business lawyer who is especially skilled at structuring private equity acquisitions and investments involving middle-market companies and executing leveraged buyouts on behalf of institutional buy-side clients.  Mr. Baltz also is a member of the Southeast chapter of the Business Executives for National Security (BENS), and a former member of the Boards of Directors of Big Brothers Big Sisters and Buckhead Baseball.  \nKey Clients:\nArcapita\nAssured Investment Management\nBrookfield Asset Management\nEagle Merchant Partners\nLevel 5 Capital Partners\nNorthlane Capital Partners\nPower Sustainable Lios\nRed Dog Equity\nRoark Capital\nSlate Asset Management\nSource Capital\n  Raymond E Baltz Partner Eastern Nazarene College  Boston University Boston University School of Law Boston College Boston College Law School Georgia State Bar of Georgia December 23, 2025\nAdvised Power Sustainable Lios on its acquisition of Crofters Food. December 12, 2025\nAdvised Slate Asset Management on its acquisition of Cold-Link Logistics. October 10, 2025\nAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of MBA Mission USA. September 26, 2025\nAdvised Eagle Merchant Partners and Guidewell Education on their acquisition of Reach Cambridge. September 24, 2025\nAdvised Eagle Merchant Partners on its acquisitions of EnviroSmart Sumter Solidification and High Pressure Investments. September 5, 2025\nAdvised Eagle Merchant Partners on its acquisition of Guidewell Education. September 2, 2025\nAdvised Red Dog Equity on its sale of Superio USA Waste to GFL Environmental. July 9, 2025\nAdvised Northlane Capital Partners on its sale of Empower Community Care to NexPhase Capital. July 1, 2025\nAdvised Arcapita on its acquisition of C\u0026amp;K Paving Contractors. July 1, 2025\nAdvised Northlane Capital Partners on its sale of The Difference Card to Stone Point Capital. February 27, 2025\nAdvised Northlane Capital Partners on its acquisition of Strategic Claim Consultants. January 16, 2025\nAdvised Northlane Capital Partners on its acquisition of Plus Delta Partners. November 12, 2024\nAdvised Northlane Capital Partners on its acquisition of Stellar Public Adjusting Services. October 11, 2024\nAdvised Eagle Merchant Partners on its acquisition of Sam the Concrete Man. July 5, 2024\nAdvised Source Capital and Backyard Products on their acquisition of KidKraft in a Chapter 11 process. July 1, 2024\nAdvised Northlane Capital Partners on its sale of BrandMuscle Holdings to Truelink Capital Partners. April 27, 2024\nAdvised Northlane Capital Partners on its sale of VMG Health to Incline Partners. February 28, 2024\nAdvised Eagle Merchant Partners on its acquisition of AYA Medical Spa. October 27, 2023\nAdvised Brookfield Capital Partners on its sale of Rotomaster to MidOcean Partners and Cloyes Gear \u0026amp; Products. September 26, 2023\nAdvised Arcapita on its sale of Waste Harmonics to TPG and Keter Environmental Services. June 30, 2023\nAdvised Brookfield Capital Partners on its sale of Cardone Industries to First Brands Group. June 30, 2023\nAdvised Arcapita and Nationwide Property \u0026amp; Appraisal Services on their acquisition of Integrity Appraisal Management. April 28, 2023\nAdvised Northland Capital Partners and VMG Health on their acquisition of the assets of BSM Financial. April 28, 2023\nAdvised Eagle Merchant Partners on its acquisition of Impact Home Services. March 31, 2023\nAdvised Eagle Merchant Partners on its acquisition of AmeriSpec and Furniture Medic from Roark Capital. October 21, 2022\nAdvised Eagle Merchant Partners on its acquisition of Eskola Roofing. September 12, 2022\nAdvised Eagle Merchant Partners on its acquisition of assets from Driven Brands. December 1, 2025\nAdvised Eagle Merchant Partners on its acquisition of Atlantic Pipe Services. March 29, 2022\nAdvised Eagle Merchant Partners on its acquisition of Enviro-Master International Franchise. March 24, 2022\nAdvised Source Capital and Backyard Products in its completion of a continuation fund involving Timber Bay Partners. December 31, 2021\nAdvised Arcapita on its acquisition of Nationwide Property \u0026amp; Appraisal Services. December 24, 2021\nAdvised Eagle Merchant Partners on its sale of Caliber Car Wash to Percheon Capital. December 21, 2021\nAdvised Eagle Merchant Partners on its sale of Recreational Group to Sentinel Capital Partners. December 15, 2021\nAdvised Eagle Merchant Partners on its investment in Impact Auto. September 24, 2021\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Illinois. September 17, 2021\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Missouri. August 19, 2021\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness franchises in Utah. July 19, 2021\nAdvised Arcapita on its acquisition of One Plus Systems. June 30, 2021\nAdvised Arcapita on its sale of Stratus Unlimited to Vestar Capital Partners. June 1, 2021\nAdvised Northlane Capital Partners on its acquisition of The Difference Card. April 30, 2021\nAdvised Red Dog Equity on its acquisition of PureMagic Carwash. March 29, 2021\nAdvised Northlane Capital Partners on its acquisition of Empower Community Care. January 28, 2021\nAdvised Source Capital and Backyard Products on their acquisition of Yardistry Limited. November 24, 2020\nAdvised Eagle Merchant Partners on is sale of Lone Star Overnight to WeDo Logistics. June 11, 2020\nAdvised Eagle Merchant Partners on its investment in Code Ninjas. March 17, 2020\nAdvised Northlane Capital Partners on its acquisition of VMG Health. December 30, 2019\nAdvised Eagle Merchant Partners on the sale of Planet Fitness studio franchises to American Securities. December 26, 2019\nAdvised Arcapita on its acquisition of Waste Harmonics, a leading provider of waste and recycling management solutions. December 19, 2019\nAdvised Brookfield Infrastructure Group and Public Sector Pension Investment on their sale of Wind Energy Transmission Texas to Axiom Infrastructure. November 27, 2019\nAdvised Level 5 Capital on its sale of Corepower Yoga studio franchises to TSG Consumer Partners. November 4, 2019\nAdvised Eagle Merchant Partners on its sale of Chicken Salad Chick to Brentwood Associates. August 30, 2019\nAdvised Arcapita on its acquisition of Icon Investment Holdings, a manufacturer, servicer and installer of commercial signage. July 8, 2019\nAdvised BlueMountain Capital Management in connection with the sale of AdaptHealth Holdings to DFB Healthcare Acquisitions Corp. (NASDAQ: DFBH), a special purpose acquisition company sponsored by Deerfield Management. June 19, 2019\nAdvised Level 5 Capital Partners on its acquisition of Orangetheory Fitness studio franchises from affiliates of Michigan OT Partnership. April 11, 2019\nAdvised Brookfield Principal Credit (\"BPC\") on a transaction which resulted in BPC acquiring 85% of the limited partnership interests of Cardone Industries, a leading aftermarket auto parts manufacturer of new and remanufactured auto parts. March 15, 2019\nAdvised Northlane Capital Partners on its sale of Science Care to Levine Leichtman Capital Partners. February 27, 2019\nAdvised BlueMountain Capital Management in connection with its investment in common equity and subordinated debt of AdaptHealth Holdings. January 28, 2019\nAdvised Arcapita on its acquisition of Coastal Sign and Wayfinding, Inc., a manufacturer, servicer and installer of commercial signage.","searchable_name":"Raymond E. Baltz, Jr. (Ray)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":442360,"version":1,"owner_type":"Person","owner_id":852,"payload":{"bio":"\u003cp\u003eRandy Bassett is a first chair trial lawyer, who has tried 40 cases to juries.\u0026nbsp; Randy has represented both foreign and domestic companies in federal and state courts across the United States in individual cases, multidistrict proceedings, and class actions. He focuses on the trial of high exposure cases on behalf of corporate defendants in difficult jurisdictions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRandy has represented companies in a range of industries, including consumer products, pharmaceutical, transportation, technology. His clients include: \u003cstrong\u003eBrown-Forman Corporation, General Motors, Gilead Sciences,\u0026nbsp;Gol Linhas Aereas Inteligentes S.A., Imetric 4D, Logitech, Purdue Pharma LP, R.J. Reynolds Tobacco Company\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong\u003eUnited Parcel Service, Inc.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRandy has handled cases throughout the United States with particular emphasis in jurisdictions designated \"judicial hellholes\" by the American Tort Reform Association. He has tried cases in the state courts of Alabama, Florida, Georgia, Texas and North Carolina and in the U.S. district courts for the Northern District of Georgia and Middle District of Florida. He also has handled appeals on behalf of clients in the Federal Circuit Court of Appeals for the Fourth, Sixth and Eleventh Circuits, and has appeared in the state appellate courts of Alabama, Florida, Georgia, North Carolina and Tennessee.\u003c/p\u003e\n\u003cp\u003eRecently, Randy relocated his practice to Miami, Florida, to establish King \u0026amp; Spalding\u0026rsquo;s office in Miami.\u0026nbsp; He serves as Managing Partner of the firm\u0026rsquo;s Miami office.\u003c/p\u003e","slug":"w-randall-bassett","email":"rbassett@kslaw.com","phone":null,"matters":["\u003cp\u003eServed as lead trial counsel for\u0026nbsp;\u003cstrong\u003eUnited Parcel Service\u003c/strong\u003e\u0026nbsp;in multiple wrongful death and personal injury lawsuits in Alabama, Florida and Texas.\u003c/p\u003e","\u003cp\u003eServed as lead trial counsel for\u0026nbsp;\u003cstrong\u003eR.J. Reynolds\u003c/strong\u003e\u0026nbsp;in dozens of Engle progeny lawsuits in South Florida achieving results far below demands made by plaintiffs, including complete defense verdicts in Miami-Dade and Broward counties.\u003c/p\u003e","\u003cp\u003eServed as lead trial counsel for\u0026nbsp;\u003cstrong\u003eGol Linhas Aereas Inteligentes, SA\u003c/strong\u003e\u0026nbsp;in a three-day virtual trial in Miami-Dade Circuit Court defending Gol from a breach of contract claim involving the sale of six 737 jet aircraft. The court entered judgment in favor of Gol on all claims, which was affirmed by the 3rd DCA in\u0026nbsp;\u003cem\u003eZGA Aircraft Leasing, Inc. v. Webjet Linhas Aereas, SA\u003c/em\u003e, No. 3D22-0320.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":5}]},"expertise":[{"id":16,"guid":"16.capabilities","index":0,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":1,"source":"capabilities"},{"id":764,"guid":"764.smart_tags","index":2,"source":"smartTags"},{"id":761,"guid":"761.smart_tags","index":3,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":4,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":7,"source":"capabilities"},{"id":762,"guid":"762.smart_tags","index":8,"source":"smartTags"},{"id":74,"guid":"74.capabilities","index":9,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":10,"source":"smartTags"},{"id":112,"guid":"112.capabilities","index":11,"source":"capabilities"},{"id":1270,"guid":"1270.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Bassett","nick_name":"Randy","clerkships":[],"first_name":"W. Randall","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Best Lawyers in America","detail":"2010–2016"},{"title":"Chambers USA","detail":"2010–2015"},{"title":"Legal 500","detail":"2010–2016"}],"linked_in_url":"https://www.linkedin.com/in/wrandallbassett/","seodescription":null,"primary_title_id":126,"translated_fields":{"en":{"bio":"\u003cp\u003eRandy Bassett is a first chair trial lawyer, who has tried 40 cases to juries.\u0026nbsp; Randy has represented both foreign and domestic companies in federal and state courts across the United States in individual cases, multidistrict proceedings, and class actions. He focuses on the trial of high exposure cases on behalf of corporate defendants in difficult jurisdictions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRandy has represented companies in a range of industries, including consumer products, pharmaceutical, transportation, technology. His clients include: \u003cstrong\u003eBrown-Forman Corporation, General Motors, Gilead Sciences,\u0026nbsp;Gol Linhas Aereas Inteligentes S.A., Imetric 4D, Logitech, Purdue Pharma LP, R.J. Reynolds Tobacco Company\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong\u003eUnited Parcel Service, Inc.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRandy has handled cases throughout the United States with particular emphasis in jurisdictions designated \"judicial hellholes\" by the American Tort Reform Association. He has tried cases in the state courts of Alabama, Florida, Georgia, Texas and North Carolina and in the U.S. district courts for the Northern District of Georgia and Middle District of Florida. He also has handled appeals on behalf of clients in the Federal Circuit Court of Appeals for the Fourth, Sixth and Eleventh Circuits, and has appeared in the state appellate courts of Alabama, Florida, Georgia, North Carolina and Tennessee.\u003c/p\u003e\n\u003cp\u003eRecently, Randy relocated his practice to Miami, Florida, to establish King \u0026amp; Spalding\u0026rsquo;s office in Miami.\u0026nbsp; He serves as Managing Partner of the firm\u0026rsquo;s Miami office.\u003c/p\u003e","matters":["\u003cp\u003eServed as lead trial counsel for\u0026nbsp;\u003cstrong\u003eUnited Parcel Service\u003c/strong\u003e\u0026nbsp;in multiple wrongful death and personal injury lawsuits in Alabama, Florida and Texas.\u003c/p\u003e","\u003cp\u003eServed as lead trial counsel for\u0026nbsp;\u003cstrong\u003eR.J. Reynolds\u003c/strong\u003e\u0026nbsp;in dozens of Engle progeny lawsuits in South Florida achieving results far below demands made by plaintiffs, including complete defense verdicts in Miami-Dade and Broward counties.\u003c/p\u003e","\u003cp\u003eServed as lead trial counsel for\u0026nbsp;\u003cstrong\u003eGol Linhas Aereas Inteligentes, SA\u003c/strong\u003e\u0026nbsp;in a three-day virtual trial in Miami-Dade Circuit Court defending Gol from a breach of contract claim involving the sale of six 737 jet aircraft. The court entered judgment in favor of Gol on all claims, which was affirmed by the 3rd DCA in\u0026nbsp;\u003cem\u003eZGA Aircraft Leasing, Inc. v. Webjet Linhas Aereas, SA\u003c/em\u003e, No. 3D22-0320.\u003c/p\u003e"],"recognitions":[{"title":"Best Lawyers in America","detail":"2010–2016"},{"title":"Chambers USA","detail":"2010–2015"},{"title":"Legal 500","detail":"2010–2016"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":5463}]},"capability_group_id":3},"created_at":"2025-11-05T05:03:28.000Z","updated_at":"2025-11-05T05:03:28.000Z","searchable_text":"Bassett{{ FIELD }}{:title=\u0026gt;\"Best Lawyers in America\", :detail=\u0026gt;\"2010–2016\"}{{ FIELD }}{:title=\u0026gt;\"Chambers USA\", :detail=\u0026gt;\"2010–2015\"}{{ FIELD }}{:title=\u0026gt;\"Legal 500\", :detail=\u0026gt;\"2010–2016\"}{{ FIELD }}Served as lead trial counsel for United Parcel Service in multiple wrongful death and personal injury lawsuits in Alabama, Florida and Texas.{{ FIELD }}Served as lead trial counsel for R.J. Reynolds in dozens of Engle progeny lawsuits in South Florida achieving results far below demands made by plaintiffs, including complete defense verdicts in Miami-Dade and Broward counties.{{ FIELD }}Served as lead trial counsel for Gol Linhas Aereas Inteligentes, SA in a three-day virtual trial in Miami-Dade Circuit Court defending Gol from a breach of contract claim involving the sale of six 737 jet aircraft. The court entered judgment in favor of Gol on all claims, which was affirmed by the 3rd DCA in ZGA Aircraft Leasing, Inc. v. Webjet Linhas Aereas, SA, No. 3D22-0320.{{ FIELD }}Randy Bassett is a first chair trial lawyer, who has tried 40 cases to juries.  Randy has represented both foreign and domestic companies in federal and state courts across the United States in individual cases, multidistrict proceedings, and class actions. He focuses on the trial of high exposure cases on behalf of corporate defendants in difficult jurisdictions.\nRandy has represented companies in a range of industries, including consumer products, pharmaceutical, transportation, technology. His clients include: Brown-Forman Corporation, General Motors, Gilead Sciences, Gol Linhas Aereas Inteligentes S.A., Imetric 4D, Logitech, Purdue Pharma LP, R.J. Reynolds Tobacco Company and United Parcel Service, Inc.\nRandy has handled cases throughout the United States with particular emphasis in jurisdictions designated \"judicial hellholes\" by the American Tort Reform Association. He has tried cases in the state courts of Alabama, Florida, Georgia, Texas and North Carolina and in the U.S. district courts for the Northern District of Georgia and Middle District of Florida. He also has handled appeals on behalf of clients in the Federal Circuit Court of Appeals for the Fourth, Sixth and Eleventh Circuits, and has appeared in the state appellate courts of Alabama, Florida, Georgia, North Carolina and Tennessee.\nRecently, Randy relocated his practice to Miami, Florida, to establish King \u0026amp; Spalding’s office in Miami.  He serves as Managing Partner of the firm’s Miami office. W Randall Bassett Partner Best Lawyers in America 2010–2016 Chambers USA 2010–2015 Legal 500 2010–2016 The Citadel  University of Georgia University of Georgia School of Law U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Sixth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the District of Hawaii U.S. District Court for the Middle District of Florida U.S. District Court for the Northern District of Florida U.S. District Court for the Southern District of Florida U.S. District Court for the Middle District of Georgia U.S. District Court for the Northern District of Georgia Florida Georgia Hawaii American Bar Association Litigation Counsel of America American Bar Fellow State Bar of Georgia Lawyers Club of Atlanta Defense Research Institute State Bar of Florida Georgia Defense Lawyers Association International Association of Defense Counsel International Society of Barristers Product Liability Advisory Council Served as lead trial counsel for United Parcel Service in multiple wrongful death and personal injury lawsuits in Alabama, Florida and Texas. Served as lead trial counsel for R.J. Reynolds in dozens of Engle progeny lawsuits in South Florida achieving results far below demands made by plaintiffs, including complete defense verdicts in Miami-Dade and Broward counties. Served as lead trial counsel for Gol Linhas Aereas Inteligentes, SA in a three-day virtual trial in Miami-Dade Circuit Court defending Gol from a breach of contract claim involving the sale of six 737 jet aircraft. The court entered judgment in favor of Gol on all claims, which was affirmed by the 3rd DCA in ZGA Aircraft Leasing, Inc. v. Webjet Linhas Aereas, SA, No. 3D22-0320.","searchable_name":"W. Randall Bassett (Randy)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":446413,"version":1,"owner_type":"Person","owner_id":826,"payload":{"bio":"\u003cp\u003eAndy Bayman is a trial lawyer who represents pharmaceutical companies, medical device manufacturers, retailers, automotive manufacturers and other major companies in complex and novel product liability,\u0026nbsp;toxic tort, and other tort\u0026nbsp;cases. He has tried over 20 cases in state and federal courts, many of which are first of kind such as the first pharmaceutical products liability lawsuit ever tried under the theory of \u0026ldquo;Innovator Liability,\u0026rdquo; the first MDL bellwether trial involving an atypical femur fracture allegedly caused by Merck\u0026rsquo;s osteoporosis medicine, Fosamax\u0026reg; and, more recently, the first Zantac case to go to trial.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAndy is often called upon as coordinating and lead counsel on some of the most brand-threatening, high-profile crisis matters for major manufacturers, many of which are in MDLs.\u0026nbsp; He is lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and one of four Defense Co-Leads in personal injury and class actions in the \u003cem\u003eIn Re Zantac \u003c/em\u003eMDL in the United States District Court for the Southern District of Florida and in coordinated state court proceedings in various states.\u003c/p\u003e\n\u003cp\u003eAndy successfully tried the first Zantac case to a defense verdict in Cook County, IL. The plaintiff claimed that ingestion of Zantac for heartburn caused her colon cancer and asked the jury to award $640 million.\u0026nbsp; \u003cem\u003eThe American Lawyer\u003c/em\u003e recognized Andy as a \u0026ldquo;Litigator of the Week\u0026rdquo; for that victory.\u0026nbsp; In his second Zantac trial in Cook County, the jury deadlocked 11-1 in Andy\u0026rsquo;s client\u0026rsquo;s favor. In his third Zantac trial (involving the retrial of two plaintiffs whose cases had previously mistried), Andy and his team won a complete defense verdict in less than 90 minutes.\u0026nbsp;\u0026nbsp;He and his team also won two subsequent Zantac trials in Cook County.\u0026nbsp; Cook County continues to be ranked in the American Tort Reform Association\u0026rsquo;s list of most difficult jurisdictions for corporate defendants and has been labelled \u0026ldquo;Gound Zero for Nuclear Verdicts in the State.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eHe led a King \u0026amp; Spalding team that successfully argued, alongside co-defendants\u0026rsquo; counsel, that the plaintiffs\u0026rsquo; general causation experts in the Zantac MDL should be excluded under FRE 702.\u0026nbsp; At the Daubert hearing, Andy argued, among other things, that the plaintiffs\u0026rsquo; testing expert used unreliable and unvalidated methodologies with a lack of documentation on how experiments were conducted, and that the expert offered to opine on the testing did not perform any of the analyses or assess their reliability himself but rather parroted the results given to him.\u0026nbsp; After excluding the plaintiffs\u0026rsquo; experts in a 340+ page Order, the MDL Court entered summary judgment for the defendants, dismissing thousands of cases and claims and effectively terminating the MDL before any case-specific discovery had begun. The Zantac Daubert win is considered as by far the largest in scale and magnitude of any MDL Daubert win.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAndy has frequently been recognized for his leading practice including by being named as a Product Liability MVP by \u003cem\u003eLaw360 \u003c/em\u003eand in Chambers Nationwide and Legal 500. He is notably a fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers.\u003c/p\u003e\n\u003cp\u003eIn addition to his client work, Andy also is the Co-Chair of the firm\u0026rsquo;s new Product Liability and Mass Tort Practice Group.\u0026nbsp; He served for five years as the\u0026nbsp;Practice Group Leader of King \u0026amp; Spalding\u0026rsquo;s former Trial \u0026amp; Global Disputes practice group, a diverse group of over 550 litigators in 22 offices globally.\u003c/p\u003e","slug":"andrew-bayman","email":"abayman@kslaw.com","phone":null,"matters":["\u003cp\u003eActing as lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and as one of four Defense Co-Leads in personal injury and class actions in the\u0026nbsp;\u003cem\u003eIn Re Zantac\u003c/em\u003e\u0026nbsp;MDL with more than 100,000 claimants in the United States District Court for the Southern District of Florida, as well as in various state courts and States Attorneys General actions.\u003c/p\u003e","\u003cp\u003eActing as co-lead counsel for The Renco Group, Inc. and Doe Run Resources Corp. in connection with thousands of lawsuits pending in the E.D. Missouri (St. Louis) filed on behalf of Peruvian children allegedly injured from exposure to lead and other contaminants at a metallurgical facility in La Oroya, Peru.\u003c/p\u003e","\u003cp\u003eActing as lead counsel for ride share company in defending against claims of driver assault.\u003c/p\u003e","\u003cp\u003eSuccessfully represented 3M in defeating two Combat Arms Earplugs plaintiffs\u0026rsquo; lawsuit to enjoin 3M from issuing dividends and spinning off its healthcare business.\u003c/p\u003e","\u003cp\u003eRepresented pharmaceutical giant GlaxoSmithKline (\u0026ldquo;GSK\u0026rdquo;) in the first lawsuit ever tried under a theory of \u0026ldquo;Innovator Liability\u0026rdquo; in which the plaintiff alleged that GSK was liable for the suicide of her late husband, the Chair of a global law firm\u0026rsquo;s Corporate and Securities practice following his ingestion of a generic version of GSK\u0026rsquo;s antidepressant Paxil\u0026reg;. The lawsuit alleged that the company had been negligent in its failure to warn of an increased risk of suicidal behavior in adult patients over the age of twenty-four. The United States District Court for the Northern District of Illinois denied GSK\u0026rsquo;s motion for summary judgment and the case proceeded to trial with the plaintiff seeking to hold GSK liable for injuries stemming from the ingestion of a product it did not manufacture. The case was the subject of extensive media coverage. After a five-week jury trial of which three days were spent deliberating, the jury came back with a verdict for the plaintiff in the amount of $3 million. This award was significantly less than the $39 million in damages that the plaintiff requested and less than the $14 million in economic losses that was put in front of the jury. The Seventh Circuit reversed the verdict and rendered judgment in GSK\u0026rsquo;s favor on federal preemption grounds in August 2018.\u003c/p\u003e","\u003cp\u003eObtained a complete defense verdict for Merck in the first bellwether trial in an MDL in the U.S. District Court for the District of New Jersey (\u003cem\u003eGlynn v. Merck)\u003c/em\u003e, in a case alleging that Merck\u0026rsquo;s osteoporosis drug Fosamax\u0026reg; caused the plaintiff\u0026rsquo;s atypical femur fracture. Following that trial, Judge Joel Pisano entered an Order to Show Cause dismissing Glynn and hundreds of other Fosamax\u0026reg; atypical femur fracture cases in the MDL on federal preemption grounds. Merck ultimately prevailed on preemption in that case in the United States Supreme Court.\u0026nbsp;\u003cem\u003eMerck v. Albrecht\u003c/em\u003e, 139 S.Ct. 1668 (2019).\u003c/p\u003e","\u003cp\u003eServes as lead, national coordinating counsel and trial counsel in product liability litigation involving allegations that\u0026nbsp;\u003cstrong\u003eGSK\u0026rsquo;s\u0026nbsp;\u003c/strong\u003eantidepressant, Paxil\u0026reg;, causes birth defects. In this role, which has spanned more than a decade and involves emotionally charged cases that are brand and business threatening, Andy and the King \u0026amp; Spalding team have defeated certification of both state and national classes of Paxil\u0026reg; consumers on consumer fraud, medical monitoring and personal injury allegations.\u003c/p\u003e","\u003cp\u003eActed as trial counsel for an international medical device company in female pelvic mesh litigation.\u003c/p\u003e","\u003cp\u003eActing as lead counsel for a Fortune 50 company in an MDL pending in the Northern District of California alleging that it marketed and sold purportedly defective JUUL e\u0026shy; cigarette products, including to minors.\u003c/p\u003e","\u003cp\u003eAchieved a motion to dismiss from the U.S. District Court of South Carolina as lead counsel for\u0026nbsp;\u003cstrong\u003eAllergan\u0026nbsp;\u003c/strong\u003ein a case alleging lip lesions and Lyme-disease-like symptoms after receiving injections with Allergan\u0026rsquo;s product Juviderm\u0026reg;, a Class III medical device.\u003c/p\u003e","\u003cp\u003eActed as Lead trial counsel or second chair trial counsel in 16 automotive product liability cases and in a dealership termination trial in the federal and state courts in New York, New Jersey, Georgia, Mississippi and Alabama.\u003c/p\u003e","\u003cp\u003eServed as national coordinating counsel for\u0026nbsp;\u003cstrong\u003ea large consumer healthcare product manufacturer\u0026nbsp;\u003c/strong\u003eand has supervised a national document collection and company-wide interviews for that client.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003ea major medical device manufacturer\u0026nbsp;\u003c/strong\u003eas national coordinating counsel and lead trial counsel in product liability class actions and individual lawsuits involving a recalled medical device in which death or serious injury was alleged.\u003c/p\u003e","\u003cp\u003eAchieved a defense verdict for\u0026nbsp;\u003cstrong\u003eNissan\u0026nbsp;\u003c/strong\u003eas trial counsel in the first-ever case tried involving an alleged defect in a motorized seatbelt system\u0026nbsp;\u003cem\u003e(Smith-Green v. Nissan).\u003c/em\u003e\u003c/p\u003e","\u003cp\u003eServed as national trial counsel for\u0026nbsp;\u003cstrong\u003eQuest Diagnostics Incorporated,\u0026nbsp;\u003c/strong\u003ethe country\u0026rsquo;s largest private clinical laboratory company, in lawsuits arising out of the interpretation of laboratory specimens.\u003c/p\u003e","\u003cp\u003eActed as lead trial counsel in cases in Missouri and Ohio in which it was alleged that a misread Pap smear led to a delay in the diagnosis of cervical cancer and caused wrongful death or the loss of fertility.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":131}]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":1,"source":"capabilities"},{"id":3,"guid":"3.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":4,"source":"smartTags"},{"id":17,"guid":"17.capabilities","index":5,"source":"capabilities"},{"id":16,"guid":"16.capabilities","index":6,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":7,"source":"smartTags"},{"id":112,"guid":"112.capabilities","index":8,"source":"capabilities"},{"id":764,"guid":"764.smart_tags","index":9,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":10,"source":"smartTags"},{"id":1256,"guid":"1256.smart_tags","index":11,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Bayman","nick_name":"Andy","clerkships":[],"first_name":"Andrew","title_rank":9999,"updated_by":202,"law_schools":[{"id":2442,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1989-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"T.","name_suffix":"","recognitions":[{"title":"Named Distinguished Leader","detail":"DAILY REPORT’S SOUTHEASTERN LEGAL AWARDS, 2024"},{"title":"Named Litigator of the Week","detail":"THE AMERICAN LAWYER, MAY 2024"},{"title":"“Highly Reputable, Skilled and a Phenomenal Counselor”","detail":"CHAMBERS USA"},{"title":"Named National Practice Area Star for Health Care and Mass Tort; Local Litigation Star.","detail":"Benchmark, 2019"},{"title":"Named a 2017 Product Liability MVP","detail":"Law360"},{"title":"Named Atlanta Product Liability Litigation-Defendants “Lawyer of the Year”","detail":"Best Lawyers, 2015"},{"title":"Ranked in Product Liability and Mass Torts (Nationwide)","detail":"Chambers USA"},{"title":"Representing “major pharmaceutical companies on their most significant product liability cases.” ","detail":"CHAMBER USA"},{"title":"Representing \"market-leading MDLs in the life sciences sector.\" ","detail":"CHAMBERS USA"},{"title":"“Accessible, responsive and will move heaven and earth to accommodate the client’s needs.”","detail":"Chambers USA"},{"title":"Ranked as a top defense lawyer in the nation","detail":"Super Lawyers Corporate Counsel, 2009–2022"},{"title":"Selected as a Georgia “Super Lawyer”","detail":"Law \u0026 Politics and Atlanta magazine, 2006–2022"},{"title":"Recognized as having “substantial lead trial expertise” ","detail":"Legal 500"},{"title":"An “excellent lawyer” who “gets results at a great value in automotive and pharmaceutical products litigation.” ","detail":"Legal 500"},{"title":"Elected Fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers","detail":"Litigation Counsel of America, 2014"},{"title":"Named by The Best Lawyers in America","detail":"2006–2022"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAndy Bayman is a trial lawyer who represents pharmaceutical companies, medical device manufacturers, retailers, automotive manufacturers and other major companies in complex and novel product liability,\u0026nbsp;toxic tort, and other tort\u0026nbsp;cases. He has tried over 20 cases in state and federal courts, many of which are first of kind such as the first pharmaceutical products liability lawsuit ever tried under the theory of \u0026ldquo;Innovator Liability,\u0026rdquo; the first MDL bellwether trial involving an atypical femur fracture allegedly caused by Merck\u0026rsquo;s osteoporosis medicine, Fosamax\u0026reg; and, more recently, the first Zantac case to go to trial.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAndy is often called upon as coordinating and lead counsel on some of the most brand-threatening, high-profile crisis matters for major manufacturers, many of which are in MDLs.\u0026nbsp; He is lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and one of four Defense Co-Leads in personal injury and class actions in the \u003cem\u003eIn Re Zantac \u003c/em\u003eMDL in the United States District Court for the Southern District of Florida and in coordinated state court proceedings in various states.\u003c/p\u003e\n\u003cp\u003eAndy successfully tried the first Zantac case to a defense verdict in Cook County, IL. The plaintiff claimed that ingestion of Zantac for heartburn caused her colon cancer and asked the jury to award $640 million.\u0026nbsp; \u003cem\u003eThe American Lawyer\u003c/em\u003e recognized Andy as a \u0026ldquo;Litigator of the Week\u0026rdquo; for that victory.\u0026nbsp; In his second Zantac trial in Cook County, the jury deadlocked 11-1 in Andy\u0026rsquo;s client\u0026rsquo;s favor. In his third Zantac trial (involving the retrial of two plaintiffs whose cases had previously mistried), Andy and his team won a complete defense verdict in less than 90 minutes.\u0026nbsp;\u0026nbsp;He and his team also won two subsequent Zantac trials in Cook County.\u0026nbsp; Cook County continues to be ranked in the American Tort Reform Association\u0026rsquo;s list of most difficult jurisdictions for corporate defendants and has been labelled \u0026ldquo;Gound Zero for Nuclear Verdicts in the State.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eHe led a King \u0026amp; Spalding team that successfully argued, alongside co-defendants\u0026rsquo; counsel, that the plaintiffs\u0026rsquo; general causation experts in the Zantac MDL should be excluded under FRE 702.\u0026nbsp; At the Daubert hearing, Andy argued, among other things, that the plaintiffs\u0026rsquo; testing expert used unreliable and unvalidated methodologies with a lack of documentation on how experiments were conducted, and that the expert offered to opine on the testing did not perform any of the analyses or assess their reliability himself but rather parroted the results given to him.\u0026nbsp; After excluding the plaintiffs\u0026rsquo; experts in a 340+ page Order, the MDL Court entered summary judgment for the defendants, dismissing thousands of cases and claims and effectively terminating the MDL before any case-specific discovery had begun. The Zantac Daubert win is considered as by far the largest in scale and magnitude of any MDL Daubert win.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAndy has frequently been recognized for his leading practice including by being named as a Product Liability MVP by \u003cem\u003eLaw360 \u003c/em\u003eand in Chambers Nationwide and Legal 500. He is notably a fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers.\u003c/p\u003e\n\u003cp\u003eIn addition to his client work, Andy also is the Co-Chair of the firm\u0026rsquo;s new Product Liability and Mass Tort Practice Group.\u0026nbsp; He served for five years as the\u0026nbsp;Practice Group Leader of King \u0026amp; Spalding\u0026rsquo;s former Trial \u0026amp; Global Disputes practice group, a diverse group of over 550 litigators in 22 offices globally.\u003c/p\u003e","matters":["\u003cp\u003eActing as lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and as one of four Defense Co-Leads in personal injury and class actions in the\u0026nbsp;\u003cem\u003eIn Re Zantac\u003c/em\u003e\u0026nbsp;MDL with more than 100,000 claimants in the United States District Court for the Southern District of Florida, as well as in various state courts and States Attorneys General actions.\u003c/p\u003e","\u003cp\u003eActing as co-lead counsel for The Renco Group, Inc. and Doe Run Resources Corp. in connection with thousands of lawsuits pending in the E.D. Missouri (St. Louis) filed on behalf of Peruvian children allegedly injured from exposure to lead and other contaminants at a metallurgical facility in La Oroya, Peru.\u003c/p\u003e","\u003cp\u003eActing as lead counsel for ride share company in defending against claims of driver assault.\u003c/p\u003e","\u003cp\u003eSuccessfully represented 3M in defeating two Combat Arms Earplugs plaintiffs\u0026rsquo; lawsuit to enjoin 3M from issuing dividends and spinning off its healthcare business.\u003c/p\u003e","\u003cp\u003eRepresented pharmaceutical giant GlaxoSmithKline (\u0026ldquo;GSK\u0026rdquo;) in the first lawsuit ever tried under a theory of \u0026ldquo;Innovator Liability\u0026rdquo; in which the plaintiff alleged that GSK was liable for the suicide of her late husband, the Chair of a global law firm\u0026rsquo;s Corporate and Securities practice following his ingestion of a generic version of GSK\u0026rsquo;s antidepressant Paxil\u0026reg;. The lawsuit alleged that the company had been negligent in its failure to warn of an increased risk of suicidal behavior in adult patients over the age of twenty-four. The United States District Court for the Northern District of Illinois denied GSK\u0026rsquo;s motion for summary judgment and the case proceeded to trial with the plaintiff seeking to hold GSK liable for injuries stemming from the ingestion of a product it did not manufacture. The case was the subject of extensive media coverage. After a five-week jury trial of which three days were spent deliberating, the jury came back with a verdict for the plaintiff in the amount of $3 million. This award was significantly less than the $39 million in damages that the plaintiff requested and less than the $14 million in economic losses that was put in front of the jury. The Seventh Circuit reversed the verdict and rendered judgment in GSK\u0026rsquo;s favor on federal preemption grounds in August 2018.\u003c/p\u003e","\u003cp\u003eObtained a complete defense verdict for Merck in the first bellwether trial in an MDL in the U.S. District Court for the District of New Jersey (\u003cem\u003eGlynn v. Merck)\u003c/em\u003e, in a case alleging that Merck\u0026rsquo;s osteoporosis drug Fosamax\u0026reg; caused the plaintiff\u0026rsquo;s atypical femur fracture. Following that trial, Judge Joel Pisano entered an Order to Show Cause dismissing Glynn and hundreds of other Fosamax\u0026reg; atypical femur fracture cases in the MDL on federal preemption grounds. Merck ultimately prevailed on preemption in that case in the United States Supreme Court.\u0026nbsp;\u003cem\u003eMerck v. Albrecht\u003c/em\u003e, 139 S.Ct. 1668 (2019).\u003c/p\u003e","\u003cp\u003eServes as lead, national coordinating counsel and trial counsel in product liability litigation involving allegations that\u0026nbsp;\u003cstrong\u003eGSK\u0026rsquo;s\u0026nbsp;\u003c/strong\u003eantidepressant, Paxil\u0026reg;, causes birth defects. In this role, which has spanned more than a decade and involves emotionally charged cases that are brand and business threatening, Andy and the King \u0026amp; Spalding team have defeated certification of both state and national classes of Paxil\u0026reg; consumers on consumer fraud, medical monitoring and personal injury allegations.\u003c/p\u003e","\u003cp\u003eActed as trial counsel for an international medical device company in female pelvic mesh litigation.\u003c/p\u003e","\u003cp\u003eActing as lead counsel for a Fortune 50 company in an MDL pending in the Northern District of California alleging that it marketed and sold purportedly defective JUUL e\u0026shy; cigarette products, including to minors.\u003c/p\u003e","\u003cp\u003eAchieved a motion to dismiss from the U.S. District Court of South Carolina as lead counsel for\u0026nbsp;\u003cstrong\u003eAllergan\u0026nbsp;\u003c/strong\u003ein a case alleging lip lesions and Lyme-disease-like symptoms after receiving injections with Allergan\u0026rsquo;s product Juviderm\u0026reg;, a Class III medical device.\u003c/p\u003e","\u003cp\u003eActed as Lead trial counsel or second chair trial counsel in 16 automotive product liability cases and in a dealership termination trial in the federal and state courts in New York, New Jersey, Georgia, Mississippi and Alabama.\u003c/p\u003e","\u003cp\u003eServed as national coordinating counsel for\u0026nbsp;\u003cstrong\u003ea large consumer healthcare product manufacturer\u0026nbsp;\u003c/strong\u003eand has supervised a national document collection and company-wide interviews for that client.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong\u003ea major medical device manufacturer\u0026nbsp;\u003c/strong\u003eas national coordinating counsel and lead trial counsel in product liability class actions and individual lawsuits involving a recalled medical device in which death or serious injury was alleged.\u003c/p\u003e","\u003cp\u003eAchieved a defense verdict for\u0026nbsp;\u003cstrong\u003eNissan\u0026nbsp;\u003c/strong\u003eas trial counsel in the first-ever case tried involving an alleged defect in a motorized seatbelt system\u0026nbsp;\u003cem\u003e(Smith-Green v. Nissan).\u003c/em\u003e\u003c/p\u003e","\u003cp\u003eServed as national trial counsel for\u0026nbsp;\u003cstrong\u003eQuest Diagnostics Incorporated,\u0026nbsp;\u003c/strong\u003ethe country\u0026rsquo;s largest private clinical laboratory company, in lawsuits arising out of the interpretation of laboratory specimens.\u003c/p\u003e","\u003cp\u003eActed as lead trial counsel in cases in Missouri and Ohio in which it was alleged that a misread Pap smear led to a delay in the diagnosis of cervical cancer and caused wrongful death or the loss of fertility.\u003c/p\u003e"],"recognitions":[{"title":"Named Distinguished Leader","detail":"DAILY REPORT’S SOUTHEASTERN LEGAL AWARDS, 2024"},{"title":"Named Litigator of the Week","detail":"THE AMERICAN LAWYER, MAY 2024"},{"title":"“Highly Reputable, Skilled and a Phenomenal Counselor”","detail":"CHAMBERS USA"},{"title":"Named National Practice Area Star for Health Care and Mass Tort; Local Litigation Star.","detail":"Benchmark, 2019"},{"title":"Named a 2017 Product Liability MVP","detail":"Law360"},{"title":"Named Atlanta Product Liability Litigation-Defendants “Lawyer of the Year”","detail":"Best Lawyers, 2015"},{"title":"Ranked in Product Liability and Mass Torts (Nationwide)","detail":"Chambers USA"},{"title":"Representing “major pharmaceutical companies on their most significant product liability cases.” ","detail":"CHAMBER USA"},{"title":"Representing \"market-leading MDLs in the life sciences sector.\" ","detail":"CHAMBERS USA"},{"title":"“Accessible, responsive and will move heaven and earth to accommodate the client’s needs.”","detail":"Chambers USA"},{"title":"Ranked as a top defense lawyer in the nation","detail":"Super Lawyers Corporate Counsel, 2009–2022"},{"title":"Selected as a Georgia “Super Lawyer”","detail":"Law \u0026 Politics and Atlanta magazine, 2006–2022"},{"title":"Recognized as having “substantial lead trial expertise” ","detail":"Legal 500"},{"title":"An “excellent lawyer” who “gets results at a great value in automotive and pharmaceutical products litigation.” ","detail":"Legal 500"},{"title":"Elected Fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers","detail":"Litigation Counsel of America, 2014"},{"title":"Named by The Best Lawyers in America","detail":"2006–2022"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":719}]},"capability_group_id":3},"created_at":"2026-03-03T21:41:51.000Z","updated_at":"2026-03-03T21:41:51.000Z","searchable_text":"Bayman{{ FIELD }}{:title=\u0026gt;\"Named Distinguished Leader\", :detail=\u0026gt;\"DAILY REPORT’S SOUTHEASTERN LEGAL AWARDS, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Named Litigator of the Week\", :detail=\u0026gt;\"THE AMERICAN LAWYER, MAY 2024\"}{{ FIELD }}{:title=\u0026gt;\"“Highly Reputable, Skilled and a Phenomenal Counselor”\", :detail=\u0026gt;\"CHAMBERS USA\"}{{ FIELD }}{:title=\u0026gt;\"Named National Practice Area Star for Health Care and Mass Tort; Local Litigation Star.\", :detail=\u0026gt;\"Benchmark, 2019\"}{{ FIELD }}{:title=\u0026gt;\"Named a 2017 Product Liability MVP\", :detail=\u0026gt;\"Law360\"}{{ FIELD }}{:title=\u0026gt;\"Named Atlanta Product Liability Litigation-Defendants “Lawyer of the Year”\", :detail=\u0026gt;\"Best Lawyers, 2015\"}{{ FIELD }}{:title=\u0026gt;\"Ranked in Product Liability and Mass Torts (Nationwide)\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Representing “major pharmaceutical companies on their most significant product liability cases.” \", :detail=\u0026gt;\"CHAMBER USA\"}{{ FIELD }}{:title=\u0026gt;\"Representing \\\"market-leading MDLs in the life sciences sector.\\\" \", :detail=\u0026gt;\"CHAMBERS USA\"}{{ FIELD }}{:title=\u0026gt;\"“Accessible, responsive and will move heaven and earth to accommodate the client’s needs.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Ranked as a top defense lawyer in the nation\", :detail=\u0026gt;\"Super Lawyers Corporate Counsel, 2009–2022\"}{{ FIELD }}{:title=\u0026gt;\"Selected as a Georgia “Super Lawyer”\", :detail=\u0026gt;\"Law \u0026amp; Politics and Atlanta magazine, 2006–2022\"}{{ FIELD }}{:title=\u0026gt;\"Recognized as having “substantial lead trial expertise” \", :detail=\u0026gt;\"Legal 500\"}{{ FIELD }}{:title=\u0026gt;\"An “excellent lawyer” who “gets results at a great value in automotive and pharmaceutical products litigation.” \", :detail=\u0026gt;\"Legal 500\"}{{ FIELD }}{:title=\u0026gt;\"Elected Fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers\", :detail=\u0026gt;\"Litigation Counsel of America, 2014\"}{{ FIELD }}{:title=\u0026gt;\"Named by The Best Lawyers in America\", :detail=\u0026gt;\"2006–2022\"}{{ FIELD }}Acting as lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and as one of four Defense Co-Leads in personal injury and class actions in the In Re Zantac MDL with more than 100,000 claimants in the United States District Court for the Southern District of Florida, as well as in various state courts and States Attorneys General actions.{{ FIELD }}Acting as co-lead counsel for The Renco Group, Inc. and Doe Run Resources Corp. in connection with thousands of lawsuits pending in the E.D. Missouri (St. Louis) filed on behalf of Peruvian children allegedly injured from exposure to lead and other contaminants at a metallurgical facility in La Oroya, Peru.{{ FIELD }}Acting as lead counsel for ride share company in defending against claims of driver assault.{{ FIELD }}Successfully represented 3M in defeating two Combat Arms Earplugs plaintiffs’ lawsuit to enjoin 3M from issuing dividends and spinning off its healthcare business.{{ FIELD }}Represented pharmaceutical giant GlaxoSmithKline (“GSK”) in the first lawsuit ever tried under a theory of “Innovator Liability” in which the plaintiff alleged that GSK was liable for the suicide of her late husband, the Chair of a global law firm’s Corporate and Securities practice following his ingestion of a generic version of GSK’s antidepressant Paxil®. The lawsuit alleged that the company had been negligent in its failure to warn of an increased risk of suicidal behavior in adult patients over the age of twenty-four. The United States District Court for the Northern District of Illinois denied GSK’s motion for summary judgment and the case proceeded to trial with the plaintiff seeking to hold GSK liable for injuries stemming from the ingestion of a product it did not manufacture. The case was the subject of extensive media coverage. After a five-week jury trial of which three days were spent deliberating, the jury came back with a verdict for the plaintiff in the amount of $3 million. This award was significantly less than the $39 million in damages that the plaintiff requested and less than the $14 million in economic losses that was put in front of the jury. The Seventh Circuit reversed the verdict and rendered judgment in GSK’s favor on federal preemption grounds in August 2018.{{ FIELD }}Obtained a complete defense verdict for Merck in the first bellwether trial in an MDL in the U.S. District Court for the District of New Jersey (Glynn v. Merck), in a case alleging that Merck’s osteoporosis drug Fosamax® caused the plaintiff’s atypical femur fracture. Following that trial, Judge Joel Pisano entered an Order to Show Cause dismissing Glynn and hundreds of other Fosamax® atypical femur fracture cases in the MDL on federal preemption grounds. Merck ultimately prevailed on preemption in that case in the United States Supreme Court. Merck v. Albrecht, 139 S.Ct. 1668 (2019).{{ FIELD }}Serves as lead, national coordinating counsel and trial counsel in product liability litigation involving allegations that GSK’s antidepressant, Paxil®, causes birth defects. In this role, which has spanned more than a decade and involves emotionally charged cases that are brand and business threatening, Andy and the King \u0026amp; Spalding team have defeated certification of both state and national classes of Paxil® consumers on consumer fraud, medical monitoring and personal injury allegations.{{ FIELD }}Acted as trial counsel for an international medical device company in female pelvic mesh litigation.{{ FIELD }}Acting as lead counsel for a Fortune 50 company in an MDL pending in the Northern District of California alleging that it marketed and sold purportedly defective JUUL e­ cigarette products, including to minors.{{ FIELD }}Achieved a motion to dismiss from the U.S. District Court of South Carolina as lead counsel for Allergan in a case alleging lip lesions and Lyme-disease-like symptoms after receiving injections with Allergan’s product Juviderm®, a Class III medical device.{{ FIELD }}Acted as Lead trial counsel or second chair trial counsel in 16 automotive product liability cases and in a dealership termination trial in the federal and state courts in New York, New Jersey, Georgia, Mississippi and Alabama.{{ FIELD }}Served as national coordinating counsel for a large consumer healthcare product manufacturer and has supervised a national document collection and company-wide interviews for that client.{{ FIELD }}Represented a major medical device manufacturer as national coordinating counsel and lead trial counsel in product liability class actions and individual lawsuits involving a recalled medical device in which death or serious injury was alleged.{{ FIELD }}Achieved a defense verdict for Nissan as trial counsel in the first-ever case tried involving an alleged defect in a motorized seatbelt system (Smith-Green v. Nissan).{{ FIELD }}Served as national trial counsel for Quest Diagnostics Incorporated, the country’s largest private clinical laboratory company, in lawsuits arising out of the interpretation of laboratory specimens.{{ FIELD }}Acted as lead trial counsel in cases in Missouri and Ohio in which it was alleged that a misread Pap smear led to a delay in the diagnosis of cervical cancer and caused wrongful death or the loss of fertility.{{ FIELD }}Andy Bayman is a trial lawyer who represents pharmaceutical companies, medical device manufacturers, retailers, automotive manufacturers and other major companies in complex and novel product liability, toxic tort, and other tort cases. He has tried over 20 cases in state and federal courts, many of which are first of kind such as the first pharmaceutical products liability lawsuit ever tried under the theory of “Innovator Liability,” the first MDL bellwether trial involving an atypical femur fracture allegedly caused by Merck’s osteoporosis medicine, Fosamax® and, more recently, the first Zantac case to go to trial.\nAndy is often called upon as coordinating and lead counsel on some of the most brand-threatening, high-profile crisis matters for major manufacturers, many of which are in MDLs.  He is lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and one of four Defense Co-Leads in personal injury and class actions in the In Re Zantac MDL in the United States District Court for the Southern District of Florida and in coordinated state court proceedings in various states.\nAndy successfully tried the first Zantac case to a defense verdict in Cook County, IL. The plaintiff claimed that ingestion of Zantac for heartburn caused her colon cancer and asked the jury to award $640 million.  The American Lawyer recognized Andy as a “Litigator of the Week” for that victory.  In his second Zantac trial in Cook County, the jury deadlocked 11-1 in Andy’s client’s favor. In his third Zantac trial (involving the retrial of two plaintiffs whose cases had previously mistried), Andy and his team won a complete defense verdict in less than 90 minutes.  He and his team also won two subsequent Zantac trials in Cook County.  Cook County continues to be ranked in the American Tort Reform Association’s list of most difficult jurisdictions for corporate defendants and has been labelled “Gound Zero for Nuclear Verdicts in the State.”\nHe led a King \u0026amp; Spalding team that successfully argued, alongside co-defendants’ counsel, that the plaintiffs’ general causation experts in the Zantac MDL should be excluded under FRE 702.  At the Daubert hearing, Andy argued, among other things, that the plaintiffs’ testing expert used unreliable and unvalidated methodologies with a lack of documentation on how experiments were conducted, and that the expert offered to opine on the testing did not perform any of the analyses or assess their reliability himself but rather parroted the results given to him.  After excluding the plaintiffs’ experts in a 340+ page Order, the MDL Court entered summary judgment for the defendants, dismissing thousands of cases and claims and effectively terminating the MDL before any case-specific discovery had begun. The Zantac Daubert win is considered as by far the largest in scale and magnitude of any MDL Daubert win. \nAndy has frequently been recognized for his leading practice including by being named as a Product Liability MVP by Law360 and in Chambers Nationwide and Legal 500. He is notably a fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers.\nIn addition to his client work, Andy also is the Co-Chair of the firm’s new Product Liability and Mass Tort Practice Group.  He served for five years as the Practice Group Leader of King \u0026amp; Spalding’s former Trial \u0026amp; Global Disputes practice group, a diverse group of over 550 litigators in 22 offices globally. Andrew T Bayman Partner Named Distinguished Leader DAILY REPORT’S SOUTHEASTERN LEGAL AWARDS, 2024 Named Litigator of the Week THE AMERICAN LAWYER, MAY 2024 “Highly Reputable, Skilled and a Phenomenal Counselor” CHAMBERS USA Named National Practice Area Star for Health Care and Mass Tort; Local Litigation Star. Benchmark, 2019 Named a 2017 Product Liability MVP Law360 Named Atlanta Product Liability Litigation-Defendants “Lawyer of the Year” Best Lawyers, 2015 Ranked in Product Liability and Mass Torts (Nationwide) Chambers USA Representing “major pharmaceutical companies on their most significant product liability cases.”  CHAMBER USA Representing \"market-leading MDLs in the life sciences sector.\"  CHAMBERS USA “Accessible, responsive and will move heaven and earth to accommodate the client’s needs.” Chambers USA Ranked as a top defense lawyer in the nation Super Lawyers Corporate Counsel, 2009–2022 Selected as a Georgia “Super Lawyer” Law \u0026amp; Politics and Atlanta magazine, 2006–2022 Recognized as having “substantial lead trial expertise”  Legal 500 An “excellent lawyer” who “gets results at a great value in automotive and pharmaceutical products litigation.”  Legal 500 Elected Fellow of the Litigation Counsel of America, an honorary society limited to less than .05% of U.S. lawyers Litigation Counsel of America, 2014 Named by The Best Lawyers in America 2006–2022 Miami University-Oxford  Vanderbilt University Vanderbilt University School of Law Supreme Court of the United States U.S. Court of Appeals for the Third Circuit U.S. Court of Appeals for the Seventh Circuit U.S. Court of Appeals for the Tenth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Western District of Michigan U.S. District Court for the Western District of Tennessee U.S. District Court for the Central District of Illinois U.S. District Court for the Eastern District of Wisconsin U.S. District Court for the District of Colorado U.S. District Court for the Middle District of Georgia U.S. District Court for the Northern District of Georgia U.S. District Court for the Southern District of Georgia Georgia Court of Appeals of Georgia Supreme Court of Georgia American Bar Association State Bar of Georgia Atlanta Bar Association Federal Bar Association Acting as lead counsel for Boehringer Ingelheim Pharmaceuticals, Inc. and as one of four Defense Co-Leads in personal injury and class actions in the In Re Zantac MDL with more than 100,000 claimants in the United States District Court for the Southern District of Florida, as well as in various state courts and States Attorneys General actions. Acting as co-lead counsel for The Renco Group, Inc. and Doe Run Resources Corp. in connection with thousands of lawsuits pending in the E.D. Missouri (St. Louis) filed on behalf of Peruvian children allegedly injured from exposure to lead and other contaminants at a metallurgical facility in La Oroya, Peru. Acting as lead counsel for ride share company in defending against claims of driver assault. Successfully represented 3M in defeating two Combat Arms Earplugs plaintiffs’ lawsuit to enjoin 3M from issuing dividends and spinning off its healthcare business. Represented pharmaceutical giant GlaxoSmithKline (“GSK”) in the first lawsuit ever tried under a theory of “Innovator Liability” in which the plaintiff alleged that GSK was liable for the suicide of her late husband, the Chair of a global law firm’s Corporate and Securities practice following his ingestion of a generic version of GSK’s antidepressant Paxil®. The lawsuit alleged that the company had been negligent in its failure to warn of an increased risk of suicidal behavior in adult patients over the age of twenty-four. The United States District Court for the Northern District of Illinois denied GSK’s motion for summary judgment and the case proceeded to trial with the plaintiff seeking to hold GSK liable for injuries stemming from the ingestion of a product it did not manufacture. The case was the subject of extensive media coverage. After a five-week jury trial of which three days were spent deliberating, the jury came back with a verdict for the plaintiff in the amount of $3 million. This award was significantly less than the $39 million in damages that the plaintiff requested and less than the $14 million in economic losses that was put in front of the jury. The Seventh Circuit reversed the verdict and rendered judgment in GSK’s favor on federal preemption grounds in August 2018. Obtained a complete defense verdict for Merck in the first bellwether trial in an MDL in the U.S. District Court for the District of New Jersey (Glynn v. Merck), in a case alleging that Merck’s osteoporosis drug Fosamax® caused the plaintiff’s atypical femur fracture. Following that trial, Judge Joel Pisano entered an Order to Show Cause dismissing Glynn and hundreds of other Fosamax® atypical femur fracture cases in the MDL on federal preemption grounds. Merck ultimately prevailed on preemption in that case in the United States Supreme Court. Merck v. Albrecht, 139 S.Ct. 1668 (2019). Serves as lead, national coordinating counsel and trial counsel in product liability litigation involving allegations that GSK’s antidepressant, Paxil®, causes birth defects. In this role, which has spanned more than a decade and involves emotionally charged cases that are brand and business threatening, Andy and the King \u0026amp; Spalding team have defeated certification of both state and national classes of Paxil® consumers on consumer fraud, medical monitoring and personal injury allegations. Acted as trial counsel for an international medical device company in female pelvic mesh litigation. Acting as lead counsel for a Fortune 50 company in an MDL pending in the Northern District of California alleging that it marketed and sold purportedly defective JUUL e­ cigarette products, including to minors. Achieved a motion to dismiss from the U.S. District Court of South Carolina as lead counsel for Allergan in a case alleging lip lesions and Lyme-disease-like symptoms after receiving injections with Allergan’s product Juviderm®, a Class III medical device. Acted as Lead trial counsel or second chair trial counsel in 16 automotive product liability cases and in a dealership termination trial in the federal and state courts in New York, New Jersey, Georgia, Mississippi and Alabama. Served as national coordinating counsel for a large consumer healthcare product manufacturer and has supervised a national document collection and company-wide interviews for that client. Represented a major medical device manufacturer as national coordinating counsel and lead trial counsel in product liability class actions and individual lawsuits involving a recalled medical device in which death or serious injury was alleged. Achieved a defense verdict for Nissan as trial counsel in the first-ever case tried involving an alleged defect in a motorized seatbelt system (Smith-Green v. Nissan). Served as national trial counsel for Quest Diagnostics Incorporated, the country’s largest private clinical laboratory company, in lawsuits arising out of the interpretation of laboratory specimens. Acted as lead trial counsel in cases in Missouri and Ohio in which it was alleged that a misread Pap smear led to a delay in the diagnosis of cervical cancer and caused wrongful death or the loss of fertility.","searchable_name":"Andrew T. Bayman (Andy)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":436417,"version":1,"owner_type":"Person","owner_id":3488,"payload":{"bio":"\u003cp\u003eJessica Beess und Chrostin is a partner in King \u0026amp; Spalding\u0026rsquo;s Trial and Global Disputes Group.\u0026nbsp; Jessica\u0026rsquo;s practice focuses on complex international dispute resolution, with particular expertise in high-stakes commercial, investor-state, construction, and global award enforcement disputes.\u0026nbsp; Jessica regularly represents clients in international disputes in the infrastructure, oil and gas, mining, construction, and renewable energy sectors, and has significant experience in consumer goods, real estate, and telecommunications disputes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJessica is a zealous advocate for her clients and strives tirelessly to ensure they receive the best legal representation. She understands that representing her clients\u0026rsquo; interests requires understanding their business and objectives, and tailoring the strategy to achieve the best possible outcome, whether inside or out of the hearing room. Jessica represents clients in arbitrations before all major arbitral forums, including the AAA, ICC, ICDR, ICSID, JAMS, LCIA, and SCC as well as ad hoc arbitrations, such as UNCITRAL. She is experienced in all phases of international arbitration and award enforcement, and handles disputes from inception to collection. Jessica also regularly represents clients global award recognition and enforcement efforts as coordinating counsel and in litigations before U.S. courts under the New York Convention and the Federal Arbitration Act.\u003c/p\u003e\n\u003cp\u003eJessica represents clients in jurisdictions across the world. Her matters include representing a wind farm owner in a construction arbitration dispute with a turbine supplier and operations \u0026amp; maintenance provider (concerning the latter\u0026rsquo;s failure to comply with O\u0026amp;M obligations and failure to remediate certain serial defects); representing a client in a multi-hundred million dollar commercial dispute with Oman over a project in the extractive industries (concerning certain licenses and failure to use best efforts to support the project); representing Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning the scope of environmental release agreements and due process violations by a court of Ecuador that issued a multi-billion dollar fraudulent judgment against Chevron); and representing a sovereign state in a global campaign to enforce an ICC arbitration award against another sovereign.\u003c/p\u003e\n\u003cp\u003eJessica is a frequent writer and speaker on topics relating to international arbitration and has been recognized by IFLR Americas as a Rising Star in Commercial Arbitration and by CPR as a Rising Star in Alternative Dispute Resolution. In 2023, she was awarded the prestigious Smit-Lowenfeld Prize, which recognizes annually an outstanding article published in the previous year on any aspect of international arbitration, for her article on \u0026ldquo;The Illegality Objection in Investor-State Arbitration\u0026rdquo; (co-authored with Caline Mouawad, published in\u0026nbsp;\u003cem\u003eArbitration International\u003c/em\u003e, Volume 37, Issue 1).\u003c/p\u003e\n\u003cp\u003eJessica is fluent in English and German, and proficient in French and Spanish. She received her J.D.\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;from Harvard Law School and her B.A.\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;from Columbia University. She has conducted legal studies at Cambridge University.\u003c/p\u003e","slug":"jessica-beess-und-chrostin","email":"jbeessundchrostin@kslaw.com","phone":null,"matters":["\u003cp\u003eRepresenting sovereign award creditor in global enforcement proceedings against another sovereign relating to a multibillion-dollar ICC award\u003c/p\u003e","\u003cp\u003eRepresenting numerous investors in disputes against Spain and Italy under the Energy Charter Treaty regarding changes to the regulatory regime applicable to certain renewable energy producers in the wind and solar sectors (renewable energy)\u003c/p\u003e","\u003cp\u003eRepresented Dutch investor in UNCITRAL arbitration against the Government of Vietnam under the Netherlands-Vietnam Bilateral Investment Treaty (real estate and human rights; obtained favorable award, including largest moral damages award in favor of an individual in investment arbitration)\u003c/p\u003e","\u003cp\u003eRepresented Bear Creek Mining Corporation in an ICSID Arbitration against the Republic of Peru under the Canada-Peru Free Trade Agreement (mining sector; obtained favorable award of damages)\u003c/p\u003e","\u003cp\u003eRepresenting Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning scope of environmental release agreements and due process violations by a court of Ecuador that had issued a multi-billion dollar judgment against Chevron; obtained favorable award declaring,\u003cem\u003e\u0026nbsp;inter alia\u003c/em\u003e, that the Ecuadorian judgment was the product of fraud)\u003c/p\u003e","\u003cp\u003eRepresented KBR, Inc. in a NAFTA arbitration against the United Mexican States (concerning Mexican court\u0026rsquo;s annulment of a commercial arbitral award and related US enforcement proceedings)\u003c/p\u003e","\u003cp\u003eRepresented Reficar in an ICC arbitration against Chicago Bridge \u0026amp; Iron (construction sector; obtained favorable multibillion-dollar award)\u003c/p\u003e","\u003cp\u003eRepresented Sergei Viktorovich Pugachev in an UNCITRAL arbitration against the Russian Federation (construction and real estate sectors)\u003c/p\u003e","\u003cp\u003eRepresented international producer of household goods in an UNCITRAL arbitration against Latin American country under bilateral investment treaty (consumer goods; obtained favorable award)\u003c/p\u003e","\u003cp\u003eRepresented major telecommunications company in\u0026nbsp;\u003cem\u003ead hoc\u003c/em\u003e\u0026nbsp;arbitration against another telecommunications company regarding fraudulently originated telephone traffic and resulting disputed charges under global hubbing agreement (telecommunications sector; obtained favorable award)\u003c/p\u003e","\u003cp\u003eRepresented Indian pharmaceuticals manufacturer in contract dispute against U.S. pharmaceutical company (pharmaceuticals sector; successfully settled claims)\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":14,"guid":"14.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":4,"guid":"4.capabilities","index":3,"source":"capabilities"},{"id":35,"guid":"35.capabilities","index":4,"source":"capabilities"},{"id":40,"guid":"40.capabilities","index":5,"source":"capabilities"},{"id":1303,"guid":"1303.smart_tags","index":6,"source":"smartTags"}],"is_active":true,"last_name":"Beess und Chrostin","nick_name":"Jessica","clerkships":[],"first_name":"Jessica","title_rank":9999,"updated_by":35,"law_schools":[{"id":824,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":1,"graduation_date":"2013-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Ones to Watch - New York","detail":"Best Lawyers in America 2025"},{"title":"Future Leaders","detail":"Who's Who Legal (WWL): Arbitration 2024"},{"title":"Rising ADR Stars 2023","detail":"International Institute for Conflict Prevention \u0026 Resolution"},{"title":"Rising Star Awards Americas, Commercial Arbitration","detail":"IFLR, 2020 and 2021"},{"title":"Smit-Lowenfeld Prize for the Best Article in the Field of International Arbitration Published in 2021","detail":"The International Arbitration Club of New York; https://www.arbitrationclub.org/smit-lowenfeld-prize"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJessica Beess und Chrostin is a partner in King \u0026amp; Spalding\u0026rsquo;s Trial and Global Disputes Group.\u0026nbsp; Jessica\u0026rsquo;s practice focuses on complex international dispute resolution, with particular expertise in high-stakes commercial, investor-state, construction, and global award enforcement disputes.\u0026nbsp; Jessica regularly represents clients in international disputes in the infrastructure, oil and gas, mining, construction, and renewable energy sectors, and has significant experience in consumer goods, real estate, and telecommunications disputes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJessica is a zealous advocate for her clients and strives tirelessly to ensure they receive the best legal representation. She understands that representing her clients\u0026rsquo; interests requires understanding their business and objectives, and tailoring the strategy to achieve the best possible outcome, whether inside or out of the hearing room. Jessica represents clients in arbitrations before all major arbitral forums, including the AAA, ICC, ICDR, ICSID, JAMS, LCIA, and SCC as well as ad hoc arbitrations, such as UNCITRAL. She is experienced in all phases of international arbitration and award enforcement, and handles disputes from inception to collection. Jessica also regularly represents clients global award recognition and enforcement efforts as coordinating counsel and in litigations before U.S. courts under the New York Convention and the Federal Arbitration Act.\u003c/p\u003e\n\u003cp\u003eJessica represents clients in jurisdictions across the world. Her matters include representing a wind farm owner in a construction arbitration dispute with a turbine supplier and operations \u0026amp; maintenance provider (concerning the latter\u0026rsquo;s failure to comply with O\u0026amp;M obligations and failure to remediate certain serial defects); representing a client in a multi-hundred million dollar commercial dispute with Oman over a project in the extractive industries (concerning certain licenses and failure to use best efforts to support the project); representing Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning the scope of environmental release agreements and due process violations by a court of Ecuador that issued a multi-billion dollar fraudulent judgment against Chevron); and representing a sovereign state in a global campaign to enforce an ICC arbitration award against another sovereign.\u003c/p\u003e\n\u003cp\u003eJessica is a frequent writer and speaker on topics relating to international arbitration and has been recognized by IFLR Americas as a Rising Star in Commercial Arbitration and by CPR as a Rising Star in Alternative Dispute Resolution. In 2023, she was awarded the prestigious Smit-Lowenfeld Prize, which recognizes annually an outstanding article published in the previous year on any aspect of international arbitration, for her article on \u0026ldquo;The Illegality Objection in Investor-State Arbitration\u0026rdquo; (co-authored with Caline Mouawad, published in\u0026nbsp;\u003cem\u003eArbitration International\u003c/em\u003e, Volume 37, Issue 1).\u003c/p\u003e\n\u003cp\u003eJessica is fluent in English and German, and proficient in French and Spanish. She received her J.D.\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;from Harvard Law School and her B.A.\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;from Columbia University. She has conducted legal studies at Cambridge University.\u003c/p\u003e","matters":["\u003cp\u003eRepresenting sovereign award creditor in global enforcement proceedings against another sovereign relating to a multibillion-dollar ICC award\u003c/p\u003e","\u003cp\u003eRepresenting numerous investors in disputes against Spain and Italy under the Energy Charter Treaty regarding changes to the regulatory regime applicable to certain renewable energy producers in the wind and solar sectors (renewable energy)\u003c/p\u003e","\u003cp\u003eRepresented Dutch investor in UNCITRAL arbitration against the Government of Vietnam under the Netherlands-Vietnam Bilateral Investment Treaty (real estate and human rights; obtained favorable award, including largest moral damages award in favor of an individual in investment arbitration)\u003c/p\u003e","\u003cp\u003eRepresented Bear Creek Mining Corporation in an ICSID Arbitration against the Republic of Peru under the Canada-Peru Free Trade Agreement (mining sector; obtained favorable award of damages)\u003c/p\u003e","\u003cp\u003eRepresenting Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning scope of environmental release agreements and due process violations by a court of Ecuador that had issued a multi-billion dollar judgment against Chevron; obtained favorable award declaring,\u003cem\u003e\u0026nbsp;inter alia\u003c/em\u003e, that the Ecuadorian judgment was the product of fraud)\u003c/p\u003e","\u003cp\u003eRepresented KBR, Inc. in a NAFTA arbitration against the United Mexican States (concerning Mexican court\u0026rsquo;s annulment of a commercial arbitral award and related US enforcement proceedings)\u003c/p\u003e","\u003cp\u003eRepresented Reficar in an ICC arbitration against Chicago Bridge \u0026amp; Iron (construction sector; obtained favorable multibillion-dollar award)\u003c/p\u003e","\u003cp\u003eRepresented Sergei Viktorovich Pugachev in an UNCITRAL arbitration against the Russian Federation (construction and real estate sectors)\u003c/p\u003e","\u003cp\u003eRepresented international producer of household goods in an UNCITRAL arbitration against Latin American country under bilateral investment treaty (consumer goods; obtained favorable award)\u003c/p\u003e","\u003cp\u003eRepresented major telecommunications company in\u0026nbsp;\u003cem\u003ead hoc\u003c/em\u003e\u0026nbsp;arbitration against another telecommunications company regarding fraudulently originated telephone traffic and resulting disputed charges under global hubbing agreement (telecommunications sector; obtained favorable award)\u003c/p\u003e","\u003cp\u003eRepresented Indian pharmaceuticals manufacturer in contract dispute against U.S. pharmaceutical company (pharmaceuticals sector; successfully settled claims)\u003c/p\u003e"],"recognitions":[{"title":"Ones to Watch - New York","detail":"Best Lawyers in America 2025"},{"title":"Future Leaders","detail":"Who's Who Legal (WWL): Arbitration 2024"},{"title":"Rising ADR Stars 2023","detail":"International Institute for Conflict Prevention \u0026 Resolution"},{"title":"Rising Star Awards Americas, Commercial Arbitration","detail":"IFLR, 2020 and 2021"},{"title":"Smit-Lowenfeld Prize for the Best Article in the Field of International Arbitration Published in 2021","detail":"The International Arbitration Club of New York; https://www.arbitrationclub.org/smit-lowenfeld-prize"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10178}]},"capability_group_id":3},"created_at":"2025-09-02T04:52:49.000Z","updated_at":"2025-09-02T04:52:49.000Z","searchable_text":"Beess und Chrostin{{ FIELD }}{:title=\u0026gt;\"Ones to Watch - New York\", :detail=\u0026gt;\"Best Lawyers in America 2025\"}{{ FIELD }}{:title=\u0026gt;\"Future Leaders\", :detail=\u0026gt;\"Who's Who Legal (WWL): Arbitration 2024\"}{{ FIELD }}{:title=\u0026gt;\"Rising ADR Stars 2023\", :detail=\u0026gt;\"International Institute for Conflict Prevention \u0026amp; Resolution\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star Awards Americas, Commercial Arbitration\", :detail=\u0026gt;\"IFLR, 2020 and 2021\"}{{ FIELD }}{:title=\u0026gt;\"Smit-Lowenfeld Prize for the Best Article in the Field of International Arbitration Published in 2021\", :detail=\u0026gt;\"The International Arbitration Club of New York; https://www.arbitrationclub.org/smit-lowenfeld-prize\"}{{ FIELD }}Representing sovereign award creditor in global enforcement proceedings against another sovereign relating to a multibillion-dollar ICC award{{ FIELD }}Representing numerous investors in disputes against Spain and Italy under the Energy Charter Treaty regarding changes to the regulatory regime applicable to certain renewable energy producers in the wind and solar sectors (renewable energy){{ FIELD }}Represented Dutch investor in UNCITRAL arbitration against the Government of Vietnam under the Netherlands-Vietnam Bilateral Investment Treaty (real estate and human rights; obtained favorable award, including largest moral damages award in favor of an individual in investment arbitration){{ FIELD }}Represented Bear Creek Mining Corporation in an ICSID Arbitration against the Republic of Peru under the Canada-Peru Free Trade Agreement (mining sector; obtained favorable award of damages){{ FIELD }}Representing Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning scope of environmental release agreements and due process violations by a court of Ecuador that had issued a multi-billion dollar judgment against Chevron; obtained favorable award declaring, inter alia, that the Ecuadorian judgment was the product of fraud){{ FIELD }}Represented KBR, Inc. in a NAFTA arbitration against the United Mexican States (concerning Mexican court’s annulment of a commercial arbitral award and related US enforcement proceedings){{ FIELD }}Represented Reficar in an ICC arbitration against Chicago Bridge \u0026amp; Iron (construction sector; obtained favorable multibillion-dollar award){{ FIELD }}Represented Sergei Viktorovich Pugachev in an UNCITRAL arbitration against the Russian Federation (construction and real estate sectors){{ FIELD }}Represented international producer of household goods in an UNCITRAL arbitration against Latin American country under bilateral investment treaty (consumer goods; obtained favorable award){{ FIELD }}Represented major telecommunications company in ad hoc arbitration against another telecommunications company regarding fraudulently originated telephone traffic and resulting disputed charges under global hubbing agreement (telecommunications sector; obtained favorable award){{ FIELD }}Represented Indian pharmaceuticals manufacturer in contract dispute against U.S. pharmaceutical company (pharmaceuticals sector; successfully settled claims){{ FIELD }}Jessica Beess und Chrostin is a partner in King \u0026amp; Spalding’s Trial and Global Disputes Group.  Jessica’s practice focuses on complex international dispute resolution, with particular expertise in high-stakes commercial, investor-state, construction, and global award enforcement disputes.  Jessica regularly represents clients in international disputes in the infrastructure, oil and gas, mining, construction, and renewable energy sectors, and has significant experience in consumer goods, real estate, and telecommunications disputes.\nJessica is a zealous advocate for her clients and strives tirelessly to ensure they receive the best legal representation. She understands that representing her clients’ interests requires understanding their business and objectives, and tailoring the strategy to achieve the best possible outcome, whether inside or out of the hearing room. Jessica represents clients in arbitrations before all major arbitral forums, including the AAA, ICC, ICDR, ICSID, JAMS, LCIA, and SCC as well as ad hoc arbitrations, such as UNCITRAL. She is experienced in all phases of international arbitration and award enforcement, and handles disputes from inception to collection. Jessica also regularly represents clients global award recognition and enforcement efforts as coordinating counsel and in litigations before U.S. courts under the New York Convention and the Federal Arbitration Act.\nJessica represents clients in jurisdictions across the world. Her matters include representing a wind farm owner in a construction arbitration dispute with a turbine supplier and operations \u0026amp; maintenance provider (concerning the latter’s failure to comply with O\u0026amp;M obligations and failure to remediate certain serial defects); representing a client in a multi-hundred million dollar commercial dispute with Oman over a project in the extractive industries (concerning certain licenses and failure to use best efforts to support the project); representing Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning the scope of environmental release agreements and due process violations by a court of Ecuador that issued a multi-billion dollar fraudulent judgment against Chevron); and representing a sovereign state in a global campaign to enforce an ICC arbitration award against another sovereign.\nJessica is a frequent writer and speaker on topics relating to international arbitration and has been recognized by IFLR Americas as a Rising Star in Commercial Arbitration and by CPR as a Rising Star in Alternative Dispute Resolution. In 2023, she was awarded the prestigious Smit-Lowenfeld Prize, which recognizes annually an outstanding article published in the previous year on any aspect of international arbitration, for her article on “The Illegality Objection in Investor-State Arbitration” (co-authored with Caline Mouawad, published in Arbitration International, Volume 37, Issue 1).\nJessica is fluent in English and German, and proficient in French and Spanish. She received her J.D. cum laude from Harvard Law School and her B.A. cum laude from Columbia University. She has conducted legal studies at Cambridge University. Partner Ones to Watch - New York Best Lawyers in America 2025 Future Leaders Who's Who Legal (WWL): Arbitration 2024 Rising ADR Stars 2023 International Institute for Conflict Prevention \u0026amp; Resolution Rising Star Awards Americas, Commercial Arbitration IFLR, 2020 and 2021 Smit-Lowenfeld Prize for the Best Article in the Field of International Arbitration Published in 2021 The International Arbitration Club of New York; https://www.arbitrationclub.org/smit-lowenfeld-prize Columbia University Columbia University School of Law Harvard University Harvard Law School University of Cambridge, UK  New York City Bar of New York, International Law Committee Representing sovereign award creditor in global enforcement proceedings against another sovereign relating to a multibillion-dollar ICC award Representing numerous investors in disputes against Spain and Italy under the Energy Charter Treaty regarding changes to the regulatory regime applicable to certain renewable energy producers in the wind and solar sectors (renewable energy) Represented Dutch investor in UNCITRAL arbitration against the Government of Vietnam under the Netherlands-Vietnam Bilateral Investment Treaty (real estate and human rights; obtained favorable award, including largest moral damages award in favor of an individual in investment arbitration) Represented Bear Creek Mining Corporation in an ICSID Arbitration against the Republic of Peru under the Canada-Peru Free Trade Agreement (mining sector; obtained favorable award of damages) Representing Chevron Corporation (U.S.A.) and Texaco Petroleum Company (U.S.A.) in an UNCITRAL arbitration under the U.S.-Ecuador Bilateral Investment Treaty (concerning scope of environmental release agreements and due process violations by a court of Ecuador that had issued a multi-billion dollar judgment against Chevron; obtained favorable award declaring, inter alia, that the Ecuadorian judgment was the product of fraud) Represented KBR, Inc. in a NAFTA arbitration against the United Mexican States (concerning Mexican court’s annulment of a commercial arbitral award and related US enforcement proceedings) Represented Reficar in an ICC arbitration against Chicago Bridge \u0026amp; Iron (construction sector; obtained favorable multibillion-dollar award) Represented Sergei Viktorovich Pugachev in an UNCITRAL arbitration against the Russian Federation (construction and real estate sectors) Represented international producer of household goods in an UNCITRAL arbitration against Latin American country under bilateral investment treaty (consumer goods; obtained favorable award) Represented major telecommunications company in ad hoc arbitration against another telecommunications company regarding fraudulently originated telephone traffic and resulting disputed charges under global hubbing agreement (telecommunications sector; obtained favorable award) Represented Indian pharmaceuticals manufacturer in contract dispute against U.S. pharmaceutical company (pharmaceuticals sector; successfully settled claims)","searchable_name":"Jessica Beess und Chrostin","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":445539,"version":1,"owner_type":"Person","owner_id":6785,"payload":{"bio":"\u003cp\u003eDana Berkowitz represents healthcare providers in\u0026nbsp;a variety of high-stakes matters,\u0026nbsp;including reimbursement disputes, regulatory proceedings,\u0026nbsp;and commercial litigation and arbitration.\u0026nbsp; She also provides strategic advice to healthcare and life sciences startups and handles bet-the-company litigation on their behalf. \u0026nbsp;Dana has deep expertise in ERISA and behavioral healthcare. \u0026nbsp;\u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;describes her as \u0026ldquo;the full package\u0026rdquo; and \u0026ldquo;a gifted litigator and strategist\u0026rdquo; who is \u0026ldquo;knowledgeable and solutions-based.\u0026rdquo;\u0026nbsp; \u003cem\u003eLegal500\u003c/em\u003e\u0026nbsp;calls Dana \u0026ldquo;a superlative advocate and tactician.\u0026rdquo;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDana has a\u0026nbsp;long track record of achieving favorable outcomes for healthcare providers in a wide variety of payor disputes.\u0026nbsp; Her practice focuses on managed care litigation and arbitration.\u0026nbsp; Dana also helps providers navigate audits, rate disputes, recoupment demands, and other high-risk aspects of their payor relationships. Dana leverages her ERISA expertise to help her clients take advantage of opportunities, such as by using the Parity Act to improve reimbursement for mental health services.\u0026nbsp; Dana also advises providers on best practices, often in anticipation of sale.\u003c/p\u003e\n\u003cp\u003eDana has achieved success in several bet-the-company litigations and appeals for providers and other business clients.\u0026nbsp; For example, in 2019, she secured a complete defense verdict for a behavioral healthcare provider in a $195 million false advertising case.\u0026nbsp; In 2020, she successfully defended another provider in a four-week administrative trial against the State of California.\u0026nbsp; And in 2022, Dana led a large theft of trade secrets case to a favorable resolution for her biotech startup client.\u0026nbsp; Dana has also briefed and argued\u0026nbsp;high-profile appeals in federal and state courts across the nation.\u003c/p\u003e\n\u003cp\u003eSince 2022,\u0026nbsp;\u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;has recognized Dana as one of the top ERISA litigators in the nation.\u0026nbsp; \u003cem\u003eLegal500\u003c/em\u003e says that she is \u0026ldquo;unmatched in her ability to quickly ingest, organize, and master an enormous amount of factual information and synthesize it into a winning narrative.\u0026rdquo;\u0026nbsp; Dana has also been listed as a leading lawyer under 40 in \u003cem\u003eBenchmark Litigation\u003c/em\u003e and \u003cem\u003eNew York Law Journal\u003c/em\u003e.\u0026nbsp;\u003c/p\u003e","slug":"dana-berkowitz","email":"dberkowitz@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003e\u003cem\u003eParties Confidential.\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eLead counsel to behavioral health company in rate dispute with major payor. Resolved after service of draft complaint for $30 million more than prior offer.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eHammell v. Pilot Products, Inc. Defined Benefit Pension Plan\u003c/em\u003e.\u003c/strong\u003e\u0026nbsp;Lead trial counsel for plaintiff in ERISA pension dispute. Won more than 90 percent of relief sought including over $1M in attorneys\u0026rsquo; fees.\u003c/p\u003e","\u003cp\u003eLead trial counsel to American biotech startup in nine-figure federal trade secrets litigation and international arbitration relating to next-generation COVID-19 vaccine. Matter resolved on favorable terms.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eGrasshopper House LLC v. Clean \u0026amp; Sober Media LLC.\u003c/em\u003e\u003c/strong\u003e\u003cem\u003e\u0026nbsp;\u003c/em\u003eFirst-chaired bench trial on equitable relief after adverse jury verdict in Lanham Act case against well-known treatment facility, where plaintiff sought $195M. Court found unclean hands and awarded $0 to plaintiff.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eParties Confidential.\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eResolved dispute on behalf of hospital against independent physician organization on eve of trial for double amount of claimed loss.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eIn re Creative Care.\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eFirst-chaired four-week administrative trial against California in license revocation action. Secured complete defense victory for substance abuse treatment facility client.\u003c/p\u003e","\u003cp\u003eLead trial counsel in franchise arbitration against international coffeehouse chain. Awarded full amount of claimed loss.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eBechard v. Brody.\u003c/em\u003e\u003c/strong\u003e\u0026nbsp;Successfully briefed and argued California appeal of order denying motion to compel arbitration in dispute involving Michael Avenatti and Republican fundraiser Elliott Brody.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3251}]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":2,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":502,"guid":"502.smart_tags","index":5,"source":"smartTags"},{"id":740,"guid":"740.smart_tags","index":6,"source":"smartTags"}],"is_active":true,"last_name":"Berkowitz","nick_name":"Dana","clerkships":[],"first_name":"Dana","title_rank":9999,"updated_by":202,"law_schools":[{"id":824,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2011-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"\"She is a superlative advocate and tactician.\"","detail":"Legal 500, 2025"},{"title":"\"She's the full package: smart, good on her feet, dogged and fierce in all the right ways.\"","detail":"Chambers USA, 2025"},{"title":"Ranked in \"ERISA Litigation: Mainly Plaintiffs (Nationwide)\"","detail":"Chambers USA, 2022-25"},{"title":"Future Star","detail":"Benchmark Litigation, 2023"},{"title":"40 and Under Hot List","detail":"Benchmark Litigation, 2021-2022, 2024"},{"title":"Rising Star","detail":"New York Law Journal, 2018"}],"linked_in_url":null,"seodescription":"Dana is a lawyer at King \u0026 Spalding's New York Office. Read more about her.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDana Berkowitz represents healthcare providers in\u0026nbsp;a variety of high-stakes matters,\u0026nbsp;including reimbursement disputes, regulatory proceedings,\u0026nbsp;and commercial litigation and arbitration.\u0026nbsp; She also provides strategic advice to healthcare and life sciences startups and handles bet-the-company litigation on their behalf. \u0026nbsp;Dana has deep expertise in ERISA and behavioral healthcare. \u0026nbsp;\u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;describes her as \u0026ldquo;the full package\u0026rdquo; and \u0026ldquo;a gifted litigator and strategist\u0026rdquo; who is \u0026ldquo;knowledgeable and solutions-based.\u0026rdquo;\u0026nbsp; \u003cem\u003eLegal500\u003c/em\u003e\u0026nbsp;calls Dana \u0026ldquo;a superlative advocate and tactician.\u0026rdquo;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDana has a\u0026nbsp;long track record of achieving favorable outcomes for healthcare providers in a wide variety of payor disputes.\u0026nbsp; Her practice focuses on managed care litigation and arbitration.\u0026nbsp; Dana also helps providers navigate audits, rate disputes, recoupment demands, and other high-risk aspects of their payor relationships. Dana leverages her ERISA expertise to help her clients take advantage of opportunities, such as by using the Parity Act to improve reimbursement for mental health services.\u0026nbsp; Dana also advises providers on best practices, often in anticipation of sale.\u003c/p\u003e\n\u003cp\u003eDana has achieved success in several bet-the-company litigations and appeals for providers and other business clients.\u0026nbsp; For example, in 2019, she secured a complete defense verdict for a behavioral healthcare provider in a $195 million false advertising case.\u0026nbsp; In 2020, she successfully defended another provider in a four-week administrative trial against the State of California.\u0026nbsp; And in 2022, Dana led a large theft of trade secrets case to a favorable resolution for her biotech startup client.\u0026nbsp; Dana has also briefed and argued\u0026nbsp;high-profile appeals in federal and state courts across the nation.\u003c/p\u003e\n\u003cp\u003eSince 2022,\u0026nbsp;\u003cem\u003eChambers USA\u003c/em\u003e\u0026nbsp;has recognized Dana as one of the top ERISA litigators in the nation.\u0026nbsp; \u003cem\u003eLegal500\u003c/em\u003e says that she is \u0026ldquo;unmatched in her ability to quickly ingest, organize, and master an enormous amount of factual information and synthesize it into a winning narrative.\u0026rdquo;\u0026nbsp; Dana has also been listed as a leading lawyer under 40 in \u003cem\u003eBenchmark Litigation\u003c/em\u003e and \u003cem\u003eNew York Law Journal\u003c/em\u003e.\u0026nbsp;\u003c/p\u003e","matters":["\u003cp\u003e\u003cstrong\u003e\u003cem\u003eParties Confidential.\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eLead counsel to behavioral health company in rate dispute with major payor. Resolved after service of draft complaint for $30 million more than prior offer.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eHammell v. Pilot Products, Inc. Defined Benefit Pension Plan\u003c/em\u003e.\u003c/strong\u003e\u0026nbsp;Lead trial counsel for plaintiff in ERISA pension dispute. Won more than 90 percent of relief sought including over $1M in attorneys\u0026rsquo; fees.\u003c/p\u003e","\u003cp\u003eLead trial counsel to American biotech startup in nine-figure federal trade secrets litigation and international arbitration relating to next-generation COVID-19 vaccine. Matter resolved on favorable terms.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eGrasshopper House LLC v. Clean \u0026amp; Sober Media LLC.\u003c/em\u003e\u003c/strong\u003e\u003cem\u003e\u0026nbsp;\u003c/em\u003eFirst-chaired bench trial on equitable relief after adverse jury verdict in Lanham Act case against well-known treatment facility, where plaintiff sought $195M. Court found unclean hands and awarded $0 to plaintiff.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eParties Confidential.\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eResolved dispute on behalf of hospital against independent physician organization on eve of trial for double amount of claimed loss.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eIn re Creative Care.\u0026nbsp;\u003c/em\u003e\u003c/strong\u003eFirst-chaired four-week administrative trial against California in license revocation action. Secured complete defense victory for substance abuse treatment facility client.\u003c/p\u003e","\u003cp\u003eLead trial counsel in franchise arbitration against international coffeehouse chain. Awarded full amount of claimed loss.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cem\u003eBechard v. Brody.\u003c/em\u003e\u003c/strong\u003e\u0026nbsp;Successfully briefed and argued California appeal of order denying motion to compel arbitration in dispute involving Michael Avenatti and Republican fundraiser Elliott Brody.\u003c/p\u003e"],"recognitions":[{"title":"\"She is a superlative advocate and tactician.\"","detail":"Legal 500, 2025"},{"title":"\"She's the full package: smart, good on her feet, dogged and fierce in all the right ways.\"","detail":"Chambers USA, 2025"},{"title":"Ranked in \"ERISA Litigation: Mainly Plaintiffs (Nationwide)\"","detail":"Chambers USA, 2022-25"},{"title":"Future Star","detail":"Benchmark Litigation, 2023"},{"title":"40 and Under Hot List","detail":"Benchmark Litigation, 2021-2022, 2024"},{"title":"Rising Star","detail":"New York Law Journal, 2018"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11963}]},"capability_group_id":2},"created_at":"2026-02-03T16:24:39.000Z","updated_at":"2026-02-03T16:24:39.000Z","searchable_text":"Berkowitz{{ FIELD }}{:title=\u0026gt;\"\\\"She is a superlative advocate and tactician.\\\"\", :detail=\u0026gt;\"Legal 500, 2025\"}{{ FIELD }}{:title=\u0026gt;\"\\\"She's the full package: smart, good on her feet, dogged and fierce in all the right ways.\\\"\", :detail=\u0026gt;\"Chambers USA, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Ranked in \\\"ERISA Litigation: Mainly Plaintiffs (Nationwide)\\\"\", :detail=\u0026gt;\"Chambers USA, 2022-25\"}{{ FIELD }}{:title=\u0026gt;\"Future Star\", :detail=\u0026gt;\"Benchmark Litigation, 2023\"}{{ FIELD }}{:title=\u0026gt;\"40 and Under Hot List\", :detail=\u0026gt;\"Benchmark Litigation, 2021-2022, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star\", :detail=\u0026gt;\"New York Law Journal, 2018\"}{{ FIELD }}Parties Confidential. Lead counsel to behavioral health company in rate dispute with major payor. Resolved after service of draft complaint for $30 million more than prior offer.{{ FIELD }}Hammell v. Pilot Products, Inc. Defined Benefit Pension Plan. Lead trial counsel for plaintiff in ERISA pension dispute. Won more than 90 percent of relief sought including over $1M in attorneys’ fees.{{ FIELD }}Lead trial counsel to American biotech startup in nine-figure federal trade secrets litigation and international arbitration relating to next-generation COVID-19 vaccine. Matter resolved on favorable terms.{{ FIELD }}Grasshopper House LLC v. Clean \u0026amp; Sober Media LLC. First-chaired bench trial on equitable relief after adverse jury verdict in Lanham Act case against well-known treatment facility, where plaintiff sought $195M. Court found unclean hands and awarded $0 to plaintiff.{{ FIELD }}Parties Confidential. Resolved dispute on behalf of hospital against independent physician organization on eve of trial for double amount of claimed loss.{{ FIELD }}In re Creative Care. First-chaired four-week administrative trial against California in license revocation action. Secured complete defense victory for substance abuse treatment facility client.{{ FIELD }}Lead trial counsel in franchise arbitration against international coffeehouse chain. Awarded full amount of claimed loss.{{ FIELD }}Bechard v. Brody. Successfully briefed and argued California appeal of order denying motion to compel arbitration in dispute involving Michael Avenatti and Republican fundraiser Elliott Brody.{{ FIELD }}Dana Berkowitz represents healthcare providers in a variety of high-stakes matters, including reimbursement disputes, regulatory proceedings, and commercial litigation and arbitration.  She also provides strategic advice to healthcare and life sciences startups and handles bet-the-company litigation on their behalf.  Dana has deep expertise in ERISA and behavioral healthcare.  Chambers USA describes her as “the full package” and “a gifted litigator and strategist” who is “knowledgeable and solutions-based.”  Legal500 calls Dana “a superlative advocate and tactician.”\nDana has a long track record of achieving favorable outcomes for healthcare providers in a wide variety of payor disputes.  Her practice focuses on managed care litigation and arbitration.  Dana also helps providers navigate audits, rate disputes, recoupment demands, and other high-risk aspects of their payor relationships. Dana leverages her ERISA expertise to help her clients take advantage of opportunities, such as by using the Parity Act to improve reimbursement for mental health services.  Dana also advises providers on best practices, often in anticipation of sale.\nDana has achieved success in several bet-the-company litigations and appeals for providers and other business clients.  For example, in 2019, she secured a complete defense verdict for a behavioral healthcare provider in a $195 million false advertising case.  In 2020, she successfully defended another provider in a four-week administrative trial against the State of California.  And in 2022, Dana led a large theft of trade secrets case to a favorable resolution for her biotech startup client.  Dana has also briefed and argued high-profile appeals in federal and state courts across the nation.\nSince 2022, Chambers USA has recognized Dana as one of the top ERISA litigators in the nation.  Legal500 says that she is “unmatched in her ability to quickly ingest, organize, and master an enormous amount of factual information and synthesize it into a winning narrative.”  Dana has also been listed as a leading lawyer under 40 in Benchmark Litigation and New York Law Journal.  Dana Berkowitz lawyer Partner \"She is a superlative advocate and tactician.\" Legal 500, 2025 \"She's the full package: smart, good on her feet, dogged and fierce in all the right ways.\" Chambers USA, 2025 Ranked in \"ERISA Litigation: Mainly Plaintiffs (Nationwide)\" Chambers USA, 2022-25 Future Star Benchmark Litigation, 2023 40 and Under Hot List Benchmark Litigation, 2021-2022, 2024 Rising Star New York Law Journal, 2018 Princeton University  Harvard University Harvard Law School U.S. Court of Appeals for the Federal Circuit Supreme Court of the United States U.S. Court of Appeals for the Fifth Circuit U.S. Court of Appeals for the Sixth Circuit U.S. Court of Appeals for the Ninth Circuit Central District of California California New York American Bar Association, Employee Benefits Committee Parties Confidential. Lead counsel to behavioral health company in rate dispute with major payor. Resolved after service of draft complaint for $30 million more than prior offer. Hammell v. Pilot Products, Inc. Defined Benefit Pension Plan. Lead trial counsel for plaintiff in ERISA pension dispute. Won more than 90 percent of relief sought including over $1M in attorneys’ fees. Lead trial counsel to American biotech startup in nine-figure federal trade secrets litigation and international arbitration relating to next-generation COVID-19 vaccine. Matter resolved on favorable terms. Grasshopper House LLC v. Clean \u0026amp; Sober Media LLC. First-chaired bench trial on equitable relief after adverse jury verdict in Lanham Act case against well-known treatment facility, where plaintiff sought $195M. Court found unclean hands and awarded $0 to plaintiff. Parties Confidential. Resolved dispute on behalf of hospital against independent physician organization on eve of trial for double amount of claimed loss. In re Creative Care. First-chaired four-week administrative trial against California in license revocation action. Secured complete defense victory for substance abuse treatment facility client. Lead trial counsel in franchise arbitration against international coffeehouse chain. Awarded full amount of claimed loss. Bechard v. Brody. Successfully briefed and argued California appeal of order denying motion to compel arbitration in dispute involving Michael Avenatti and Republican fundraiser Elliott Brody.","searchable_name":"Dana Berkowitz","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":427654,"version":1,"owner_type":"Person","owner_id":1263,"payload":{"bio":"\u003cp\u003eMatt Blaschke focuses on complex litigation involving scientific or technical issues, as well as general litigation. As a partner in our Environmental and Mass Tort and Toxic Tort practices, Matt represents energy, pharmaceutical, consumer product and chemical industry clients in state and federal courts throughout the country.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMatt\u0026rsquo;s experience ranges from large-scale multiparty litigation to individual product liability actions. He also advises clients on environmental laws and regulations, including the federal Insecticide, Fungicide and Rodenticide Act.\u003c/p\u003e","slug":"matthew-blaschke","email":"mblaschke@kslaw.com","phone":null,"matters":["\u003cp\u003eCurrently representing \u003cstrong data-redactor-tag=\"strong\"\u003ea large energy company\u003c/strong\u003e in mass tort litigation arising from facility fire in California.\u003c/p\u003e","\u003cp\u003eMember of national coordinating team of lawyers representing \u003cstrong data-redactor-tag=\"strong\"\u003eGlaxoSmithKline\u003c/strong\u003e (\u0026ldquo;GSK\u0026rdquo;) in product liability litigation throughout the country, including allegations that the antidepressant Paxil\u0026reg; causes congenital defects. Matt has prepared numerous cases for trial; deposed plaintiffs as well as third-party witnesses and treating physicians; developed and executed pretrial strategy; briefed dispositive and procedural motions; and coordinated discovery.\u003c/p\u003e","\u003cp\u003eDefended \u003cstrong data-redactor-tag=\"strong\"\u003eGSK\u003c/strong\u003e before Pennsylvania appellate courts following summary judgment for GSK in product liability litigation including allegations that Paxil\u0026reg; caused congenital defects.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea\u003c/strong\u003e \u003cstrong data-redactor-tag=\"strong\"\u003emultinational pharmaceuticals manufacturer\u003c/strong\u003e in personal injury action filed in Florida State Court. Matt coordinated removal of the action to federal court and then successfully moved to dismiss the action at the pleadings stage.\u003c/p\u003e","\u003cp\u003eDefended \u003cstrong data-redactor-tag=\"strong\"\u003ethe Dow Chemical Company\u003c/strong\u003e (\"Dow\") in California product liability litigation in which plaintiffs allege that certain Dow products caused injuries to an employee at a manufacturing facility.\u003c/p\u003e","\u003cp\u003eDefended \u003cstrong data-redactor-tag=\"strong\"\u003eDow\u003c/strong\u003e in a commercial dispute in California involving product liability claims concerning a plastic resin formerly manufactured by Dow.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003econsumer product manufacturers\u003c/strong\u003e in enforcement actions brought by California's Department of Pesticide Regulation.\u003c/p\u003e","\u003cp\u003ePreparation for trial in \u003cstrong data-redactor-tag=\"strong\"\u003emultiple mass tort lawsuits\u003c/strong\u003e alleging health and property claims, including drafting discovery, interviewing witnesses, and preparing fact witnesses for deposition testimony; also responsible for interviewing and preparing expert witnesses in fields of toxicology and municipal water delivery systems.\u003c/p\u003e","\u003cp\u003eParticipated as part of a multi-disciplinary team of attorneys and consultants conducting a risk assessment for \u003cstrong data-redactor-tag=\"strong\"\u003ea multinational pharmaceutical manufacturer\u003c/strong\u003e in connection with the approval of a new medication. Matt assisted with Company by identifying and recommending steps to minimize product liability risk.\u003c/p\u003e","\u003cp\u003eParticipated in the defense of \u003cstrong data-redactor-tag=\"strong\"\u003ea bellwether lawsuit\u003c/strong\u003e alleging health claims arising from exposure to dioxins, vinyl chloride, TCE and other soil and groundwater contaminants, including drafting \u003cem data-redactor-tag=\"em\"\u003eDaubert\u003c/em\u003e motions to exclude plaintiffs\u0026rsquo; expert witnesses.\u003c/p\u003e","\u003cp\u003eDefended litigation arising under the Freedom of Information Act (FOIA) against \u003cstrong data-redactor-tag=\"strong\"\u003eclient in the healthcare industry,\u003c/strong\u003e including developing case strategy with codefendant federal agency, drafting dispositive motions, and negotiations with opposing counsel.\u003c/p\u003e","\u003cp\u003eDefended litigation arising under state freedom of information laws for \u003cstrong data-redactor-tag=\"strong\"\u003ea nuclear power trade group,\u003c/strong\u003e including drafting of dispositive motions, discovery responses, and settlement agreement to protect the confidentiality of client documents.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":107}]},"expertise":[{"id":16,"guid":"16.capabilities","index":0,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":1,"source":"smartTags"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":5,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":6,"source":"capabilities"}],"is_active":true,"last_name":"Blaschke","nick_name":"Matt","clerkships":[],"first_name":"Matthew","title_rank":9999,"updated_by":32,"law_schools":[],"middle_name":"J.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eMatt Blaschke focuses on complex litigation involving scientific or technical issues, as well as general litigation. As a partner in our Environmental and Mass Tort and Toxic Tort practices, Matt represents energy, pharmaceutical, consumer product and chemical industry clients in state and federal courts throughout the country.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMatt\u0026rsquo;s experience ranges from large-scale multiparty litigation to individual product liability actions. He also advises clients on environmental laws and regulations, including the federal Insecticide, Fungicide and Rodenticide Act.\u003c/p\u003e","matters":["\u003cp\u003eCurrently representing \u003cstrong data-redactor-tag=\"strong\"\u003ea large energy company\u003c/strong\u003e in mass tort litigation arising from facility fire in California.\u003c/p\u003e","\u003cp\u003eMember of national coordinating team of lawyers representing \u003cstrong data-redactor-tag=\"strong\"\u003eGlaxoSmithKline\u003c/strong\u003e (\u0026ldquo;GSK\u0026rdquo;) in product liability litigation throughout the country, including allegations that the antidepressant Paxil\u0026reg; causes congenital defects. Matt has prepared numerous cases for trial; deposed plaintiffs as well as third-party witnesses and treating physicians; developed and executed pretrial strategy; briefed dispositive and procedural motions; and coordinated discovery.\u003c/p\u003e","\u003cp\u003eDefended \u003cstrong data-redactor-tag=\"strong\"\u003eGSK\u003c/strong\u003e before Pennsylvania appellate courts following summary judgment for GSK in product liability litigation including allegations that Paxil\u0026reg; caused congenital defects.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea\u003c/strong\u003e \u003cstrong data-redactor-tag=\"strong\"\u003emultinational pharmaceuticals manufacturer\u003c/strong\u003e in personal injury action filed in Florida State Court. Matt coordinated removal of the action to federal court and then successfully moved to dismiss the action at the pleadings stage.\u003c/p\u003e","\u003cp\u003eDefended \u003cstrong data-redactor-tag=\"strong\"\u003ethe Dow Chemical Company\u003c/strong\u003e (\"Dow\") in California product liability litigation in which plaintiffs allege that certain Dow products caused injuries to an employee at a manufacturing facility.\u003c/p\u003e","\u003cp\u003eDefended \u003cstrong data-redactor-tag=\"strong\"\u003eDow\u003c/strong\u003e in a commercial dispute in California involving product liability claims concerning a plastic resin formerly manufactured by Dow.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003econsumer product manufacturers\u003c/strong\u003e in enforcement actions brought by California's Department of Pesticide Regulation.\u003c/p\u003e","\u003cp\u003ePreparation for trial in \u003cstrong data-redactor-tag=\"strong\"\u003emultiple mass tort lawsuits\u003c/strong\u003e alleging health and property claims, including drafting discovery, interviewing witnesses, and preparing fact witnesses for deposition testimony; also responsible for interviewing and preparing expert witnesses in fields of toxicology and municipal water delivery systems.\u003c/p\u003e","\u003cp\u003eParticipated as part of a multi-disciplinary team of attorneys and consultants conducting a risk assessment for \u003cstrong data-redactor-tag=\"strong\"\u003ea multinational pharmaceutical manufacturer\u003c/strong\u003e in connection with the approval of a new medication. Matt assisted with Company by identifying and recommending steps to minimize product liability risk.\u003c/p\u003e","\u003cp\u003eParticipated in the defense of \u003cstrong data-redactor-tag=\"strong\"\u003ea bellwether lawsuit\u003c/strong\u003e alleging health claims arising from exposure to dioxins, vinyl chloride, TCE and other soil and groundwater contaminants, including drafting \u003cem data-redactor-tag=\"em\"\u003eDaubert\u003c/em\u003e motions to exclude plaintiffs\u0026rsquo; expert witnesses.\u003c/p\u003e","\u003cp\u003eDefended litigation arising under the Freedom of Information Act (FOIA) against \u003cstrong data-redactor-tag=\"strong\"\u003eclient in the healthcare industry,\u003c/strong\u003e including developing case strategy with codefendant federal agency, drafting dispositive motions, and negotiations with opposing counsel.\u003c/p\u003e","\u003cp\u003eDefended litigation arising under state freedom of information laws for \u003cstrong data-redactor-tag=\"strong\"\u003ea nuclear power trade group,\u003c/strong\u003e including drafting of dispositive motions, discovery responses, and settlement agreement to protect the confidentiality of client documents.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":731}]},"capability_group_id":3},"created_at":"2025-05-26T05:03:16.000Z","updated_at":"2025-05-26T05:03:16.000Z","searchable_text":"Blaschke{{ FIELD }}Currently representing a large energy company in mass tort litigation arising from facility fire in California.{{ FIELD }}Member of national coordinating team of lawyers representing GlaxoSmithKline (“GSK”) in product liability litigation throughout the country, including allegations that the antidepressant Paxil® causes congenital defects. Matt has prepared numerous cases for trial; deposed plaintiffs as well as third-party witnesses and treating physicians; developed and executed pretrial strategy; briefed dispositive and procedural motions; and coordinated discovery.{{ FIELD }}Defended GSK before Pennsylvania appellate courts following summary judgment for GSK in product liability litigation including allegations that Paxil® caused congenital defects.{{ FIELD }}Represented a multinational pharmaceuticals manufacturer in personal injury action filed in Florida State Court. Matt coordinated removal of the action to federal court and then successfully moved to dismiss the action at the pleadings stage.{{ FIELD }}Defended the Dow Chemical Company (\"Dow\") in California product liability litigation in which plaintiffs allege that certain Dow products caused injuries to an employee at a manufacturing facility.{{ FIELD }}Defended Dow in a commercial dispute in California involving product liability claims concerning a plastic resin formerly manufactured by Dow.{{ FIELD }}Represented consumer product manufacturers in enforcement actions brought by California's Department of Pesticide Regulation.{{ FIELD }}Preparation for trial in multiple mass tort lawsuits alleging health and property claims, including drafting discovery, interviewing witnesses, and preparing fact witnesses for deposition testimony; also responsible for interviewing and preparing expert witnesses in fields of toxicology and municipal water delivery systems.{{ FIELD }}Participated as part of a multi-disciplinary team of attorneys and consultants conducting a risk assessment for a multinational pharmaceutical manufacturer in connection with the approval of a new medication. Matt assisted with Company by identifying and recommending steps to minimize product liability risk.{{ FIELD }}Participated in the defense of a bellwether lawsuit alleging health claims arising from exposure to dioxins, vinyl chloride, TCE and other soil and groundwater contaminants, including drafting Daubert motions to exclude plaintiffs’ expert witnesses.{{ FIELD }}Defended litigation arising under the Freedom of Information Act (FOIA) against client in the healthcare industry, including developing case strategy with codefendant federal agency, drafting dispositive motions, and negotiations with opposing counsel.{{ FIELD }}Defended litigation arising under state freedom of information laws for a nuclear power trade group, including drafting of dispositive motions, discovery responses, and settlement agreement to protect the confidentiality of client documents.{{ FIELD }}Matt Blaschke focuses on complex litigation involving scientific or technical issues, as well as general litigation. As a partner in our Environmental and Mass Tort and Toxic Tort practices, Matt represents energy, pharmaceutical, consumer product and chemical industry clients in state and federal courts throughout the country.\nMatt’s experience ranges from large-scale multiparty litigation to individual product liability actions. He also advises clients on environmental laws and regulations, including the federal Insecticide, Fungicide and Rodenticide Act. Matthew J Blaschke Partner Notre Dame  George Washington University George Washington University Law School U.S. District Court for the Central District of California U.S. District Court for the Eastern District of California U.S. District Court for the Northern District of California U.S. District Court for the Southern District of California California District of Columbia Currently representing a large energy company in mass tort litigation arising from facility fire in California. Member of national coordinating team of lawyers representing GlaxoSmithKline (“GSK”) in product liability litigation throughout the country, including allegations that the antidepressant Paxil® causes congenital defects. Matt has prepared numerous cases for trial; deposed plaintiffs as well as third-party witnesses and treating physicians; developed and executed pretrial strategy; briefed dispositive and procedural motions; and coordinated discovery. Defended GSK before Pennsylvania appellate courts following summary judgment for GSK in product liability litigation including allegations that Paxil® caused congenital defects. Represented a multinational pharmaceuticals manufacturer in personal injury action filed in Florida State Court. Matt coordinated removal of the action to federal court and then successfully moved to dismiss the action at the pleadings stage. Defended the Dow Chemical Company (\"Dow\") in California product liability litigation in which plaintiffs allege that certain Dow products caused injuries to an employee at a manufacturing facility. Defended Dow in a commercial dispute in California involving product liability claims concerning a plastic resin formerly manufactured by Dow. Represented consumer product manufacturers in enforcement actions brought by California's Department of Pesticide Regulation. Preparation for trial in multiple mass tort lawsuits alleging health and property claims, including drafting discovery, interviewing witnesses, and preparing fact witnesses for deposition testimony; also responsible for interviewing and preparing expert witnesses in fields of toxicology and municipal water delivery systems. Participated as part of a multi-disciplinary team of attorneys and consultants conducting a risk assessment for a multinational pharmaceutical manufacturer in connection with the approval of a new medication. Matt assisted with Company by identifying and recommending steps to minimize product liability risk. Participated in the defense of a bellwether lawsuit alleging health claims arising from exposure to dioxins, vinyl chloride, TCE and other soil and groundwater contaminants, including drafting Daubert motions to exclude plaintiffs’ expert witnesses. Defended litigation arising under the Freedom of Information Act (FOIA) against client in the healthcare industry, including developing case strategy with codefendant federal agency, drafting dispositive motions, and negotiations with opposing counsel. Defended litigation arising under state freedom of information laws for a nuclear power trade group, including drafting of dispositive motions, discovery responses, and settlement agreement to protect the confidentiality of client documents.","searchable_name":"Matthew J. Blaschke (Matt)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":32,"capability_group_featured":null,"home_page_featured":null},{"id":427703,"version":1,"owner_type":"Person","owner_id":1673,"payload":{"bio":"\u003cp\u003eBrian Bohnenkamp specializes in regulatory and compliance matters relating to drug, biotechnology and medical device companies. A partner in our FDA practice and a member of our Life Sciences group, Brian has extensive experience counseling manufacturers on fraud and abuse laws, industry codes of conduct, federal and state transparency laws and regulations, state and local gift bans, compliance program laws and sales representative licensing requirements, as well as government ethics restrictions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith a master\u0026rsquo;s degree in healthcare administration, Brian provides counsel to companies on a variety of laws and regulations administered and enforced by FDA, OIG, DOJ, and CMS, as well as by state attorneys general, boards of pharmacy, departments of health, and similar administrative and enforcement authorities. He regularly assists manufacturers in designing and implementing comprehensive compliance programs, and conducts risk assessments, audits and other reviews of compliance programs and business activities/operations.\u003c/p\u003e\n\u003cp\u003eBrian is regarded as a national expert on life sciences transparency laws and regulations, including the federal Physician Payments Sunshine Act (aka Open Payments) and similar state laws. He provides counsel to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of pharmaceutical, biotechnology and medical device manufacturers.\u003c/p\u003e","slug":"brian-bohnenkamp","email":"bbohnenkamp@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":25}]},"expertise":[{"id":103,"guid":"103.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":4,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":5,"source":"smartTags"},{"id":122,"guid":"122.capabilities","index":6,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":7,"source":"smartTags"},{"id":1193,"guid":"1193.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Bohnenkamp","nick_name":"Brian","clerkships":[],"first_name":"Brian","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"A.","name_suffix":"","recognitions":[{"title":"Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory ","detail":"Chambers USA, District of Columbia (2020-2022)"},{"title":"\"Brian's knowledge and experience are invaluable.\" ","detail":"Chambers USA (2022) "},{"title":"Next Generation Partner","detail":"Legal 500"},{"title":"Up and Coming for Pharmaceutical/Medical Products Regulatory","detail":"Chambers"},{"title":"Rising Star ","detail":"Washington, D.C. Super Lawyers, 2017-2020"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eBrian Bohnenkamp specializes in regulatory and compliance matters relating to drug, biotechnology and medical device companies. A partner in our FDA practice and a member of our Life Sciences group, Brian has extensive experience counseling manufacturers on fraud and abuse laws, industry codes of conduct, federal and state transparency laws and regulations, state and local gift bans, compliance program laws and sales representative licensing requirements, as well as government ethics restrictions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith a master\u0026rsquo;s degree in healthcare administration, Brian provides counsel to companies on a variety of laws and regulations administered and enforced by FDA, OIG, DOJ, and CMS, as well as by state attorneys general, boards of pharmacy, departments of health, and similar administrative and enforcement authorities. He regularly assists manufacturers in designing and implementing comprehensive compliance programs, and conducts risk assessments, audits and other reviews of compliance programs and business activities/operations.\u003c/p\u003e\n\u003cp\u003eBrian is regarded as a national expert on life sciences transparency laws and regulations, including the federal Physician Payments Sunshine Act (aka Open Payments) and similar state laws. He provides counsel to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of pharmaceutical, biotechnology and medical device manufacturers.\u003c/p\u003e","recognitions":[{"title":"Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory ","detail":"Chambers USA, District of Columbia (2020-2022)"},{"title":"\"Brian's knowledge and experience are invaluable.\" ","detail":"Chambers USA (2022) "},{"title":"Next Generation Partner","detail":"Legal 500"},{"title":"Up and Coming for Pharmaceutical/Medical Products Regulatory","detail":"Chambers"},{"title":"Rising Star ","detail":"Washington, D.C. Super Lawyers, 2017-2020"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":735}]},"capability_group_id":2},"created_at":"2025-05-26T05:03:56.000Z","updated_at":"2025-05-26T05:03:56.000Z","searchable_text":"Bohnenkamp{{ FIELD }}{:title=\u0026gt;\"Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory \", :detail=\u0026gt;\"Chambers USA, District of Columbia (2020-2022)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Brian's knowledge and experience are invaluable.\\\" \", :detail=\u0026gt;\"Chambers USA (2022) \"}{{ FIELD }}{:title=\u0026gt;\"Next Generation Partner\", :detail=\u0026gt;\"Legal 500\"}{{ FIELD }}{:title=\u0026gt;\"Up and Coming for Pharmaceutical/Medical Products Regulatory\", :detail=\u0026gt;\"Chambers\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star \", :detail=\u0026gt;\"Washington, D.C. Super Lawyers, 2017-2020\"}{{ FIELD }}Brian Bohnenkamp specializes in regulatory and compliance matters relating to drug, biotechnology and medical device companies. A partner in our FDA practice and a member of our Life Sciences group, Brian has extensive experience counseling manufacturers on fraud and abuse laws, industry codes of conduct, federal and state transparency laws and regulations, state and local gift bans, compliance program laws and sales representative licensing requirements, as well as government ethics restrictions.\nWith a master’s degree in healthcare administration, Brian provides counsel to companies on a variety of laws and regulations administered and enforced by FDA, OIG, DOJ, and CMS, as well as by state attorneys general, boards of pharmacy, departments of health, and similar administrative and enforcement authorities. He regularly assists manufacturers in designing and implementing comprehensive compliance programs, and conducts risk assessments, audits and other reviews of compliance programs and business activities/operations.\nBrian is regarded as a national expert on life sciences transparency laws and regulations, including the federal Physician Payments Sunshine Act (aka Open Payments) and similar state laws. He provides counsel to the Ad Hoc Sunshine and State Law Compliance Group, a coalition of pharmaceutical, biotechnology and medical device manufacturers. Brian A Bohnenkamp Partner Up and Coming, Healthcare: Pharmaceutical /Medical Products Regulatory  Chambers USA, District of Columbia (2020-2022) \"Brian's knowledge and experience are invaluable.\"  Chambers USA (2022)  Next Generation Partner Legal 500 Up and Coming for Pharmaceutical/Medical Products Regulatory Chambers Rising Star  Washington, D.C. Super Lawyers, 2017-2020 Indiana University Indiana University School of Law St. Louis University  St. Louis University  District of Columbia Illinois","searchable_name":"Brian A. Bohnenkamp","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":442359,"version":1,"owner_type":"Person","owner_id":850,"payload":{"bio":"\u003cp\u003eJim Boswell is co-head of King \u0026amp; Spalding's national Healthcare Team. His practice is devoted to handling litigation and investigations on behalf of healthcare industry clients. Jim also assists clients with regulatory and compliance questions and in connection with the negotiation of managed care agreements. Jim has particular expertise in handling managed care litigation on behalf of healthcare provider clients. He has also served as counsel in false claims act lawsuits in California, Georgia, Mississippi, Nevada, New York and Texas.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAn experienced healthcare litigator, Jim regularly handles motion arguments, hearings, arbitrations and trials\u0026nbsp;regarding specialized healthcare issues. He joined King \u0026amp; Spalding in 1992 after clerking on the United States Court of Appeals for the Fifth Circuit and became a partner of the firm in 1999.\u003c/p\u003e\n\u003cp\u003eJim has been listed in\u0026nbsp;\u003cem\u003eChambers USA, Super Lawyers, Best Lawyers in America,\u003c/em\u003e\u0026nbsp;and\u0026nbsp;\u003cem\u003eGeorgia Trend\u0026rsquo;s\u003c/em\u003e\u0026nbsp;Legal Elite. A member of the American Health Lawyers Association\u0026rsquo;s Board of Directors, he chaired their Healthcare Liability and Litigation Practice Group from 2009-2012. In 2008, Jim was recognized as one of 12 \u0026ldquo;Outstanding Healthcare Litigators\u0026rdquo; nationwide by\u0026nbsp;\u003cem\u003eNightingale\u0026rsquo;s Healthcare News.\u003c/em\u003e\u0026nbsp;He is a past Chair of the Health Law Section of the State Bar of Georgia. Jim is also a frequent speaker and presenter.\u003c/p\u003e","slug":"james-boswell","email":"jboswell@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":151}]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":3,"source":"smartTags"},{"id":114,"guid":"114.capabilities","index":4,"source":"capabilities"},{"id":740,"guid":"740.smart_tags","index":5,"source":"smartTags"},{"id":120,"guid":"120.capabilities","index":6,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":7,"source":"capabilities"},{"id":1187,"guid":"1187.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Boswell","nick_name":"Jim","clerkships":[{"name":"Law Clerk, Hon. Rhesa H. Barksdale, U.S. Court of Appeals for the Fifth Circuit","years_held":"1991 - 1992"}],"first_name":"James","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"W.","name_suffix":"III","recognitions":[{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Georgia (2014-2015, 2019-2022)"},{"title":"\"He's incredibly knowledgeable and can explain extremely complex healthcare regulations to the court.\"","detail":"Chambers USA (2022)"}],"linked_in_url":"https://www.linkedin.com/in/jimboswell2/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJim Boswell is co-head of King \u0026amp; Spalding's national Healthcare Team. His practice is devoted to handling litigation and investigations on behalf of healthcare industry clients. Jim also assists clients with regulatory and compliance questions and in connection with the negotiation of managed care agreements. Jim has particular expertise in handling managed care litigation on behalf of healthcare provider clients. He has also served as counsel in false claims act lawsuits in California, Georgia, Mississippi, Nevada, New York and Texas.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAn experienced healthcare litigator, Jim regularly handles motion arguments, hearings, arbitrations and trials\u0026nbsp;regarding specialized healthcare issues. He joined King \u0026amp; Spalding in 1992 after clerking on the United States Court of Appeals for the Fifth Circuit and became a partner of the firm in 1999.\u003c/p\u003e\n\u003cp\u003eJim has been listed in\u0026nbsp;\u003cem\u003eChambers USA, Super Lawyers, Best Lawyers in America,\u003c/em\u003e\u0026nbsp;and\u0026nbsp;\u003cem\u003eGeorgia Trend\u0026rsquo;s\u003c/em\u003e\u0026nbsp;Legal Elite. A member of the American Health Lawyers Association\u0026rsquo;s Board of Directors, he chaired their Healthcare Liability and Litigation Practice Group from 2009-2012. In 2008, Jim was recognized as one of 12 \u0026ldquo;Outstanding Healthcare Litigators\u0026rdquo; nationwide by\u0026nbsp;\u003cem\u003eNightingale\u0026rsquo;s Healthcare News.\u003c/em\u003e\u0026nbsp;He is a past Chair of the Health Law Section of the State Bar of Georgia. Jim is also a frequent speaker and presenter.\u003c/p\u003e","recognitions":[{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Georgia (2014-2015, 2019-2022)"},{"title":"\"He's incredibly knowledgeable and can explain extremely complex healthcare regulations to the court.\"","detail":"Chambers USA (2022)"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":5812}]},"capability_group_id":2},"created_at":"2025-11-05T05:03:26.000Z","updated_at":"2025-11-05T05:03:26.000Z","searchable_text":"Boswell{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, Healthcare\", :detail=\u0026gt;\"Chambers USA, Georgia (2014-2015, 2019-2022)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"He's incredibly knowledgeable and can explain extremely complex healthcare regulations to the court.\\\"\", :detail=\u0026gt;\"Chambers USA (2022)\"}{{ FIELD }}Jim Boswell is co-head of King \u0026amp; Spalding's national Healthcare Team. His practice is devoted to handling litigation and investigations on behalf of healthcare industry clients. Jim also assists clients with regulatory and compliance questions and in connection with the negotiation of managed care agreements. Jim has particular expertise in handling managed care litigation on behalf of healthcare provider clients. He has also served as counsel in false claims act lawsuits in California, Georgia, Mississippi, Nevada, New York and Texas.\nAn experienced healthcare litigator, Jim regularly handles motion arguments, hearings, arbitrations and trials regarding specialized healthcare issues. He joined King \u0026amp; Spalding in 1992 after clerking on the United States Court of Appeals for the Fifth Circuit and became a partner of the firm in 1999.\nJim has been listed in Chambers USA, Super Lawyers, Best Lawyers in America, and Georgia Trend’s Legal Elite. A member of the American Health Lawyers Association’s Board of Directors, he chaired their Healthcare Liability and Litigation Practice Group from 2009-2012. In 2008, Jim was recognized as one of 12 “Outstanding Healthcare Litigators” nationwide by Nightingale’s Healthcare News. He is a past Chair of the Health Law Section of the State Bar of Georgia. Jim is also a frequent speaker and presenter. James W Boswell Partner Top Ranked Lawyer, Healthcare Chambers USA, Georgia (2014-2015, 2019-2022) \"He's incredibly knowledgeable and can explain extremely complex healthcare regulations to the court.\" Chambers USA (2022) Millsaps College  Harvard University Harvard Law School Georgia State Bar of Georgia Law Clerk, Hon. Rhesa H. Barksdale, U.S. Court of Appeals for the Fifth Circuit","searchable_name":"James W. Boswell III (Jim)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":447104,"version":1,"owner_type":"Person","owner_id":6224,"payload":{"bio":"\u003cp\u003eSara Brinkmann represents healthcare and life sciences clients in investigations and litigation in federal courts, state courts, arbitrations, and administrative proceedings across the country.\u0026nbsp; Sara has particular expertise in handling matters that arise under the federal False Claims Act and its state law analogues.\u0026nbsp; Sara also focuses on managed care litigation and has successfully recovered millions of dollars for healthcare providers in disputes against heath plans.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAn experienced litigator, Sara also represents her clients in disputes involving contracts, business torts, antitrust, and products liability issues. Sara's clients include hospitals, academic medical centers, medical groups, retail pharmacies, medical device companies, pharmaceutical companies, and other life sciences companies.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn additional to her litigation practice, she regularly advises clients on regulatory and compliance matters, including those that involved the Stark Law, the Anti-Kickback Statute, and other fraud and abuse laws. She also provides counseling and training regarding policies, compliance programs, self-disclosures, and billing matters.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThrough \u003cem\u003eChambers USA\u003c/em\u003e, her clients have said:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \"Sara Brinkmann is an excellent litigator. She is very knowledgeable, highly organized, and a pleasure to work with.\"\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \"She cares about each of her cases and comes up with creative ideas to problem-solve.\" \u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \"Sara Brinkmann is a fantastic lawyer.\"\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eSara is regularly recognized by publications like \u003cem\u003eChambers,\u0026nbsp;\u003c/em\u003e\u003cem\u003eBest Lawyers in America, \u003c/em\u003eand \u003cem\u003eSuper Lawyers\u003c/em\u003e. She is the past\u0026nbsp;Chair of the Health Law Section of the Houston Bar Association. She is also a frequent speaker and presenter on a variety of healthcare topics.\u003c/p\u003e","slug":"sara-brinkmann","email":"sbrinkmann@kslaw.com","phone":"+1 713 295 9930","matters":["\u003cp\u003eSuccessfully defended a nationwide retail pharmacy client in a False Claims Act case in the Southern District of Texas and on appeal in the Fifth Circuit Court of Appeals involving allegations of regulatory violations related to the dispensing of certain pharmaceuticals, resulting in a full dismissal of the case prior to discovery and was affirmed on appeal at the Fifth Circuit.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a hospital system in a False Claims Act case in the Southern District of Texas involving allegations of Stark Law and Anti-Kickback Statute violations related to physician recruitment and compensation arrangements, resulting in a favorable settlement for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a hospital system in a False Claims Act case in the Eastern District of Wisconsin involving allegations of Stark Law and Anti-Kickback Statute violations related to physician group compensation, resulting in a favorable settlement for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully defended an international medical device company in a False Claims Act case in the District of New Jersey involving allegations of coding errors on claim submissions, resulting in a favorable settlement for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully defended nationwide retail pharmacy in a False Claims Act case in the Central District of Illinois involving allegations related to usual and customary pricing, resulting in the Court\u0026rsquo;s grant of a Motion for Summary Judgment and dismissal of case.\u003c/p\u003e","\u003cp\u003eSuccessfully defended several higher education institutions, academic medical centers, and life sciences companies in responding to Civil Investigative Demands and other government investigation, including conducting internal investigations and presenting to the government.\u003c/p\u003e","\u003cp\u003eAdvised several higher education institutions on legal and compliance issues, including developing, implementing, and providing training to employees.\u003c/p\u003e","\u003cp\u003eAdvised hospital systems regarding affiliation agreements and other complex transactions.\u003c/p\u003e","\u003cp\u003eAdvised and provided due diligence support to healthcare companies and hospital systems for mergers and acquisitions.\u003c/p\u003e","\u003cp\u003eAdvised hospital system regarding data privacy and HIPAA compliance issues in responding to third-party subpoenas.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a government defense contractor in a False Claims Act case in the Eastern District of Texas involving allegations of kickbacks and failure to comply with certain Federal Acquisition Regulations.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a pharmaceutical company in several product liability cases in federal and state courts across the country.\u003c/p\u003e","\u003cp\u003eSuccessfully represented hospitals systems and other healthcare providers in Texas federal and state court cases involving allegations of breach of contract, violations of Texas Deceptive Trade Practices Act and Texas Uniform Fraudulent Transfer Act, and health care liability claim cases.\u003c/p\u003e","\u003cp\u003eSuccessfully represented a hospital system in responding to Medicare RAC audits, securing full reimbursements for hospital system.\u003c/p\u003e","\u003cp\u003eRepresented a Louisiana hospital system in federal antitrust case.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a managed care organization in response to investigation by the Texas Office of Inspector General, resulting in a favorable result for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully represented a hospital system in responding to third-party subpoenas successfully securing full reimbursements for hospital systems, including obtaining recovery of attorneys\u0026rsquo; fees after prosecuting numerous motions to quash and motions for protection of medical and forensic records in civil, family, and criminal cases.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":1,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":2,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":3,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":109,"guid":"109.capabilities","index":6,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":7,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":8,"source":"smartTags"},{"id":761,"guid":"761.smart_tags","index":9,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"Brinkmann","nick_name":"Sara","clerkships":[{"name":"Law Clerk, Hon. David Hittner, Texas","years_held":"2009 - 2011"}],"first_name":"Sara","title_rank":9999,"updated_by":202,"law_schools":[{"id":2197,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2009-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"\"She is very calm, organized and responsive.\"","detail":"Chambers USA, 2025"},{"title":"\"Sara has a very service-oriented ethos in how she practices.\"","detail":"Chambers USA, 2025"},{"title":"Ranked as a Band 3 lawyer for Healthcare: Government Matters \u0026 Regulation","detail":"Chambers USA, 2025"},{"title":"Ranked as a Key Lawyer for Healthcare: Service Providers","detail":"Legal 500 USA, 2025"},{"title":"\"Sara is very good at keeping larger business outcomes in mind.\"","detail":"Chambers USA 2024"},{"title":"\"Sara is intelligent and customer-focused, responsive and competent.\"","detail":"Chambers USA 2024"},{"title":"\"Sara is an exceptional attorney who provided outstanding legal analysis.\"","detail":"Chambers USA 2024"},{"title":"Ranked Band 3 for Healthcare in Texas","detail":"Chambers USA 2024"},{"title":"Women in the Law","detail":"Best Lawyers, 2022"},{"title":"Top Rated Houston, TX Health Care Attorney","detail":"Super Lawyers, 2023-2024"},{"title":"Top Women Attorneys in Texas","detail":"2024"},{"title":"Best Lawyers in America","detail":"Best Lawyers - Texas, 2021 - 2023"},{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Texas, 2021-2023"},{"title":"“Sara Brinkmann comes recommended for her expert handling of qui tam actions brought under the False Claims Act.”","detail":"Chambers USA 2022"},{"title":"“Sara offers notable experience in litigation and administrative proceedings.”","detail":"Chambers USA 2022"},{"title":"“Sara Brinkmann possesses significant experience and knowledge on complex issues.”","detail":"Chambers USA 2022"},{"title":"Sara is “organized and approachable, and offers thoughtful approaches on ways to achieve the desired result.”","detail":"Chambers USA 2022"},{"title":"“She is a really sharp lawyer.”","detail":"Chambers USA 2022"}],"linked_in_url":"https://www.linkedin.com/in/sara-brinkmann-23b78335","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eSara Brinkmann represents healthcare and life sciences clients in investigations and litigation in federal courts, state courts, arbitrations, and administrative proceedings across the country.\u0026nbsp; Sara has particular expertise in handling matters that arise under the federal False Claims Act and its state law analogues.\u0026nbsp; Sara also focuses on managed care litigation and has successfully recovered millions of dollars for healthcare providers in disputes against heath plans.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAn experienced litigator, Sara also represents her clients in disputes involving contracts, business torts, antitrust, and products liability issues. Sara's clients include hospitals, academic medical centers, medical groups, retail pharmacies, medical device companies, pharmaceutical companies, and other life sciences companies.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn additional to her litigation practice, she regularly advises clients on regulatory and compliance matters, including those that involved the Stark Law, the Anti-Kickback Statute, and other fraud and abuse laws. She also provides counseling and training regarding policies, compliance programs, self-disclosures, and billing matters.\u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThrough \u003cem\u003eChambers USA\u003c/em\u003e, her clients have said:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \"Sara Brinkmann is an excellent litigator. She is very knowledgeable, highly organized, and a pleasure to work with.\"\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \"She cares about each of her cases and comes up with creative ideas to problem-solve.\" \u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp; \"Sara Brinkmann is a fantastic lawyer.\"\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eSara is regularly recognized by publications like \u003cem\u003eChambers,\u0026nbsp;\u003c/em\u003e\u003cem\u003eBest Lawyers in America, \u003c/em\u003eand \u003cem\u003eSuper Lawyers\u003c/em\u003e. She is the past\u0026nbsp;Chair of the Health Law Section of the Houston Bar Association. She is also a frequent speaker and presenter on a variety of healthcare topics.\u003c/p\u003e","matters":["\u003cp\u003eSuccessfully defended a nationwide retail pharmacy client in a False Claims Act case in the Southern District of Texas and on appeal in the Fifth Circuit Court of Appeals involving allegations of regulatory violations related to the dispensing of certain pharmaceuticals, resulting in a full dismissal of the case prior to discovery and was affirmed on appeal at the Fifth Circuit.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a hospital system in a False Claims Act case in the Southern District of Texas involving allegations of Stark Law and Anti-Kickback Statute violations related to physician recruitment and compensation arrangements, resulting in a favorable settlement for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a hospital system in a False Claims Act case in the Eastern District of Wisconsin involving allegations of Stark Law and Anti-Kickback Statute violations related to physician group compensation, resulting in a favorable settlement for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully defended an international medical device company in a False Claims Act case in the District of New Jersey involving allegations of coding errors on claim submissions, resulting in a favorable settlement for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully defended nationwide retail pharmacy in a False Claims Act case in the Central District of Illinois involving allegations related to usual and customary pricing, resulting in the Court\u0026rsquo;s grant of a Motion for Summary Judgment and dismissal of case.\u003c/p\u003e","\u003cp\u003eSuccessfully defended several higher education institutions, academic medical centers, and life sciences companies in responding to Civil Investigative Demands and other government investigation, including conducting internal investigations and presenting to the government.\u003c/p\u003e","\u003cp\u003eAdvised several higher education institutions on legal and compliance issues, including developing, implementing, and providing training to employees.\u003c/p\u003e","\u003cp\u003eAdvised hospital systems regarding affiliation agreements and other complex transactions.\u003c/p\u003e","\u003cp\u003eAdvised and provided due diligence support to healthcare companies and hospital systems for mergers and acquisitions.\u003c/p\u003e","\u003cp\u003eAdvised hospital system regarding data privacy and HIPAA compliance issues in responding to third-party subpoenas.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a government defense contractor in a False Claims Act case in the Eastern District of Texas involving allegations of kickbacks and failure to comply with certain Federal Acquisition Regulations.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a pharmaceutical company in several product liability cases in federal and state courts across the country.\u003c/p\u003e","\u003cp\u003eSuccessfully represented hospitals systems and other healthcare providers in Texas federal and state court cases involving allegations of breach of contract, violations of Texas Deceptive Trade Practices Act and Texas Uniform Fraudulent Transfer Act, and health care liability claim cases.\u003c/p\u003e","\u003cp\u003eSuccessfully represented a hospital system in responding to Medicare RAC audits, securing full reimbursements for hospital system.\u003c/p\u003e","\u003cp\u003eRepresented a Louisiana hospital system in federal antitrust case.\u003c/p\u003e","\u003cp\u003eSuccessfully defended a managed care organization in response to investigation by the Texas Office of Inspector General, resulting in a favorable result for the client.\u003c/p\u003e","\u003cp\u003eSuccessfully represented a hospital system in responding to third-party subpoenas successfully securing full reimbursements for hospital systems, including obtaining recovery of attorneys\u0026rsquo; fees after prosecuting numerous motions to quash and motions for protection of medical and forensic records in civil, family, and criminal cases.\u003c/p\u003e"],"recognitions":[{"title":"\"She is very calm, organized and responsive.\"","detail":"Chambers USA, 2025"},{"title":"\"Sara has a very service-oriented ethos in how she practices.\"","detail":"Chambers USA, 2025"},{"title":"Ranked as a Band 3 lawyer for Healthcare: Government Matters \u0026 Regulation","detail":"Chambers USA, 2025"},{"title":"Ranked as a Key Lawyer for Healthcare: Service Providers","detail":"Legal 500 USA, 2025"},{"title":"\"Sara is very good at keeping larger business outcomes in mind.\"","detail":"Chambers USA 2024"},{"title":"\"Sara is intelligent and customer-focused, responsive and competent.\"","detail":"Chambers USA 2024"},{"title":"\"Sara is an exceptional attorney who provided outstanding legal analysis.\"","detail":"Chambers USA 2024"},{"title":"Ranked Band 3 for Healthcare in Texas","detail":"Chambers USA 2024"},{"title":"Women in the Law","detail":"Best Lawyers, 2022"},{"title":"Top Rated Houston, TX Health Care Attorney","detail":"Super Lawyers, 2023-2024"},{"title":"Top Women Attorneys in Texas","detail":"2024"},{"title":"Best Lawyers in America","detail":"Best Lawyers - Texas, 2021 - 2023"},{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Texas, 2021-2023"},{"title":"“Sara Brinkmann comes recommended for her expert handling of qui tam actions brought under the False Claims Act.”","detail":"Chambers USA 2022"},{"title":"“Sara offers notable experience in litigation and administrative proceedings.”","detail":"Chambers USA 2022"},{"title":"“Sara Brinkmann possesses significant experience and knowledge on complex issues.”","detail":"Chambers USA 2022"},{"title":"Sara is “organized and approachable, and offers thoughtful approaches on ways to achieve the desired result.”","detail":"Chambers USA 2022"},{"title":"“She is a really sharp lawyer.”","detail":"Chambers USA 2022"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9607}]},"capability_group_id":2},"created_at":"2026-03-27T19:04:30.000Z","updated_at":"2026-03-27T19:04:30.000Z","searchable_text":"Brinkmann{{ FIELD }}{:title=\u0026gt;\"\\\"She is very calm, organized and responsive.\\\"\", :detail=\u0026gt;\"Chambers USA, 2025\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Sara has a very service-oriented ethos in how she practices.\\\"\", :detail=\u0026gt;\"Chambers USA, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Ranked as a Band 3 lawyer for Healthcare: Government Matters \u0026amp; Regulation\", :detail=\u0026gt;\"Chambers USA, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Ranked as a Key Lawyer for Healthcare: Service Providers\", :detail=\u0026gt;\"Legal 500 USA, 2025\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Sara is very good at keeping larger business outcomes in mind.\\\"\", :detail=\u0026gt;\"Chambers USA 2024\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Sara is intelligent and customer-focused, responsive and competent.\\\"\", :detail=\u0026gt;\"Chambers USA 2024\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Sara is an exceptional attorney who provided outstanding legal analysis.\\\"\", :detail=\u0026gt;\"Chambers USA 2024\"}{{ FIELD }}{:title=\u0026gt;\"Ranked Band 3 for Healthcare in Texas\", :detail=\u0026gt;\"Chambers USA 2024\"}{{ FIELD }}{:title=\u0026gt;\"Women in the Law\", :detail=\u0026gt;\"Best Lawyers, 2022\"}{{ FIELD }}{:title=\u0026gt;\"Top Rated Houston, TX Health Care Attorney\", :detail=\u0026gt;\"Super Lawyers, 2023-2024\"}{{ FIELD }}{:title=\u0026gt;\"Top Women Attorneys in Texas\", :detail=\u0026gt;\"2024\"}{{ FIELD }}{:title=\u0026gt;\"Best Lawyers in America\", :detail=\u0026gt;\"Best Lawyers - Texas, 2021 - 2023\"}{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, Healthcare\", :detail=\u0026gt;\"Chambers USA, Texas, 2021-2023\"}{{ FIELD }}{:title=\u0026gt;\"“Sara Brinkmann comes recommended for her expert handling of qui tam actions brought under the False Claims Act.”\", :detail=\u0026gt;\"Chambers USA 2022\"}{{ FIELD }}{:title=\u0026gt;\"“Sara offers notable experience in litigation and administrative proceedings.”\", :detail=\u0026gt;\"Chambers USA 2022\"}{{ FIELD }}{:title=\u0026gt;\"“Sara Brinkmann possesses significant experience and knowledge on complex issues.”\", :detail=\u0026gt;\"Chambers USA 2022\"}{{ FIELD }}{:title=\u0026gt;\"Sara is “organized and approachable, and offers thoughtful approaches on ways to achieve the desired result.”\", :detail=\u0026gt;\"Chambers USA 2022\"}{{ FIELD }}{:title=\u0026gt;\"“She is a really sharp lawyer.”\", :detail=\u0026gt;\"Chambers USA 2022\"}{{ FIELD }}Successfully defended a nationwide retail pharmacy client in a False Claims Act case in the Southern District of Texas and on appeal in the Fifth Circuit Court of Appeals involving allegations of regulatory violations related to the dispensing of certain pharmaceuticals, resulting in a full dismissal of the case prior to discovery and was affirmed on appeal at the Fifth Circuit.{{ FIELD }}Successfully defended a hospital system in a False Claims Act case in the Southern District of Texas involving allegations of Stark Law and Anti-Kickback Statute violations related to physician recruitment and compensation arrangements, resulting in a favorable settlement for the client.{{ FIELD }}Successfully defended a hospital system in a False Claims Act case in the Eastern District of Wisconsin involving allegations of Stark Law and Anti-Kickback Statute violations related to physician group compensation, resulting in a favorable settlement for the client.{{ FIELD }}Successfully defended an international medical device company in a False Claims Act case in the District of New Jersey involving allegations of coding errors on claim submissions, resulting in a favorable settlement for the client.{{ FIELD }}Successfully defended nationwide retail pharmacy in a False Claims Act case in the Central District of Illinois involving allegations related to usual and customary pricing, resulting in the Court’s grant of a Motion for Summary Judgment and dismissal of case.{{ FIELD }}Successfully defended several higher education institutions, academic medical centers, and life sciences companies in responding to Civil Investigative Demands and other government investigation, including conducting internal investigations and presenting to the government.{{ FIELD }}Advised several higher education institutions on legal and compliance issues, including developing, implementing, and providing training to employees.{{ FIELD }}Advised hospital systems regarding affiliation agreements and other complex transactions.{{ FIELD }}Advised and provided due diligence support to healthcare companies and hospital systems for mergers and acquisitions.{{ FIELD }}Advised hospital system regarding data privacy and HIPAA compliance issues in responding to third-party subpoenas.{{ FIELD }}Successfully defended a government defense contractor in a False Claims Act case in the Eastern District of Texas involving allegations of kickbacks and failure to comply with certain Federal Acquisition Regulations.{{ FIELD }}Successfully defended a pharmaceutical company in several product liability cases in federal and state courts across the country.{{ FIELD }}Successfully represented hospitals systems and other healthcare providers in Texas federal and state court cases involving allegations of breach of contract, violations of Texas Deceptive Trade Practices Act and Texas Uniform Fraudulent Transfer Act, and health care liability claim cases.{{ FIELD }}Successfully represented a hospital system in responding to Medicare RAC audits, securing full reimbursements for hospital system.{{ FIELD }}Represented a Louisiana hospital system in federal antitrust case.{{ FIELD }}Successfully defended a managed care organization in response to investigation by the Texas Office of Inspector General, resulting in a favorable result for the client.{{ FIELD }}Successfully represented a hospital system in responding to third-party subpoenas successfully securing full reimbursements for hospital systems, including obtaining recovery of attorneys’ fees after prosecuting numerous motions to quash and motions for protection of medical and forensic records in civil, family, and criminal cases.{{ FIELD }}Sara Brinkmann represents healthcare and life sciences clients in investigations and litigation in federal courts, state courts, arbitrations, and administrative proceedings across the country.  Sara has particular expertise in handling matters that arise under the federal False Claims Act and its state law analogues.  Sara also focuses on managed care litigation and has successfully recovered millions of dollars for healthcare providers in disputes against heath plans. \nAn experienced litigator, Sara also represents her clients in disputes involving contracts, business torts, antitrust, and products liability issues. Sara's clients include hospitals, academic medical centers, medical groups, retail pharmacies, medical device companies, pharmaceutical companies, and other life sciences companies.  \nIn additional to her litigation practice, she regularly advises clients on regulatory and compliance matters, including those that involved the Stark Law, the Anti-Kickback Statute, and other fraud and abuse laws. She also provides counseling and training regarding policies, compliance programs, self-disclosures, and billing matters.  \nThrough Chambers USA, her clients have said: \n     \"Sara Brinkmann is an excellent litigator. She is very knowledgeable, highly organized, and a pleasure to work with.\"\n     \"She cares about each of her cases and comes up with creative ideas to problem-solve.\" \n     \"Sara Brinkmann is a fantastic lawyer.\"\nSara is regularly recognized by publications like Chambers, Best Lawyers in America, and Super Lawyers. She is the past Chair of the Health Law Section of the Houston Bar Association. She is also a frequent speaker and presenter on a variety of healthcare topics. Partner \"She is very calm, organized and responsive.\" Chambers USA, 2025 \"Sara has a very service-oriented ethos in how she practices.\" Chambers USA, 2025 Ranked as a Band 3 lawyer for Healthcare: Government Matters \u0026amp; Regulation Chambers USA, 2025 Ranked as a Key Lawyer for Healthcare: Service Providers Legal 500 USA, 2025 \"Sara is very good at keeping larger business outcomes in mind.\" Chambers USA 2024 \"Sara is intelligent and customer-focused, responsive and competent.\" Chambers USA 2024 \"Sara is an exceptional attorney who provided outstanding legal analysis.\" Chambers USA 2024 Ranked Band 3 for Healthcare in Texas Chambers USA 2024 Women in the Law Best Lawyers, 2022 Top Rated Houston, TX Health Care Attorney Super Lawyers, 2023-2024 Top Women Attorneys in Texas 2024 Best Lawyers in America Best Lawyers - Texas, 2021 - 2023 Top Ranked Lawyer, Healthcare Chambers USA, Texas, 2021-2023 “Sara Brinkmann comes recommended for her expert handling of qui tam actions brought under the False Claims Act.” Chambers USA 2022 “Sara offers notable experience in litigation and administrative proceedings.” Chambers USA 2022 “Sara Brinkmann possesses significant experience and knowledge on complex issues.” Chambers USA 2022 Sara is “organized and approachable, and offers thoughtful approaches on ways to achieve the desired result.” Chambers USA 2022 “She is a really sharp lawyer.” Chambers USA 2022 Baylor University Baylor University School of Law University of Houston University of Houston Law Center University of Houston University of Houston Law Center Texas Houston Bar Association, Member (Health Law Section, Chair 2021-2022; Campaign for the Homeless Committee, Former Member; Law Week Committee, Former Member) Federal Bar Association, Member State Bar of Texas, Member Texas Bar Foundation, Fellow Defense Research Institute, Member Greater Houston Society for Healthcare Risk Management Law Clerk, Hon. David Hittner, Texas Successfully defended a nationwide retail pharmacy client in a False Claims Act case in the Southern District of Texas and on appeal in the Fifth Circuit Court of Appeals involving allegations of regulatory violations related to the dispensing of certain pharmaceuticals, resulting in a full dismissal of the case prior to discovery and was affirmed on appeal at the Fifth Circuit. Successfully defended a hospital system in a False Claims Act case in the Southern District of Texas involving allegations of Stark Law and Anti-Kickback Statute violations related to physician recruitment and compensation arrangements, resulting in a favorable settlement for the client. Successfully defended a hospital system in a False Claims Act case in the Eastern District of Wisconsin involving allegations of Stark Law and Anti-Kickback Statute violations related to physician group compensation, resulting in a favorable settlement for the client. Successfully defended an international medical device company in a False Claims Act case in the District of New Jersey involving allegations of coding errors on claim submissions, resulting in a favorable settlement for the client. Successfully defended nationwide retail pharmacy in a False Claims Act case in the Central District of Illinois involving allegations related to usual and customary pricing, resulting in the Court’s grant of a Motion for Summary Judgment and dismissal of case. Successfully defended several higher education institutions, academic medical centers, and life sciences companies in responding to Civil Investigative Demands and other government investigation, including conducting internal investigations and presenting to the government. Advised several higher education institutions on legal and compliance issues, including developing, implementing, and providing training to employees. Advised hospital systems regarding affiliation agreements and other complex transactions. Advised and provided due diligence support to healthcare companies and hospital systems for mergers and acquisitions. Advised hospital system regarding data privacy and HIPAA compliance issues in responding to third-party subpoenas. Successfully defended a government defense contractor in a False Claims Act case in the Eastern District of Texas involving allegations of kickbacks and failure to comply with certain Federal Acquisition Regulations. Successfully defended a pharmaceutical company in several product liability cases in federal and state courts across the country. Successfully represented hospitals systems and other healthcare providers in Texas federal and state court cases involving allegations of breach of contract, violations of Texas Deceptive Trade Practices Act and Texas Uniform Fraudulent Transfer Act, and health care liability claim cases. Successfully represented a hospital system in responding to Medicare RAC audits, securing full reimbursements for hospital system. Represented a Louisiana hospital system in federal antitrust case. Successfully defended a managed care organization in response to investigation by the Texas Office of Inspector General, resulting in a favorable result for the client. Successfully represented a hospital system in responding to third-party subpoenas successfully securing full reimbursements for hospital systems, including obtaining recovery of attorneys’ fees after prosecuting numerous motions to quash and motions for protection of medical and forensic records in civil, family, and criminal cases.","searchable_name":"Sara Brinkmann","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442372,"version":1,"owner_type":"Person","owner_id":883,"payload":{"bio":"\u003cp\u003eMark Brown is nationally recognized in Food \u0026amp; Drug Administration regulatory matters, civil litigation, criminal investigations and prosecutions, compliance matters and comprehensive risk assessments. Mark advises pharmaceutical, medical device and biotech companies, and pharmacies, on a broad range of FDA requirements and FDA regulatory issues that arise in products liability litigation and other disputes. A former Associate Chief Counsel for FDA, Mark is the Chair of the FDA and Life Sciences practice.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMark has developed a national reputation for successfully resolving difficult and complex FDA compliance matters and enforcement actions. For pharmaceutical, medical device and food companies, and pharmacies, he has successfully negotiated and managed numerous complex consent decrees of injunction, successfully defended an injunction action brought by FDA, and persuaded the government not to bring enforcement actions in other civil and criminal matters.\u003c/p\u003e\n\u003cp\u003eMark regularly counsels clients on drug safety issues, clinical trials, adverse event reporting, quality systems and manufacturing practices for drugs and devices. He also provides guidance concerning product failure investigations, factory inspections, recalls, product labeling, drug compounding, advertising, promotion, sales and marketing practices, and regularly advises clients on strategies for obtaining FDA approval and clearance for medical products.\u003c/p\u003e\n\u003cp\u003eMark also handles FDA-related issues in product liability and commercial litigation. He was an architect of the preemption defense for both pharmaceutical and medical device clients, developing supporting evidence, briefing and arguing federal preemption motions in various federal and state courts.\u003c/p\u003e\n\u003cp\u003eBefore joining the FDA, Mark was an attorney in the Bureau of Consumer Protection at the Federal Trade Commission, where he concentrated on consumer fraud, healthcare advertising and promotional activities. He developed FTC enforcement actions against weight-loss centers, in vitro fertilization clinics and Northern Virginia infertility doctor Cecil B. Jacobson, who was later convicted of defrauding patients.\u003c/p\u003e","slug":"mark-brown","email":"mbrown@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003e\u003cstrong data-redactor-tag=\"strong\"\u003ePhillip Morris USA\u003c/strong\u003e v. FDA\u003c/em\u003e, 202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eUnited States v. \u003cstrong data-redactor-tag=\"strong\"\u003eFranck's Lab\u003c/strong\u003e\u003c/em\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e,\u003c/strong\u003e 2011 WL 4031102 (M.D. Fla., Sept. 12, 2011). Lead counsel in successful defense of FDA enforcement action against pharmacy compounder of veterinary drugs.\u003c/p\u003e","\u003cp\u003eDuring his 30-year career, he has served as lead counsel and negotiator for numerous consent decrees of injunction, both during his tenure with FDA (1990\u0026ndash;1994), and since 1994 in private practice. For example, he has negotiated consent decrees some of the world's largest device manufacturers, including \u003cstrong data-redactor-tag=\"strong\"\u003eMedtronic\u003c/strong\u003e (2008 and 2015), \u003cstrong data-redactor-tag=\"strong\"\u003eThe General Electric Company\u003c/strong\u003e (2007) and \u003cstrong data-redactor-tag=\"strong\"\u003eBaxter Healthcare\u003c/strong\u003e (2006).\u003c/p\u003e","\u003cp\u003eSince 2002, served on the national counsel team for \u003cstrong data-redactor-tag=\"strong\"\u003eGlaxoSmithKline\u003c/strong\u003e in the Paxil Products Liability Litigation. Represented GSK on all FDA-related issues, including federal preemption. Argued and won a summary judgment motion on federal preemption grounds in \u003cem data-redactor-tag=\"em\"\u003eO'Neal v. \u003cstrong data-redactor-tag=\"strong\"\u003eSmithKline Beecham\u003c/strong\u003e\u003c/em\u003e (E.D. Cal 2008). In 2002, represented GSK in successfully defending an injunction seeking to enjoin GSK from making claims in direct-to-consumer television advertising for Paxil.\u003c/p\u003e","\u003cp\u003eFrom 1995 to 2001, served on \u003cstrong data-redactor-tag=\"strong\"\u003e3M\u003c/strong\u003e's National Trial Team in the Silicone Gel-Filled Breast Implant Litigation. Responsible for virtually all FDA issues and had primary responsibility for preparation and handling of defense expert witnesses, and cross-examination of adverse witnesses on FDA issues.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eConnaught Laboratories v. \u003cstrong data-redactor-tag=\"strong\"\u003eSmithKline Beecham\u003c/strong\u003e\u003c/em\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e,\u003c/strong\u003e 7 F.Supp. 2d 477 (D.Del. 1998), appeal dismissed, 165 F.3d 1368 (1999). Represented SmithKline Beecham in winning one of the few successful motions to compel FDA to provide testimony by its research scientists in patent litigation relating to purified form of pertactin, a component of the pertussis vaccine.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003e\u003cstrong data-redactor-tag=\"strong\"\u003eNext Nutrition\u003c/strong\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e, Inc.\u003c/strong\u003e\u003c/em\u003e \u003cem data-redactor-tag=\"em\"\u003ev. SportPharma USA, Inc.\u003c/em\u003e, No. 97-CV-1898J (1997). Served as lead counsel to a dietary supplement company that brought an action under the Lanham Act alleging false and misleading comparative advertising relating to competing products. Successfully negotiated a favorable settlement by obtaining a consent decree of permanent injunction and a damage award.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical manufacturers\u003c/strong\u003e in grand jury investigations regarding data integrity concerns in regulatory submissions to FDA, and alleged cGMP violations. In both cases, the U.S. Department of Justice declined to prosecute the company and individuals under investigation.\u003c/p\u003e","\u003cp\u003eConducted internal investigations into the sales and marketing practices of \u003cstrong data-redactor-tag=\"strong\"\u003emultiple international pharmaceutical and biotech companies\u003c/strong\u003e to develop a risk profile and recommendations for reducing potential liability and risk exposure.\u003c/p\u003e","\u003cp\u003eConducted comprehensive prelaunch risk assessments for \u003cstrong data-redactor-tag=\"strong\"\u003ea Top 10 pharmaceutical company\u003c/strong\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e\u0026rsquo;s\u003c/strong\u003e blockbuster drug to identify potential medical, scientific, regulatory and products liability risk areas.\u003c/p\u003e","\u003cp\u003eConducted a risk assessment for \u003cstrong data-redactor-tag=\"strong\"\u003ea top tier biotechnology company\u0026rsquo;s\u003c/strong\u003e drug safety system to identify areas for possible improvement in pharmacovigilence planning, postmarket signal detection and investigation, and business decision-making.\u003c/p\u003e","\u003cp\u003eLed numerous internal investigations for \u003cstrong data-redactor-tag=\"strong\"\u003ebiotechnology, pharmaceutical and medical device manufacturers\u003c/strong\u003e into allegations made by current and former employees regarding product integrity issues, sales and marketing activities, and manufacturing quality issues.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003eseveral drug and device manufacturers\u003c/strong\u003e concerning product approvals, and in responding to FDA requests for information relating to promotion and advertising, manufacturing practices, field alerts, recalls and numerous post-market issues.\u003c/p\u003e","\u003cp\u003eRepresented one of the nation\u0026rsquo;s foremost cardiovascular institutes and some of the leading interventional cardiologists in responding to deficiencies identified during FDA inspections and developing appropriate corrective action to avoid further FDA regulatory enforcement.\u003c/p\u003e","\u003cp\u003eRepresented a device manufacturer in obtaining expedited PMA review and approval in 90 days for a first-of-a-kind device to treat aneurysms in the renal vascular arteries. Successfully obtained approval for a major PMA supplement for the same product.\u003c/p\u003e","\u003cp\u003eRepresented a device manufacturer and coordinated an extensive product investigation into reported failures of an implantable device featuring sophisticated failure analyses and clinical assessments.\u003c/p\u003e","\u003cp\u003eConducted extensive training on FDA regulatory, IRB and protocol requirements for clinical investigators participating in the study of implantable devices.\u003c/p\u003e","\u003cp\u003eAssisted numerous companies in preparing for FDA inspections, developing responses to FDA observations (FDA-483 forms) and warning letters related to manufacturing practices, quality systems, adverse event reporting, deviations from approved drug master files and manufacturing processes, and a variety of other regulatory matters. Assisted these companies in preparing for meetings with FDA compliance officials in District Offices, centers for drugs and devices, and the Office of Chief Counsel.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":51}]},"expertise":[{"id":21,"guid":"21.capabilities","index":0,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":1,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":2,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":3,"source":"capabilities"},{"id":3,"guid":"3.capabilities","index":4,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":7,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":8,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":9,"source":"capabilities"},{"id":1303,"guid":"1303.smart_tags","index":10,"source":"smartTags"},{"id":970,"guid":"970.smart_tags","index":11,"source":"smartTags"},{"id":114,"guid":"114.capabilities","index":12,"source":"capabilities"}],"is_active":true,"last_name":"Brown","nick_name":"Mark","clerkships":[],"first_name":"Mark","title_rank":9999,"updated_by":196,"law_schools":[],"middle_name":"S.","name_suffix":"","recognitions":[{"title":"Recognized by Super Lawyers as Top Rated FDA Attorney ","detail":"Law \u0026 Politics, 2007, 2010–2011, 2013–2017"},{"title":"Ranked Among the Best Life Sciences Lawyers in the U.S. ","detail":"Legal 500, 2016"},{"title":"Named Life Sciences Star ","detail":"LMG Life Sciences, 2012–2016"},{"title":"Recognized as one of Washington’s Best Lawyers ","detail":"Washingtonian magazine, 2004–2016"},{"title":"Superior Achievement Award ","detail":"U.S. Department of Health \u0026 Human Services, 1992"},{"title":"Commendable Service Award ","detail":"FDA, 1992–1994"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eMark Brown is nationally recognized in Food \u0026amp; Drug Administration regulatory matters, civil litigation, criminal investigations and prosecutions, compliance matters and comprehensive risk assessments. Mark advises pharmaceutical, medical device and biotech companies, and pharmacies, on a broad range of FDA requirements and FDA regulatory issues that arise in products liability litigation and other disputes. A former Associate Chief Counsel for FDA, Mark is the Chair of the FDA and Life Sciences practice.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMark has developed a national reputation for successfully resolving difficult and complex FDA compliance matters and enforcement actions. For pharmaceutical, medical device and food companies, and pharmacies, he has successfully negotiated and managed numerous complex consent decrees of injunction, successfully defended an injunction action brought by FDA, and persuaded the government not to bring enforcement actions in other civil and criminal matters.\u003c/p\u003e\n\u003cp\u003eMark regularly counsels clients on drug safety issues, clinical trials, adverse event reporting, quality systems and manufacturing practices for drugs and devices. He also provides guidance concerning product failure investigations, factory inspections, recalls, product labeling, drug compounding, advertising, promotion, sales and marketing practices, and regularly advises clients on strategies for obtaining FDA approval and clearance for medical products.\u003c/p\u003e\n\u003cp\u003eMark also handles FDA-related issues in product liability and commercial litigation. He was an architect of the preemption defense for both pharmaceutical and medical device clients, developing supporting evidence, briefing and arguing federal preemption motions in various federal and state courts.\u003c/p\u003e\n\u003cp\u003eBefore joining the FDA, Mark was an attorney in the Bureau of Consumer Protection at the Federal Trade Commission, where he concentrated on consumer fraud, healthcare advertising and promotional activities. He developed FTC enforcement actions against weight-loss centers, in vitro fertilization clinics and Northern Virginia infertility doctor Cecil B. Jacobson, who was later convicted of defrauding patients.\u003c/p\u003e","matters":["\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003e\u003cstrong data-redactor-tag=\"strong\"\u003ePhillip Morris USA\u003c/strong\u003e v. FDA\u003c/em\u003e, 202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eUnited States v. \u003cstrong data-redactor-tag=\"strong\"\u003eFranck's Lab\u003c/strong\u003e\u003c/em\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e,\u003c/strong\u003e 2011 WL 4031102 (M.D. Fla., Sept. 12, 2011). Lead counsel in successful defense of FDA enforcement action against pharmacy compounder of veterinary drugs.\u003c/p\u003e","\u003cp\u003eDuring his 30-year career, he has served as lead counsel and negotiator for numerous consent decrees of injunction, both during his tenure with FDA (1990\u0026ndash;1994), and since 1994 in private practice. For example, he has negotiated consent decrees some of the world's largest device manufacturers, including \u003cstrong data-redactor-tag=\"strong\"\u003eMedtronic\u003c/strong\u003e (2008 and 2015), \u003cstrong data-redactor-tag=\"strong\"\u003eThe General Electric Company\u003c/strong\u003e (2007) and \u003cstrong data-redactor-tag=\"strong\"\u003eBaxter Healthcare\u003c/strong\u003e (2006).\u003c/p\u003e","\u003cp\u003eSince 2002, served on the national counsel team for \u003cstrong data-redactor-tag=\"strong\"\u003eGlaxoSmithKline\u003c/strong\u003e in the Paxil Products Liability Litigation. Represented GSK on all FDA-related issues, including federal preemption. Argued and won a summary judgment motion on federal preemption grounds in \u003cem data-redactor-tag=\"em\"\u003eO'Neal v. \u003cstrong data-redactor-tag=\"strong\"\u003eSmithKline Beecham\u003c/strong\u003e\u003c/em\u003e (E.D. Cal 2008). In 2002, represented GSK in successfully defending an injunction seeking to enjoin GSK from making claims in direct-to-consumer television advertising for Paxil.\u003c/p\u003e","\u003cp\u003eFrom 1995 to 2001, served on \u003cstrong data-redactor-tag=\"strong\"\u003e3M\u003c/strong\u003e's National Trial Team in the Silicone Gel-Filled Breast Implant Litigation. Responsible for virtually all FDA issues and had primary responsibility for preparation and handling of defense expert witnesses, and cross-examination of adverse witnesses on FDA issues.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003eConnaught Laboratories v. \u003cstrong data-redactor-tag=\"strong\"\u003eSmithKline Beecham\u003c/strong\u003e\u003c/em\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e,\u003c/strong\u003e 7 F.Supp. 2d 477 (D.Del. 1998), appeal dismissed, 165 F.3d 1368 (1999). Represented SmithKline Beecham in winning one of the few successful motions to compel FDA to provide testimony by its research scientists in patent litigation relating to purified form of pertactin, a component of the pertussis vaccine.\u003c/p\u003e","\u003cp\u003e\u003cem data-redactor-tag=\"em\"\u003e\u003cstrong data-redactor-tag=\"strong\"\u003eNext Nutrition\u003c/strong\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e, Inc.\u003c/strong\u003e\u003c/em\u003e \u003cem data-redactor-tag=\"em\"\u003ev. SportPharma USA, Inc.\u003c/em\u003e, No. 97-CV-1898J (1997). Served as lead counsel to a dietary supplement company that brought an action under the Lanham Act alleging false and misleading comparative advertising relating to competing products. Successfully negotiated a favorable settlement by obtaining a consent decree of permanent injunction and a damage award.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical manufacturers\u003c/strong\u003e in grand jury investigations regarding data integrity concerns in regulatory submissions to FDA, and alleged cGMP violations. In both cases, the U.S. Department of Justice declined to prosecute the company and individuals under investigation.\u003c/p\u003e","\u003cp\u003eConducted internal investigations into the sales and marketing practices of \u003cstrong data-redactor-tag=\"strong\"\u003emultiple international pharmaceutical and biotech companies\u003c/strong\u003e to develop a risk profile and recommendations for reducing potential liability and risk exposure.\u003c/p\u003e","\u003cp\u003eConducted comprehensive prelaunch risk assessments for \u003cstrong data-redactor-tag=\"strong\"\u003ea Top 10 pharmaceutical company\u003c/strong\u003e\u003cstrong data-redactor-tag=\"strong\"\u003e\u0026rsquo;s\u003c/strong\u003e blockbuster drug to identify potential medical, scientific, regulatory and products liability risk areas.\u003c/p\u003e","\u003cp\u003eConducted a risk assessment for \u003cstrong data-redactor-tag=\"strong\"\u003ea top tier biotechnology company\u0026rsquo;s\u003c/strong\u003e drug safety system to identify areas for possible improvement in pharmacovigilence planning, postmarket signal detection and investigation, and business decision-making.\u003c/p\u003e","\u003cp\u003eLed numerous internal investigations for \u003cstrong data-redactor-tag=\"strong\"\u003ebiotechnology, pharmaceutical and medical device manufacturers\u003c/strong\u003e into allegations made by current and former employees regarding product integrity issues, sales and marketing activities, and manufacturing quality issues.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003eseveral drug and device manufacturers\u003c/strong\u003e concerning product approvals, and in responding to FDA requests for information relating to promotion and advertising, manufacturing practices, field alerts, recalls and numerous post-market issues.\u003c/p\u003e","\u003cp\u003eRepresented one of the nation\u0026rsquo;s foremost cardiovascular institutes and some of the leading interventional cardiologists in responding to deficiencies identified during FDA inspections and developing appropriate corrective action to avoid further FDA regulatory enforcement.\u003c/p\u003e","\u003cp\u003eRepresented a device manufacturer in obtaining expedited PMA review and approval in 90 days for a first-of-a-kind device to treat aneurysms in the renal vascular arteries. Successfully obtained approval for a major PMA supplement for the same product.\u003c/p\u003e","\u003cp\u003eRepresented a device manufacturer and coordinated an extensive product investigation into reported failures of an implantable device featuring sophisticated failure analyses and clinical assessments.\u003c/p\u003e","\u003cp\u003eConducted extensive training on FDA regulatory, IRB and protocol requirements for clinical investigators participating in the study of implantable devices.\u003c/p\u003e","\u003cp\u003eAssisted numerous companies in preparing for FDA inspections, developing responses to FDA observations (FDA-483 forms) and warning letters related to manufacturing practices, quality systems, adverse event reporting, deviations from approved drug master files and manufacturing processes, and a variety of other regulatory matters. Assisted these companies in preparing for meetings with FDA compliance officials in District Offices, centers for drugs and devices, and the Office of Chief Counsel.\u003c/p\u003e"],"recognitions":[{"title":"Recognized by Super Lawyers as Top Rated FDA Attorney ","detail":"Law \u0026 Politics, 2007, 2010–2011, 2013–2017"},{"title":"Ranked Among the Best Life Sciences Lawyers in the U.S. ","detail":"Legal 500, 2016"},{"title":"Named Life Sciences Star ","detail":"LMG Life Sciences, 2012–2016"},{"title":"Recognized as one of Washington’s Best Lawyers ","detail":"Washingtonian magazine, 2004–2016"},{"title":"Superior Achievement Award ","detail":"U.S. Department of Health \u0026 Human Services, 1992"},{"title":"Commendable Service Award ","detail":"FDA, 1992–1994"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":746}]},"capability_group_id":2},"created_at":"2025-11-05T05:03:44.000Z","updated_at":"2025-11-05T05:03:44.000Z","searchable_text":"Brown{{ FIELD }}{:title=\u0026gt;\"Recognized by Super Lawyers as Top Rated FDA Attorney \", :detail=\u0026gt;\"Law \u0026amp; Politics, 2007, 2010–2011, 2013–2017\"}{{ FIELD }}{:title=\u0026gt;\"Ranked Among the Best Life Sciences Lawyers in the U.S. \", :detail=\u0026gt;\"Legal 500, 2016\"}{{ FIELD }}{:title=\u0026gt;\"Named Life Sciences Star \", :detail=\u0026gt;\"LMG Life Sciences, 2012–2016\"}{{ FIELD }}{:title=\u0026gt;\"Recognized as one of Washington’s Best Lawyers \", :detail=\u0026gt;\"Washingtonian magazine, 2004–2016\"}{{ FIELD }}{:title=\u0026gt;\"Superior Achievement Award \", :detail=\u0026gt;\"U.S. Department of Health \u0026amp; Human Services, 1992\"}{{ FIELD }}{:title=\u0026gt;\"Commendable Service Award \", :detail=\u0026gt;\"FDA, 1992–1994\"}{{ FIELD }}Phillip Morris USA v. FDA, 202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products.{{ FIELD }}United States v. Franck's Lab, 2011 WL 4031102 (M.D. Fla., Sept. 12, 2011). Lead counsel in successful defense of FDA enforcement action against pharmacy compounder of veterinary drugs.{{ FIELD }}During his 30-year career, he has served as lead counsel and negotiator for numerous consent decrees of injunction, both during his tenure with FDA (1990–1994), and since 1994 in private practice. For example, he has negotiated consent decrees some of the world's largest device manufacturers, including Medtronic (2008 and 2015), The General Electric Company (2007) and Baxter Healthcare (2006).{{ FIELD }}Since 2002, served on the national counsel team for GlaxoSmithKline in the Paxil Products Liability Litigation. Represented GSK on all FDA-related issues, including federal preemption. Argued and won a summary judgment motion on federal preemption grounds in O'Neal v. SmithKline Beecham (E.D. Cal 2008). In 2002, represented GSK in successfully defending an injunction seeking to enjoin GSK from making claims in direct-to-consumer television advertising for Paxil.{{ FIELD }}From 1995 to 2001, served on 3M's National Trial Team in the Silicone Gel-Filled Breast Implant Litigation. Responsible for virtually all FDA issues and had primary responsibility for preparation and handling of defense expert witnesses, and cross-examination of adverse witnesses on FDA issues.{{ FIELD }}Connaught Laboratories v. SmithKline Beecham, 7 F.Supp. 2d 477 (D.Del. 1998), appeal dismissed, 165 F.3d 1368 (1999). Represented SmithKline Beecham in winning one of the few successful motions to compel FDA to provide testimony by its research scientists in patent litigation relating to purified form of pertactin, a component of the pertussis vaccine.{{ FIELD }}Next Nutrition, Inc. v. SportPharma USA, Inc., No. 97-CV-1898J (1997). Served as lead counsel to a dietary supplement company that brought an action under the Lanham Act alleging false and misleading comparative advertising relating to competing products. Successfully negotiated a favorable settlement by obtaining a consent decree of permanent injunction and a damage award.{{ FIELD }}Represented pharmaceutical manufacturers in grand jury investigations regarding data integrity concerns in regulatory submissions to FDA, and alleged cGMP violations. In both cases, the U.S. Department of Justice declined to prosecute the company and individuals under investigation.{{ FIELD }}Conducted internal investigations into the sales and marketing practices of multiple international pharmaceutical and biotech companies to develop a risk profile and recommendations for reducing potential liability and risk exposure.{{ FIELD }}Conducted comprehensive prelaunch risk assessments for a Top 10 pharmaceutical company’s blockbuster drug to identify potential medical, scientific, regulatory and products liability risk areas.{{ FIELD }}Conducted a risk assessment for a top tier biotechnology company’s drug safety system to identify areas for possible improvement in pharmacovigilence planning, postmarket signal detection and investigation, and business decision-making.{{ FIELD }}Led numerous internal investigations for biotechnology, pharmaceutical and medical device manufacturers into allegations made by current and former employees regarding product integrity issues, sales and marketing activities, and manufacturing quality issues.{{ FIELD }}Represented several drug and device manufacturers concerning product approvals, and in responding to FDA requests for information relating to promotion and advertising, manufacturing practices, field alerts, recalls and numerous post-market issues.{{ FIELD }}Represented one of the nation’s foremost cardiovascular institutes and some of the leading interventional cardiologists in responding to deficiencies identified during FDA inspections and developing appropriate corrective action to avoid further FDA regulatory enforcement.{{ FIELD }}Represented a device manufacturer in obtaining expedited PMA review and approval in 90 days for a first-of-a-kind device to treat aneurysms in the renal vascular arteries. Successfully obtained approval for a major PMA supplement for the same product.{{ FIELD }}Represented a device manufacturer and coordinated an extensive product investigation into reported failures of an implantable device featuring sophisticated failure analyses and clinical assessments.{{ FIELD }}Conducted extensive training on FDA regulatory, IRB and protocol requirements for clinical investigators participating in the study of implantable devices.{{ FIELD }}Assisted numerous companies in preparing for FDA inspections, developing responses to FDA observations (FDA-483 forms) and warning letters related to manufacturing practices, quality systems, adverse event reporting, deviations from approved drug master files and manufacturing processes, and a variety of other regulatory matters. Assisted these companies in preparing for meetings with FDA compliance officials in District Offices, centers for drugs and devices, and the Office of Chief Counsel.{{ FIELD }}Mark Brown is nationally recognized in Food \u0026amp; Drug Administration regulatory matters, civil litigation, criminal investigations and prosecutions, compliance matters and comprehensive risk assessments. Mark advises pharmaceutical, medical device and biotech companies, and pharmacies, on a broad range of FDA requirements and FDA regulatory issues that arise in products liability litigation and other disputes. A former Associate Chief Counsel for FDA, Mark is the Chair of the FDA and Life Sciences practice.\nMark has developed a national reputation for successfully resolving difficult and complex FDA compliance matters and enforcement actions. For pharmaceutical, medical device and food companies, and pharmacies, he has successfully negotiated and managed numerous complex consent decrees of injunction, successfully defended an injunction action brought by FDA, and persuaded the government not to bring enforcement actions in other civil and criminal matters.\nMark regularly counsels clients on drug safety issues, clinical trials, adverse event reporting, quality systems and manufacturing practices for drugs and devices. He also provides guidance concerning product failure investigations, factory inspections, recalls, product labeling, drug compounding, advertising, promotion, sales and marketing practices, and regularly advises clients on strategies for obtaining FDA approval and clearance for medical products.\nMark also handles FDA-related issues in product liability and commercial litigation. He was an architect of the preemption defense for both pharmaceutical and medical device clients, developing supporting evidence, briefing and arguing federal preemption motions in various federal and state courts.\nBefore joining the FDA, Mark was an attorney in the Bureau of Consumer Protection at the Federal Trade Commission, where he concentrated on consumer fraud, healthcare advertising and promotional activities. He developed FTC enforcement actions against weight-loss centers, in vitro fertilization clinics and Northern Virginia infertility doctor Cecil B. Jacobson, who was later convicted of defrauding patients. Mark S Brown Partner Recognized by Super Lawyers as Top Rated FDA Attorney  Law \u0026amp; Politics, 2007, 2010–2011, 2013–2017 Ranked Among the Best Life Sciences Lawyers in the U.S.  Legal 500, 2016 Named Life Sciences Star  LMG Life Sciences, 2012–2016 Recognized as one of Washington’s Best Lawyers  Washingtonian magazine, 2004–2016 Superior Achievement Award  U.S. Department of Health \u0026amp; Human Services, 1992 Commendable Service Award  FDA, 1992–1994 University of Michigan University of Michigan Law School St. Louis University  U.S. Court of Appeals for the Federal Circuit U.S. Court of Appeals for the Second Circuit U.S. Court of Appeals for the Seventh Circuit U.S. Court of Appeals for the Ninth Circuit U.S. Court of Appeals for the Tenth Circuit U.S. District Court for the District of Maryland U.S. District Court for the Eastern District of Wisconsin District of Columbia Maryland Pennsylvania District of Columbia Bar Maryland State Bar Phillip Morris USA v. FDA, 202 F.Supp. 3d (D.D.C. 2016). Represented one of the plaintiffs in a successful legal challenge to an FDA guidance governing the Substantial Equivalence Review process for tobacco products. United States v. Franck's Lab, 2011 WL 4031102 (M.D. Fla., Sept. 12, 2011). Lead counsel in successful defense of FDA enforcement action against pharmacy compounder of veterinary drugs. During his 30-year career, he has served as lead counsel and negotiator for numerous consent decrees of injunction, both during his tenure with FDA (1990–1994), and since 1994 in private practice. For example, he has negotiated consent decrees some of the world's largest device manufacturers, including Medtronic (2008 and 2015), The General Electric Company (2007) and Baxter Healthcare (2006). Since 2002, served on the national counsel team for GlaxoSmithKline in the Paxil Products Liability Litigation. Represented GSK on all FDA-related issues, including federal preemption. Argued and won a summary judgment motion on federal preemption grounds in O'Neal v. SmithKline Beecham (E.D. Cal 2008). In 2002, represented GSK in successfully defending an injunction seeking to enjoin GSK from making claims in direct-to-consumer television advertising for Paxil. From 1995 to 2001, served on 3M's National Trial Team in the Silicone Gel-Filled Breast Implant Litigation. Responsible for virtually all FDA issues and had primary responsibility for preparation and handling of defense expert witnesses, and cross-examination of adverse witnesses on FDA issues. Connaught Laboratories v. SmithKline Beecham, 7 F.Supp. 2d 477 (D.Del. 1998), appeal dismissed, 165 F.3d 1368 (1999). Represented SmithKline Beecham in winning one of the few successful motions to compel FDA to provide testimony by its research scientists in patent litigation relating to purified form of pertactin, a component of the pertussis vaccine. Next Nutrition, Inc. v. SportPharma USA, Inc., No. 97-CV-1898J (1997). Served as lead counsel to a dietary supplement company that brought an action under the Lanham Act alleging false and misleading comparative advertising relating to competing products. Successfully negotiated a favorable settlement by obtaining a consent decree of permanent injunction and a damage award. Represented pharmaceutical manufacturers in grand jury investigations regarding data integrity concerns in regulatory submissions to FDA, and alleged cGMP violations. In both cases, the U.S. Department of Justice declined to prosecute the company and individuals under investigation. Conducted internal investigations into the sales and marketing practices of multiple international pharmaceutical and biotech companies to develop a risk profile and recommendations for reducing potential liability and risk exposure. Conducted comprehensive prelaunch risk assessments for a Top 10 pharmaceutical company’s blockbuster drug to identify potential medical, scientific, regulatory and products liability risk areas. Conducted a risk assessment for a top tier biotechnology company’s drug safety system to identify areas for possible improvement in pharmacovigilence planning, postmarket signal detection and investigation, and business decision-making. Led numerous internal investigations for biotechnology, pharmaceutical and medical device manufacturers into allegations made by current and former employees regarding product integrity issues, sales and marketing activities, and manufacturing quality issues. Represented several drug and device manufacturers concerning product approvals, and in responding to FDA requests for information relating to promotion and advertising, manufacturing practices, field alerts, recalls and numerous post-market issues. Represented one of the nation’s foremost cardiovascular institutes and some of the leading interventional cardiologists in responding to deficiencies identified during FDA inspections and developing appropriate corrective action to avoid further FDA regulatory enforcement. Represented a device manufacturer in obtaining expedited PMA review and approval in 90 days for a first-of-a-kind device to treat aneurysms in the renal vascular arteries. Successfully obtained approval for a major PMA supplement for the same product. Represented a device manufacturer and coordinated an extensive product investigation into reported failures of an implantable device featuring sophisticated failure analyses and clinical assessments. Conducted extensive training on FDA regulatory, IRB and protocol requirements for clinical investigators participating in the study of implantable devices. Assisted numerous companies in preparing for FDA inspections, developing responses to FDA observations (FDA-483 forms) and warning letters related to manufacturing practices, quality systems, adverse event reporting, deviations from approved drug master files and manufacturing processes, and a variety of other regulatory matters. Assisted these companies in preparing for meetings with FDA compliance officials in District Offices, centers for drugs and devices, and the Office of Chief Counsel.","searchable_name":"Mark S. Brown","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":196,"capability_group_featured":null,"home_page_featured":null}]}}